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1.1 A short history of the science of viral diagnostics
Long before the actual detection of filterable viruses at the end of the 19th century, the role of 
transmissible agents in diseases like yellow fever and measles was recognized.1,2 In search for therapies 
against frequently encountered and deadly diseases like rabies and smallpox, early vaccination strategies 
were developed: it was shown that inoculation with attenuated virus provided protection against these 
fatal diseases.3 Because viruses are unable to grow on artificial media, it was not until the 1890s that 
viral diseases were first acknowledged in the laboratory, when Dmitri Ivanowsky (1892) and Martinus 
Beijerinck  (1898) independently showed that the filtered extract of plants with mosaic disease caused 
disease when introduced to healthy plants (contagium vivum fluidum).4,5 The recognition that viruses 
need living cells to propagate, led to the use of nonhuman hosts to isolate and characterize viral agents. 
However, the science of diagnostic virology was not further advanced until the development of tissue 
culture techniques with cytopathic effect as read outs to detect and identify a virus from a clinical 
specimen (Table 1.1.).3 
Table 1.1. Timeline of highlights in diagnostic virology
1892 Discovery of filterable viruses (Dmitri Ivanowsky)
1898 Discovery of filterable viruses independently from Ivanowsky (Martinus Beijerinck)
1928 Cultivation of vaccinia virus
1937 Development of yellow fever vaccine by passaging through animals
1949 Poliomyelitis virus able to be cultivated in cell cultures of non-neural origin
1950 Demonstration of cytopathic effect
1950s Demonstration of usefulness of fluorescent antibodies (FA) in studies of infectious diseases
1955 Diagnosis of influenza using FA
1950-1970 Development of molecular biology techniques
1985 PCR
1996 Real time PCR
The application of culture-based methods led to the recognition and characterization of a large variety 
of virus species, notably viruses involved in respiratory tract infections. Apart from the inability of 
certain viruses, like those associated with acute gastrointestinal disease, to grow on cell lines, a major 
disadvantage of diagnostic application of cell culture techniques is the time needed to confirmation. 
It may take several weeks before a diagnosis is reached, if a virus is detected at all. The development 
of diagnostic tests using specific antibodies for antigen detection has enabled more rapid diagnoses 
compared to virus culture, albeit at the cost of reduced sensitivity (the proportion of true viral diseases 
detected with a positive test).6,7 These latter developments in diagnostic virology greatly enhanced the 
ability to associate specific viruses with clinical disease.  Furthermore, those techniques enabled to fight 
against endemic viral infections like polio and smallpox with the development of targeted vaccination, 
which have proven successful for eradication. The poxvirus (variola) eradication in 1977 is the first example 
of the successful vaccination strategies, while poliovirus is the next target for the WHO, possibly followed 
by measles. Their eradication is helped by the fact that these viruses have humans as the only natural 
host and spread among other vectors such as animals is absent. In the early 1970s several scientists 
believed that virtually all viral illnesses could be fought back through effective immunization strategies.
The HIV-1 epidemic in the beginning of the 1980s marked a turning point in the optimistic believes 
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on victory of mankind over viral diseases. The occurrence of severe opportunistic infections in young 
homosexual men, who were at highest risk for attracting this syndrome, led to worldwide studies into the 
cause of Acquired Immune Deficiency Syndrome (AIDS) and the use of molecular nucleic acid methods 
in clinical diagnostic virology was first explored.8-10 The discovery of the polymerase chain reaction (PCR) 
in the beginning of 1990s further revolutionized clinical diagnostic virology, allowing the identification 
of very small amounts of genetic material by exponential expansion of a viral target sequence.11,12 This 
technology also enabled scientists to detect viral nucleic acids from a variety of viruses that could not 
be cultured such as hepatitis B virus (HBV) and hepatitis C virus (HCV). After the discovery of HIV as 
the causal virus for the clinical syndrome AIDS, molecular methods played a pivotal role in the design 
of therapeutic drugs. The unraveling of genomic organization and viral replication was enhanced by 
molecular techniques, paving the way for the development of antiviral compounds targeting different 
parts of the virus or its lifecycle. For some viruses, like HIV-1 and HCV, antiviral therapy has completely 
changed the fatal prognosis of infected patients.13,14 Despite these advances, for recently discovered and 
researched viruses like rhinovirus or enterovirus, no effective drugs are on the market as yet.15 When it 
was shown that the risk of progression to AIDS and death was directly related to the viral load (and CD4 
counts) in blood, monitoring these key test results for prognosis became an essential component of 
antiretroviral treatment strategies.16 From this time onwards, clinical diagnostic virology was not only 
the detection of a viral infection, but has become an essential diagnostic tool in patient management.
1.2 Molecular diagnostic virology
Molecular diagnostic techniques have evolved rapidly and gained a solid position in the daily 
routine of microbiological laboratories, especially in the field of clinical virology.17-19 One of the earliest 
applications of molecular techniques in pathogen identification was the use of PCR in patients with 
herpes virus (HSV) encephalitis.  Detection of HSV in cerebrospinal fluid by PCR was a more sensitive 
and less invasive method than brain biopsy and tissue culture.20 Similar advancements were introduced 
for the clinical diagnosis of enteroviral meningitis.21 The development of multiplex PCR, where 
several viral targets are incorporated into one single reaction, made it possible to diagnose a causal 
pathogen in clinical syndromes arising from any specific viral source, for example respiratory and 
gastrointestinal infections. Importantly, molecular tests are useful in the detection of a causative virus 
during the acute phase of a viral disease when the viral load is relatively high. During this first phase, 
conventional methods like serology and antigen detection have disadvantages compared to molecular 
tests: antibody response, even the IgM response, takes several days to develop and antigen tests have 
reduced sensitivity compared to molecular methods. Furthermore, the development and detection of 
an antibody response can be severely hampered in immunocompromised patients.
Driven by these developments in molecular techniques, continuously growing lists of previously 
unknown or uncultivable viruses are detected (Table 1.2.). In this respect, much attention has been 
given to the non-human origin of human (pathogenic) viruses for example by recent studies into 
bats as reservoirs for viruses that are capable of infecting humans. Such studies contribute to a further 
understanding of viral diversity and help to determine zoonotic risks.22-24
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Table 1.2. Newly recognized viruses over the last 20 years
1980 HTLV66 2004 H7N7 67
1983 HIV-144,68-70 2005 Human bocavirus71
1989 HCV72 2005 Coronavirus HKU1 73
1990 HHV-7 74 2007 Human Rhinovirus species C 75
1994 HHV-8 68 2007 Wu 76
1995 Sin Nombre virus 77 2007 Ki 78
1996 Australian Bat lyssavirus 79 2009 Influenza A H1N1pdm09 80
1998 Influenza A H5N1 81 2010 Severe fever with thrombocytopenia syndrome virus 82
1999 Nipah virus 83 2010 Trichodysplasia spinulosa polyomavirus 84
2001 Human metapneumovirus85 2012 MERS-CoV 62
2002 SARS-CoV 60 2013 Influenza A H7N9 86
2004 Coronavirus NL63 87
Nowadays, the ability to detect minute amounts of genetic material of viruses challenges the clinical 
interpretation of a positive test result because there may be a bystander effect. Apart from pathogen 
detection, quantitative molecular techniques have an important role in patient management. 
Quantification of viral load in order to assess progress and prognosis of disease has gained solid position 
not only in the management of HIV infections, but also for example in reactivations of cytomegalovirus 
(CMV) or Epstein Barr Virus (EBV) in immunosuppressed patients.25-27 Genotyping by molecular methods 
guides treatment protocols.28 In addition, antiviral susceptibility testing by identifying known resistance 
mutations before and during treatment has been incorporated in routine clinical care in case of HIV-1 
infection and infections with CMV, HSV, HCV or HBV when standard therapy fails. 
The more recent applications of molecular diagnostics have moved towards rapid tests which are easy 
to perform, so called point-of-care tests.29,30 These point-of-care tests can be performed in a satellite 
laboratory facility, situated for example near the emergency room thereby enhancing time efficiency.31 
Results are generated within 90 minutes after receiving the sample, providing timely input for clinical 
decision making. 
As new developments in molecular methods are rapidly moving on, many questions about the clinical 
value and application of such tests in routine diagnostics are still not fully answered and molecular viral 
diagnostics have not been optimally incorporated into routine clinical care. To optimize patient care, 
such issues need to be urgently addressed.
1.3 Benefits of molecular diagnostic tests
Molecular diagnostic methods are characterized by a high sensitivity and specificity with few false 
positives and negatives, and have the potential of providing a rapid result. Based on these characteristics, 
the benefits of molecular tests can be broadly categorized into three groups. 
(1) The use of molecular diagnostics benefits clinical management of a patient with signs and 
symptoms of a viral infection. The option of a timely diagnosis of a viral infection may lead to a reduction 
of unnecessary additional diagnostic laboratory tests and costly diagnostic imaging (e.g. X-ray or 
MRI), reduction of antibiotic use and perhaps start of proper antiviral treatment, and a reduction in 
hospitalization and length of stay.  
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(2) Molecular diagnostic tests have the advantage of a timely detection of a viral pathogen for in-hospital 
infection control: appropriate infection control measures can be installed to prevent further transmission 
within the hospital. 
(3) Information generated by molecular diagnostic tests may serve as input data for public health 
surveillance in order to monitor trends in viral diseases. Moreover, molecular tests also play an important 
role in identifying causative agents in emerging infections of unknown origin (e.g. SARS CoV).
1.3.1. Benefits of molecular viral diagnostics  for patient management
A timely and accurate diagnosis of a viral infection can be of help in explaining illness, thereby reducing 
the need for additional testing as well as guide empirical treatment. The developments in molecular 
diagnostic methods has resulted in the detection of a variety of new (or newly recognized) viruses in 
respiratory and fecal material, for instance human metapneumovirus, the polyomaviruses Wu and Ki, 
human bocavirus, human rhinovirus C, coronavirus NL63 and HKU1 (see also Table 1.2). For some of 
these new viruses, the causative relation between the detection of these viruses in the laboratory and 
clinical illness has become acknowledged (i.e. human metapneumovirus).32,33 For others, like Wu and Ki 
virus or bocavirus, the association with clinical symptoms is still under debate, because of conflicting 
results in clinical studies. The discrepancies may in part be due to differences in patient populations 
that were studied (e.g. children, immunocompromised, patients with chronic pulmonary diseases).34-38
So far, only few studies have focused on the impact of viral molecular diagnostic tests on the clinical 
management of the patients, i.e. the effect of a positive PCR on the use of antibiotics, on the length of stay 
in the hospital and on the number of additional investigations. Several studies among children showed 
a beneficial effect of the detection of a virus as the cause of respiratory disease towards discontinuation 
of antibiotics and reduced length of stay in the hospital. 39-41 However, a recent Cochrane review on 
the impact of rapid viral diagnostics for acute febrile illness in otherwise healthy children referred to 
the emergency department showed that rapid diagnostics did not significantly reduce antibiotic use, 
although there was a trend towards less antibiotic use in the rapid diagnostic group. 42 Importantly, the 
studies included in this review observed lower rates of chest X-rays and blood investigations in the rapid 
diagnostic group compared with the control group. The question remains whether these results can 
be extrapolated to unhealthy children with chronic underlying conditions such as asthma or cancer. In 
addition, it is unclear what the reasons are for continuation of antibiotic therapy despite the presence of 
an alternative viral diagnosis. Undoubtedly, not being able to rapidly exclude a bacterial (super)infection 
is probably an important factor, together with a lack of parameters to predict, with a high probability, 
that the disease is indeed of viral origin.
One recent study evaluated the impact of under-diagnosis of a norovirus infection in patients with 
gastrointestinal disease in whom fecal material was referred only for bacterial examination and the 
consequences of not knowing the viral cause of disease for patient management. 43 In these patients, the 
presence of norovirus was retrospectively determined. During the 8-month study period, the number of 
detected norovirus infected patients almost doubled by this approach (an additional 45 patients with 
norovirus infection were retrospectively detected to 50 routinely diagnosed patients). Patients who were 
norovirus positive in retrospect underwent more diagnostic imaging (including colonoscopy) and had 
a longer stay in the hospital as compared to patients who had norovirus detected at the moment they 
were in the hospital. Besides, missed norovirus positive patients were more often involved in a cluster of 
nosocomial transmission of norovirus. 
It may be that the clinical impact of a negative test is more important than the value of a positive test 
result. The ability to rule out an infection within a relevant short time-frame with high certainty helps
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in focusing on additional testing and empiric therapy towards another likely cause of disease. There is a 
need for rapid test results with a high positive as well as negative prognostic value that allow prediction 
of those patients that need hospital admission because of increased risk towards serious illness, and 
those that can be discharged safely. Point-of-care tests that can reliably detect viral pathogens with high 
sensitivity and specificity could meet these criteria, but are currently not incorporated in routine clinical 
care. 
Overall, the majority of studies using PCR as a rapid viral respiratory diagnostic test showed no significant 
differences in clinical management between patients with and without a positive viral test result, 
despite mounting data on clinical illness related to viral detection. 44-49 Besides the need for additional 
studies into clinically relevant outcome data (complications, mortality), education on the meaning 
and interpretation of a positive test result is the key requirement for the successful implementation of 
molecular methods into routine clinical care.
1.3.2. Benefits of molecular viral diagnostics for in-hospital infection control
A timely detection of a viral pathogen benefits infection control. Appropriate infection control measures 
can be installed after diagnosis of a viral pathogen, for example through “cohorting” patients with similar 
infections in order to reduce further nosocomial spread. Again, the exclusion of a viral infection based on 
a negative test results is at least as important, especially during the respiratory season when resources 
are under pressure because of the high admission rates of patients with viral infections. The benefits of 
a timely and accurate viral diagnosis in reducing nosocomial transmission have been well described 
for certain viral pathogens, most notably RSV and norovirus. The combination of early diagnosis, strict 
cohorting of patients and the implementation of appropriate infection control measures have been 
shown to reduce nosocomial transmission. 50-53  In recent years, the use of molecular epidemiology in 
tracing nosocomial transmission of viral pathogens has gained much interest, because of the increasing 
possibilities in clinical laboratories to characterize pathogens by sequence analysis. 54-56 Combining 
classical epidemiological tools, i.e. the clustering in time, place and person, with molecular data 
contributes to the understanding of how pathogens are being transmitted from one patient to the other 
with the ultimate goal of providing evidence based data to guide the implementation of appropriate 
infection control measures.  To this date, the use of sequence based data in the surveillance of (hospital 
acquired) viral infections and in infection control is not common practice and mainly confined to 
characterization of pathogens when the outbreak is already over in order to understand the possible 
transmission routes in retrospect.
1.3.3. Benefits of molecular viral diagnostics for public health
A third benefit of molecular diagnostic tests is the opportunity to provide accurate information to 
public health authorities for regional, national and international surveillance of viral diseases. These data 
are needed in order to know and understand what (sub) types of viruses are circulating and to detect 
changes in distribution patterns. This should ideally be combined with relevant clinical information on 
associated clinical illness.57 An example of a viral diagnostic network is Noronet, an informal network of 
scientists working in public health institutes and/or universities sharing virological, epidemiological and 
molecular data on the occurrence of the norovirus dynamics (www.noronet.nl). Molecular data shared 
through this network enables the linkage of an increase in norovirus activity to the emergence of new 
norovirus variants in a timely manner. A more severe norovirus season can be thus predicted and may 
serve as a warning for health care institutions to install outbreak management measures.58 Another 
example of a data-sharing network is the European Influenza Surveillance Network (EISN) based at the 
European Centre for Disease Prevention and Control (ECDC) in which epidemiological and virological 
data on influenza are collected and reported on a weekly basis. The development of a jointly owned 
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database within the Netherlands in which epidemiological, clinical and sequence data of enteroviruses 
are shared between the national public health institute and clinical diagnostic laboratories (VIRO-
Typened) is an example of the possibilities on a national level to add sequence based information to 
regular surveillance systems, in this case primarily to exclude poliovirus circulation.59
Molecular tests play also an important role in identifying causative agents of epidemics and pandemics 
and in understanding their epidemiology, as illustrated by recent global outbreaks of infections caused 
by newly recognized viruses, like SARS CoV, MERS-CoV and avian influenza H5N1 and H7N9. 60-62
1.3.4. Questions associated with benefits from molecular viral diagnostics
Several questions arise when examining the role of molecular diagnostic tests. The actual advantages 
of molecular techniques may potentially counteract the beneficial role of these tests in clinical 
management of a patient with an infectious disease:  because of its high sensitivity possibly insignificant 
amounts of nucleic acids of virus can be detected. The question then arises if these are from a pathogenic 
active virus or from degradation products. Furthermore a positive PCR test may reflect carriage of 
the virus after symptomatic infection or may indicate the period just before development of disease. 
Also, certain viruses are commonly found in healthy, asymptomatic persons, questioning their role in 
a particular symptomatic disease. 63-65 Using a multiplex format provides the opportunity to examine 
the presence of more viruses simultaneously. However, whenever co-infections are detected, do they 
correlate or contribute to more serious illness? And which virus may be the causal component?  Apart 
from the explanation for illness, the detection of a causative viral pathogen should lead to a reduction 
in unnecessary follow-up investigations and to a discontinuation of unnecessary treatment, especially 
antibiotics. But is this really the case in daily clinical practice? And if not, what are the reasons for not 
doing so?
Molecular detection of a viral pathogen could benefit infection control because actions to reduce 
nosocomial transmission can be taken in a timely matter. However, to know which infection control 
measures are the most appropriate in reducing nosocomial transmission, one has to have knowledge 
on the transmission dynamics of a pathogen: what are the main transmission routes, what is the role 
of visitors and health care workers in introducing pathogens from outside into the hospital and which 
percentage of nosocomial infections is actually due to patient-to-patient contact? Knowledge on the 
relative contribution of these factors to nosocomial infection rates is necessary to guide infection control 
policy and to focus the control efforts on key intervention points. 
In order to fully exploit the potential benefits of molecular diagnostic tests answers to the above raised 
questions need to be found. Clinical and epidemiological data are essential to relate the outcome of 
the molecular test results to the clinical illness of the patient. Information on patient characteristics 
like the presence of specific chronic underlying illnesses is necessary to gain more insight into the 
diagnostic value of molecular tests. Such knowledge may consequently be incorporated into the 
clinical management of the patient in order to avoid further investigations or unwarranted treatment. It 
is important that clinicians acquire knowledge on the clinical value of viral molecular tests.
Epidemiological and clinical data are also needed to fully exploit the benefits of molecular diagnostic 
tests for infection control. Understanding the transmission dynamics of viral pathogens by combining 
mathematical modeling techniques with epidemiological methods further contribute to the 
implementation of appropriate infection control measures.
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1.4. Scope of this thesis
The main focus of the scientific studies as part of this thesis is the clinical and epidemiological value of 
molecular diagnostic tests in viral infections. Two main issues and associated central research questions 
are studied (see also Figure 1.1.):
1. The value of molecular diagnostic tests in clinical management of the patient. 
	 	 What is the association between the molecular detection of a virus, clinical syndromes 
  and patient characteristics?
 
	 	 What is the influence of molecular detection of a virus on patient management?
2. The value of molecular diagnostic tests in infection control. 
	 	 What is the benefit of molecular detection and characterization of a virus for in-hospital   
  infection control practices?
The value of molecular diagnostic tests for respiratory and gastrointestinal illness caused by viruses is 
the object of this thesis. The usefulness of molecular techniques in clinical management and infection 
control is illustrated by studies into human rhinovirus, influenzavirus, enterovirus 68 and norovirus. 
Clinical as well as epidemiological data were systematically collected and related to the outcome of 
viral diagnostic tests and were used to gain more insight in the transmission of viral pathogens within 
the hospital.
Figure 1.1. Framework of this thesis
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Enterovirus 68 (EV68) belongs to species Human enterovirus D. It is unique among enteroviruses 
because it shares properties with human rhinoviruses. After the first isolation in 1962 from four children 
with respiratory illness, reports of (clusters of ) EV68 infections have been rare. During the autumn of 
2010, we noticed an upsurge of EV68 infections in the Northern part of the Netherlands in patients with 
severe respiratory illness.
Objectives
To give a detailed description of the clinical and virological data of patients with EV68 infection identified 
in 2010, and compare these with data collected in 2009. 
Study design
We systematically collected clinical data from patients with an EV68 infection detected in 2010. We 
added four patients with an EV68 infection from 2009. Further characterization of EV68 was performed 
by partial sequence analysis of the VP1 genomic region. 
Results
In 2010, EV68 was identified as the only cause of respiratory illness in 24 patients, of which 5 had to be 
admitted to the intensive care unit. Sequence analysis revealed different lineages in the majority of EV68 
detected in 2010 as compared to the 2009 isolates. 
Conclusions
We noticed an increase of EV68 infections and present clinical as well as sequence data, in which two 
distinct phylogenetic clusters could be identified.
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Background
Enteroviruses (HEV, family of Picornaviridae) are amongst the most common pathogens in humans. Based 
on molecular characteristics, enterovirus can be divided into four species, HEV-A to HEV-D. Currently, the 
serotypes EV68, EV70 and EV94 are the only identified members of HEV-D. EV68 is unique amongst 
enteroviruses because it has characteristic properties of both enteroviruses and rhinoviruses (HRV): it 
is acid sensitive in which it resembles HRV; however, it has close genetic similarities with EV70. Strains 
of EV68 have been independently identified as HRV serotype 87. However, molecular and antigenic 
characterization has shown that HRV87 is genetically identical to EV68.1-3 EV68 is almost exclusively 
associated with respiratory disease, in contrast to other enteroviruses which typically, but not exclusively, 
replicates in the intestinal tract. 4
Objectives
In August 2010, we noticed an upsurge of patients with serious respiratory illness in both our university 
hospital and adjacent regional hospitals. In several of these patients, EV68 was the only viral cause 
detected. We systematically collected clinical data from these patients and added four patients with an 
identified EV68 infection from 2009. We characterized the detected EV68 to determine whether different 
lineages were present in both years.
Study Design
Patients and sample collection
As part of a prospective study into respiratory infections in hospitalized children from 2009 onward, 
we systematically collect clinical data of all hospitalized children in whom samples are taken for the 
detection of a panel of 15 respiratory viruses. Besides, from August till October 2010, data of patients 
were added who were notified to us by clinicians because of a remarkable pattern of clinical illness 
(respiratory disease and wheezing during a “non-respiratory season”). Samples positive for HRV were 
further characterized and typed by sequence analysis of the VP4/VP2 region. 
Also, from July 2010 till January 2011, we systematically tested HRV positive samples from adult patients 
for the presence of enterovirus, as part of the validation of a re-optimized RT-PCR for the detection of 
HRV. All EV68 positive samples were characterized by sequence analysis of the VP1 region.
RT-PCR and sequencing
In the majority of patients nasopharyngeal swabs or nasopharyngeal aspirates were taken for the 
detections of respiratory viruses by a laboratory developed real-time PCR as has been described 
elsewhere.5 RNA was extracted using the NucliSense EasyMag (bioMérieux, Lyon, France). RT-PCR 
for the detection of HRV (also detecting EV68 due to the close sequence relationship between HRV 
and EV68) was performed on all samples.(Rahamat-Langendoen et al., manuscript in preparation) 
Identification of HRV was done by amplification and sequencing of a 549 nucleotide fragment spanning 
the hypervariable part of the 5’NTR, the entire VP4 gene and the 5’ terminus of the VP2 gene as has 
been described by Savolainen et al (Table 2.1).6 For EV68, these primers generated a 660 bp nucleotide 
fragment (nucleotide 534-1193) based on the Fermon strain (AY426531). cDNA synthesis was carried 
out in a reaction volume of 50 µl, which contained 20 µl RNA, 5.5 mM MgCl
2
, 2 mM dNTPs, 1x RT buffer, 
2.5 µM random hexamers, 20 U RNAse inhibitor (RNasin) and 62.5 U MultiScript reverse transcriptase 
(Applied Biosystems, Foster City, California, USA).
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The following cycling conditions were used for cDNA synthesis: 10 min at 25 °C, followed by 60 min 
at 48 °C, and 5 min at 95 °C. For amplification, 10 µl cDNA was added to a total of 50 µl PCR mix, 
consisting of 1x PCR buffer, 1 mM MgCl
2
, 25 pmol of both upstream and downstream primers, 2.5 U DNA 
polymerase (Hotstar polymerase, Qiagen), 1mM dNTP’s (Roche)  and DNase/RNase free water (Sigma). 
PCR was subsequently performed with the following cycling conditions: 15 min at 95 °C, followed by 40 
cycles of 1 min at 95°C, 1 min at 60°C and 1 min at 72°C, followed by 10 min at 72°C. For the EV68 strains, 
part of VP1 gene (741 base pairs, nucleotide 2323-3154) was amplified by RT-PCR using the primer 
pairs described in Table 2.1 and the same conditions as described for VP4/VP2, using an annealing 
temperature of 55°C instead of 60°C. The PCR products were sequenced on an ABI 3130 automated 
sequencer, using fluorescent dideoxy-chain terminators (3.1 BigDye Terminator kit; Applied Biosystems). 
For phylogenetic analysis a fragment of 731 bp (2399-3129bp Fermon AY426531) were aligned with 
Clustal W 2.0 and phylogenetic trees were constructed by the neighbor-joining method using MEGA 
4.0 with the maximum likelihood model and complete deletion for missing data. The EV68 sequences 
derived from this work are submitted to GenBank (accession numbers JF896287-JF896312).
Table 2.1. Primers for amplification and sequencing of EV68 isolates
Primers Sequence (5’3’) Gene Orientation Position * Reference
Rhinoseq-FW GGG-ACC-AAC-TAC-T T T-
GGG-TGT-CCG-TGT
VP4/VP2 Sense 534-560 Savolainen et al 20025
Rhinoseq-RV GCA-TCI-GGY-ARY-TTC-CAC-
CAC-CAN-CC




















VP1 Antisense 3154-3130 This study
I=inosine; Y=T, C; R=G, A; N=A, G, C, T
*Primer positions are given according to the orientation of the primer, either sense or antisense; numbers are given according to the 
EV68 Fermon strain (AY426531)3
Results
Patients and clinical data
During 2010, we did not detect EV68 within our ongoing study until August. Between August and 
November 2010, we tested 272 samples from 231 patients for the presence of respiratory viruses (134 
patients < 18 years, 97 patients ≥18 years). In 112 (41%) respiratory samples HRV was detected (as mono-
infection or in co-detection with other viruses): 30 out of 97 adult patients tested positive for HRV, of 
which 12 were identified as EV68 (12.4%). In children, HRV was detected in 82 out of 134 patients; EV68 
was found in 5 patients (3.7%). Samples from 21 children admitted to adjacent hospitals with respiratory 
infection and wheezing were sent to our laboratory for the detection of respiratory viruses; 14 patients 
tested positive for rhinovirus of which 7 were identified as EV68 (33.3%). All together we detected 24 
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patients with EV68 in a three months time. The remaining HRV positive samples were mainly typed as 
HRV species A and C, with a predominance of these species over HRV species B. 
The EV68 positive patients ranged in age from 1 month to 72 years, with a median age of 14 years. 
Ten patients (41.7%) were under two years of age. Male and female were equally divided. Twenty 
patients (83.3%) were hospitalized because of a respiratory illness, with a median duration of illness 
before admission of 3.0 days (0-10 days). Three patients (12.5%) were already hospitalized for other 
reasons before they developed respiratory symptoms (time from admission to first day of respiratory 
illness between 37 and 68 days). Five patients (20.8 %) had no relevant medical history; the remaining 
19 patients with EV68 had an underlying chronic illness, of which 14 related to the pulmonary tract 
(hyperreactivity of the lungs (6 EV68 positive patients), lung transplantation (3 EV68 positive patients), 
chronic need for oxygen or ventilation at home (4 EV68 positive patients)).
Five patients (20.8%) had to be admitted to the Intensive Care Unit (ICU) and required mechanical 
ventilation; one of them had no previous underlying illness. Dyspnoea and cough were predominant 
symptoms among all patients with EV68. Clinical diagnosis consisted mainly of exacerbation asthma/
wheezing (10 patients), pneumonia (6 patients) and upper respiratory tract infection (8 patients). In 
none of the patients other respiratory viruses were detected besides EV68. One patient (< 18 years) had 
a culture proven respiratory tract infection with Haemophilus influenzae, interpreted as a bacterial super 
infection in the presence of EV68. The median duration of hospitalization in patients with community 
acquired infection was five days (range 1-25 days). All patients survived the infection with EV68.
In our ongoing prospective study, we identified four patients, all children, with EV68 infection in the 
same period in 2009. The median age was 5.5 years; all four had an underlying chronic illness related 
to the pulmonary tract. None of these patients had to be admitted to the ICU. One also had bocavirus 
detected in the respiratory sample.
Sequence analysis and phylogeny of clinical isolates
Based on our VP4/VP2 sequence analysis, EV68 clinical isolates were divided into two distinct 
phylogenetic clusters, one containing all EV68 detected in 2009 and part of EV68 detected in 2010, 
the other containing only EV68 detected in 2010 (data not shown). Further characterization of EV68 
by partial sequencing of the VP1 genome showed a 3 nucleotide deletion in EV68 in the 2010 cluster 
as compared to the 2009 cluster, further confirming that the 2010 cluster was genetically distinct from 
the cluster which included the 2009 isolates (Figure 2.1 and 2.2). The VP1 sequence identity between 
the two clusters was 88.6-90.7%. The phylogenetic clustering did not coincide with epidemiological 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.1. Clustal W alignment of a 242- amino-acid region of VP1 of a subset of EV68 detected in this study and representatives of 
major lineages available in GenBank. The deletion is marked with an arrow.
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Figure 2.2. Neighbor-joining phylogenetic tree based on nucleotide sequences of a 731 bp fragment of the VP1 genomic region. The 




We report 24 patients identified in the autumn of 2010 with serious respiratory disease in whom only 
EV68 could be detected as the possible cause of illness. To our knowledge, this is the first detailed 
description of such a large group of patients infected with EV68. After the first isolation in 1962 from four 
children with respiratory illness, EV68 has been isolated rarely.3, 4, 7-12 Detailed clinical and epidemiological 
data are mostly limited or even lacking.
Recently, two studies reported the detection of EV68 in patients with respiratory illness: one in military 
recruits in the USA (7 recruits with febrile respiratory illness not further specified tested positive for EV68), 
and one in France, where 19 patients with lower respiratory tract infection had EV68 identified as most 
likely cause of illness.12, 13 The French study also noticed the upsurge of infections during autumn as we 
did; however, patient characteristics like age and underlying illness were not described. No comparison 
with EV68 detected in previous years was made. 
EV68 is reported to be most frequently associated with lower respiratory tract infections, notably 
bronchiolitis, pneumonia and exacerbation of asthma.3 This pattern of clinical illness was also present 
in our patients; indeed, the seriousness of illness (“RSV-like”) during a non-respiratory season in the 
absence of evidence for other causes of disease alerted the clinicians. Most of our patients had a chronic 
underlying illness, with the majority related to the pulmonary tract. This could explain the severity of 
clinical symptoms, as these patients are probably more vulnerable for severe respiratory infections. 
However, five patients had no relevant medical history, of which one even had to be admitted to the ICU. 
The fact that our institution is a tertiary referral hospital could have biased our findings towards more 
severely ill patients. In adjacent non-referral hospitals though the same observations were made, 
suggesting that referral bias probably was not of main importance.
Detection and identification of EV68 in respiratory samples are not incorporated into routine clinical use 
and could lead to underestimation of the prevalence of EV68. Also, in contrast to the rare detection of 
EV68 in clinical and environmental samples, seroprevalence studies have shown a high percentage of 
neutralizing antibodies against EV68, suggesting that EV68 may be underrepresented in clinical samples 
because of mild or subclinical symptoms.1,14 
We systematically typed all HRVs detected in children hospitalized in our tertiary hospital from 1 
September 2009 until 1 January 2011. Additionally, we tested HRV positive samples from adult patients 
for the presence of HEV from July 2010 till January 2011. We only detected EV68 during August till 
November 2010, suggesting that the observed rise in infections caused by EV68 was indeed a real 
upsurge. No other enteroviruses were detected.
The outcome of  VP1 sequence analysis showed two distinct phylogenetic clusters, which were confirmed 
in the VP4/VP2 sequence analysis. This strengthened our hypothesis of a change in the epidemiological 
and clinical spectrum of EV68 infections. The majority of EV68 detected and identified in 2010 were 
phylogenetically distinct from the ones detected in 2009. These findings could suggest that different 
genetic lineages of circulating EV68 strains might have contributed to a rise in (serious) infections.
The upsurge of serious infections caused by EV68 in our patients coincided with a peak in EV68 detections 
in the Dutch sentinel surveillance system into respiratory illness among patients seen by general 
practitioners. Preliminary sequence data showed genetic changes in EV68 comparable to our findings 
(personal communication Dr. A. Meijer, National Institute for Public Health and the Environment, The 
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Netherlands). This provides further evidence for the hypothesis of a potential widespread distribution of 
a phylogenetically distinct virus, which could have accounted for more infections in the population, with 
serious illness in hospitalized patients. However, although the majority of EV68 identified in 2010 were 
phylogenetically distinct from those detected in 2009, some EV68 detected in 2010 clustered with the 
ones identified in 2009, which could not be explained by the available epidemiological data. Probably, 
the changes in the virus do not exclusively explain the observed rise in patients with serious respiratory 
illness. Virological and epidemiological data over a longer period are needed to give further evidence 
to our hypothesis.
Although antiviral therapy is not yet available for patients infected with HRV in general and EV68 in 
particular, the detection and identification of these viruses could help in explaining serious respiratory 
illness, giving guidance to medical care and preventing unnecessary treatment with antibiotics. Also, 
we detected three hospital acquired infections, emphasizing the need of awareness of the possibility of 
EV68 infection in already hospitalized patients.
In conclusion, during the autumn of 2010 we noticed an upsurge of severe respiratory illness caused 
by infection with EV68. These epidemiological and clinical observations coincided with distinct 
phylogenetic clustering of the virus, suggesting sequence variation as possible contributing factor to 
more and severe infections caused by EV68.
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Enterovirus 68, a member of the genus Enterovirus species D, has first been isolated in 1962, in four 
children with respiratory disease. Until 2010, it was only sporadically reported. However, it gained 
much more interest in recent years because its association with outbreaks of respiratory illness with 
varying seriousness. Currently, the virus is regarded as an emerging pathogen. Although much about 
the virological, epidemiological and clinical features of Enterovirus 68 still remains to be elucidated, 
information is rapidly evolving. This chapter gives an overview of the current knowledge of Enterovirus 
68, from virology to clinical disease patterns and prevention and control.
Virology of Enterovirus 68, classification and replication
Enterovirus 68 (EV68) belongs to the family of Picornaviridae (“pico’ meaning small, “rna” for RNA genome), 
genus Enterovirus, which gained its name because members were known to replicate in the human 
gastrointestinal tract. Other well known members of the Picornaviridae family capable of infecting 
humans are the genus Rhinovirus (with over a hundred different serotypes), Kobuvirus (with Aichivirus 
A, B and C), Hepatovirus (with Hepatitis A virus as single species) and Parechovirus. Enteroviruses are 
common viruses associated with a variety of clinical syndromes, ranging from mild febrile illness to 
aseptic meningitis, myocarditis  and neonatal sepsis.1 The initial taxonomic classification within the genus 
Enterovirus was based on the ability of different serotypes to grow in various cell cultures, followed 
by further characterization using virus neutralization by type-specific reference antisera.2 However, the 
advent of molecular techniques in clinical virology has led to a further refinement of the classification 
of the genus Enterovirus and its species. The current classification is now based more upon genome 
organization and sequence similarity combined with their  biological properties. This divides the genus 
Enterovirus into four species (A-D) known to cause human disease (Table 3.1, www.picornaviridae.com).
Table 3.1. Classification of Enteroviruses
Enterovirus A Coxsackievirus* A2-A8, A10, A12, A14, A16
Enterovirus 71, 76, 89-91, 114, 119
Enterovirus B Coxsackievirus A9, Coxsackievirus B1-B6
Echovirus E1-E7, E9, E11-E21, E24-E27, E29-E33
Enterovirus 69, 73-75, 77-88, 93, 97, 98, 100, 101, 106, 
107
Enterovirus C Poliovirus 1-3
Coxsackievirus A1, A11, A13, A17, A19-A22, A24
Enterovirus 95, 96, 99, 102, 104, 105, 109, 113, 116-118
Enterovirus D Enterovirus 68, 70, 94, 111
*) named after a small town in New York State where the virus was first isolated.71
Enteroviruses are small (30 nm in diameter), non-enveloped viruses with an iscosahedral symmetry. 
Because of their lack of a lipid envelope, enteroviruses are able to resist organic solvents and nonionic 
detergents. Much of the information about the biophysical characteristics of enteroviruses are based 
on studies with poliovirus.2 Formaldehyde, gluteraldehyde, sodium hypochlorite and chlorine are able 
to inactivate enteroviruses. Most enteroviruses are already inactivated at 42°C, although some chemical 
agents as sulfhydral reducing agents and magnesium cations can stabilize the viruses at higher 
temperatures up to 50°C.3,4 Comparable to other infectious agents, ultraviolet light also can be used to 
inactivate enteroviruses, particular on surfaces, because it covalently links RNA molecules. Enteroviruses 
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are even stable at a pH lower than 3, which allows them to pass the stomach and gain access to the 
mucosa of the gastrointestinal tract where they replicate. These features permit enteroviruses to survive 
in this hostile environment for days to weeks.
Picornaviridae with the same physical characteristics as enteroviruses have been found in many animals, 
however, these animal Picornaviridae are not able to infect humans.2 One of the most well known 
animal Picornaviridae is Foot-and-mouth disease virus, member of the genus Aphthovirus, with a high 
economic impact.
This chapter deals specifically with Enterovirus type 68 (EV68). EV68 is a member of Enterovirus species 
D, together with EV70, EV94 and EV111 and is almost exclusively related to respiratory tract illnesses. In 
contrast to other enteroviruses, its biological properties resemble those of Human rhinoviruses: EV68 is 
acid labile and grows efficiently at an optimum temperature of approximately 33°C, the temperature 
of the upper respiratory tract.5,6 In fact, Human rhinovirus type 87 (HRV87) was demonstrated to be 
genetically and antigenically identical to EV68 and both viruses are now regarded as strains of the same 
Enterovirus serotype.
The cytopathic effect induced by EV68 was shown to be inhibited by monoclonal antibodies to the 
decay-accelerating factor (DAF, a membrane protein involved in the regulation of complement), which 
is also known to be the receptor of EV70.5,7 Besides, phylogenetic analysis of the EV68 prototype strain 
(Fermon strain, GenBank ID: AY426531) showed clustering of EV68 with EV70 in four genomic regions, 
thus providing convincing evidence of EV68 being a member of Enterovirus D. The other members 
of Enterovirus D are, as far as now known, not associated with respiratory disease: EV70 is regarded 
as an important cause of acute hemorrhagic conjunctivitis and EV94 is associated with acute flaccid 
paralysis.8,9 Recently, EV111 is identified as a new member of species D in fecal samples collected from 
chimpanzees in Cameroon. Phylogenetic analysis revealed that this isolate clustered with a human 
isolate from a patient  with acute flaccid paralysis in Congo, which was at first identified as EV70.10,11
The length of the enteroviral single stranded RNA genome is approximately 7.500 bases with a positive 
polarity. It has one single open reading frame (ORF) which is preceded at the 5’end by a long noncoding 
region (NCR) of approximately one tenth of the total length of the genome, and followed by a short 
3’NCR. This 5’NCR is a very complex structural part of the genome with a lot of structured series of 
branched and unbranched stem structures and pseudoknots.12 The largest and most dominant structure 
within this part of the genome is the socalled IRES, or Internal Ribosomal Entry Site, which is immediately 
followed by the AUG startcodon for the polyprotein. Attached at the 5’ end is a covalently linked protein 
called VPg, coded by gene segment 3B, allowing a CAP-independent translation process. Since this 
virus replicates in an eukaryotic cell, only one polyprotein can be synthesized which is subsequently 
processed through a series of primary, secondary and maturation cleavages.12 
The 5’NCR is a highly conserved, but species specific region and  can therefore be the chosen target for 
the design of primers and probes for the detection of Enteroviruses by molecular techniques. 
The enterovirus ORF can be divided into three regions, P1-P3 (Figure 3.1). The P1 region encodes for the 
viral structural proteins VP1-VP4, arranged 5’ to 3’ as VP4, VP2, VP3 and VP1. VP1 contains type-specific 
epitopes and has the highest density of neutralization sites. The VP1 sequence, or part of it, is used 
as the target for molecular typing of enteroviruses.13 The P2 and P3 region encode for non-structural 
proteins, necessary for the viral life cycle. The viral genome gives rise to a viral polyprotein which is 
further processed by viral encoded proteases encoded by segment 2A and 3C, some of which can act in 
a cis or in a trans form.12 The RNA dependent RNA polymerase is encoded by 3Dpol.
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Figure 3.1.  Picornavirus genome organization.70
The viral capsid consists of four proteins, VP1-VP4. These four proteins form a protomer with VP1, VP2 and 
VP3 located on the surface of the virion (Figure 3.2). VP4 is beneath them and lacks surface exposure. Five 
protomers form a pentamer, and one virion consists of twelve pentamers. Thus a total of 60 copies of 
each of the four proteins surround the viral RNA. This gives the virus the icosahedral structure. VP1, VP2 
and VP3 together form a so-called canyon structure into which the cellular receptor for enteroviruses fits. 
When the virus binds to its receptor, destabilization of VP4 leads to uncoating of the virus.




EV68 was first isolated in 1962 in respiratory samples received from four children with pneumonia 
and bronchiolitis, using primary monkey-kidney cell cultures.14 Until 2008, reports of respiratory 
disease caused by EV68 were rare. Between 1970 and 2005, EV68 was reported only 26 times within 
the framework of the enterovirus surveillance system in the United States.15 Patients with a respiratory 
disease are generally not systematically tested for the presence of enterovirus. Besides, most surveillance 
systems focus on the detection of enteroviruses in stool specimen, in which EV68 cannot be detected. 
Therefore, the absence of reports of EV68 does not necessarily indicates the absence of EV68 itself. A 
seroprevalence study in Finland among pregnant women in the first trimester of pregnancy showed 
that the prevalence of antibodies against EV68 was 100%, with declining antibody titers over the years.16 
This suggest that EV68 might have been around for a long time, despite the absence of reports about 
clinical illness caused by EV68.
From 2009 onwards, a growing number of reports are published describing outbreaks or clusters of EV68 
infection, indicating that EV68 is an emerging respiratory pathogen.17-20 Although the observed increase 
in cases might be caused by enhanced surveillance for example in patients with asthma, the fact that 
the increase in EV68 infections is independently reported from different countries in different continents 
during the same time period favors a real re-emergence (Figure 3.3).
Figure 3.3. Occurrence of human enterovirus 68, by month, duration, and geographic location – Asia, Europe, and United States, 
2008-2010.20 
Several retrospective studies looking for EV68 in respiratory samples from 1996 onwards, confirmed 
the upsurge of EV68 infections in recent years. In several clusters, new genetic variants were described 
based on VP1 sequence analysis. Phylogenetic analysis of all available EV68 sequences in 2012 revealed 
the presence of three primary clades of EV68 (clade A, B and C, Figure 3.4).21 Based on the evolutionary 
relationship of the viral sequences it was determined that between 1960 and mid-1990s, the EV68 
genome underwent a rearrangement in the 5’NCR, which resulted in a 24 nucleotide deletion. In the 
mid-1990s, the virus underwent a large diversification, resulting in two clades (A and C). The further 
deviation of clade B from clade C occurred around 2007. All three clades were distributed globally.
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enterovirus detection and typing. In the clusters reported during 
2008–2010, HEV68 was detected by real-time RT-PCR. Some 
sites used commercial, multipathogen detection systems that can 
detect enteroviruses. Two such systems, Luminex xTAG RVP and 
Idaho Technologies (Salt Lake City, Utah) FilmArray Respiratory 
Panel, are approved by the Food and Drug Administration for 
use in clinical settings in the United States. Both systems use 
broadly reactive primers that amplify RNA from either HRVs 
or enteroviruses (results are reported as “entero-rhinovirus” or 
“human rhinovirus/enterovirus”). 
Classic enteroviruses have prominent summer-fall seasonality 
in temperate climates (7,8), and outbreaks of enteroviruses tend 
to occur in several-year cycles. In the United States, echovirus 9 
typically peaks every 3 to 5 years; echovirus 30 occurs irregularly 
and can remain active for several years (7). In France, HEV68 was 
associated with an autumnal peak of spiratory tract inf ctions 
in 2008 (6). The seasonality of the HEV68 clusters described in 
this report typically fall within or later than the typical enterovirus 
season in the areas from which cases were reported (Figure) (7). 
These recent clusters confirm that HEV68 is associated 
with outbreaks of respiratory illness severe enough to require 
hospitalization, and in some cases, might contribute to 
patient death. New-onset wheezing or asthma exacerbation 
were notable symptoms. However, in each cluster, respiratory 
specimens typically were collected from persons who had 
sought medical care or were hospitalized, which would have 
biased these reports toward more severe disease. 
The spectrum of illness caused by HEV68 remains unclear. 
HEV68, like other enteroviruses, has been associated with 
central nervous system disease (9). Further investigation could 
help clarify the epidemiology and spectrum of disease caused 
by HEV68. Some diagnostic tests might not detect HEV68 
or might misidentify it as an HRV. The gold standard test for 
HEV68 detection is partial sequencing of the structural protein 
genes, VP4-VP2 or VP1. Cases in this report were confirmed 
with this method. However, the sensitivity of multipathogen 
detection systems for HEV68 detection is unknown. 
Laboratories using the CDC rhinovirus real-time RT-PCR assay 
(10) as originally described and as recently modified (forward 
primer 5’-CPALNAGCCTLNAGCGTGGY-3’) should be aware 
that it might misidentify HEV68 as an HRV and lacks the 
sensitivity to detect all HEV68 cases. 
Clinicians should be aware of HEV68 as one of many causes 
of viral respiratory disease. Clusters of unexplained respiratory 
illness should be reported to the appropriate public health 
agency. Local or state health departments may contact the 
CDC for assistance with laboratory diagnostics or consultation 
through the Unexplained Respiratory Disease Outbreak 
network (http://emergency.cdc.gov/urdo). 
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Figure 3.4. Evolutionary history of EV-D68 based on complete VP1 sequences (adapted from Tokarz R et al. Worldwide emergence of 
multiple clades of enterovirus 68.21)
Clade C is characterized by an additional 11 nucleotide deletion in the 5’NCR region. Little is known 
about the effect of these deletions in the 5’NCR on the virulence or fitness of the virus. However, these 
deletions might alter the virulence of the virus by enhancing the translational efficiency and thus could 
be associated with the recent increase in EV68 cases. Clade A lacks the 5’NCR deletion, but instead has a 
3 nucleotide (or 1 amino acid) deletion in the VP1 gene. Besides this deletion in the VP1 gene, it has been 
shown that in the exposed immunogenic parts of the VP1 gene, amino acid substitutions relative to the 
Fermon strain could be identified.21,22 These changes could have influenced the immune response to the 
virus. The observation in the Finnish study among pregnant women that the mean titers of neutralizing 
antibodies against EV68 (Fermon strain) declined over the years is in line with the hypothesis that the 
amino acid substitutions in VP1 could have had an immune modulatory effect.16,22 


































Fig. 1. Evolutionary history of EV-D68 based on complete VP1 sequences. The maximum clade credibility tree is shown with BPP values of 0.7–0.8 and 0.9–1.0 indicated by
X ande at the nodes, respectively. Clades A, B and C are indicated and supported by BPP51.0. The Bayesian skyline plots (BSPs) are shown for the overall dataset (bottom
left) and for clades A, B and C. Th black line i dicates the median relative geneti diversity (log10 scale) over time and the grey curves represent the upper and lower 95%
HPD intervals. $ at the tips of the branch s indicates novel sequences generat d in this study. The v rti al arrow indi ates the branch along which the VP1 asparagine























Thus, the antigenic drift in the VP1 gene might explain the recent increase in incidence of EV68 
infections. In temperate regions, EV68 infections display a clear seasonality, with most cases reported 
through autumn and into the winter period.19,23,24 This is in contrast to other enteroviruses, which 
typically circulate during the summer and early in autumn. Until now, little information is available on 
seasonality in tropical regions.
Transmission of EV68 from one person to the other most likely occurs via the respiratory route. Similar 
to other viruses causing respiratory tract infections, hand contact with respiratory secretions and 
autoinoculation to the mouth, nose or eyes are probably the most important routes. Also, airborne 
droplets may contribute to transmission of respiratory viruses in general and EV68 in particular.25 In 
general, children are thought to play a prominent role in the introduction and transmission of respiratory 
viruses within the household.26,27 Crowding and poor hygiene may facilitate further spread, not only in 
households, but also in institutions and hospitals. Nosocomial transmission has been well documented 
for respiratory viruses and for enteroviruses.28-32 However, EV68 specific information on the transmission 
dynamics in the community and in healthcare associated institutions is lacking. 
The high seroprevalence of EV68 within the community and the relatively few reports of clinical 
illness suggests that infection with EV68 occurs very frequently, in majority associated with mild or 
asymptomatic disease. Which host factors contribute to the occurrence of more serious, symptomatic 
respiratory disease are largely unknown. Until now, most studies suggest that clinical illness caused by 
EV68 is most commonly found in children.33-35 However, this could have been biased because most 
studies were performed in pediatric patients. In studies where patients regardless of their age were 
included, 20-50% of EV68 infections were detected in adults.15,19,22 The age distribution of infections 
might thus have been blurred by the study designs and EV68 could probably be recognized as a 
pathogen for all age groups.
The close relationship of EV68 with human rhinovirus and their cross-reactivity in molecular diagnostic 
tests (see also section on diagnosis), together with the fact that diagnostics for enteroviruses are 
mainly performed on fecal samples instead of respiratory specimen,  further contributes to the gaps in 
knowledge on EV68 as a true respiratory pathogen.36 This diagnostic bias is illustrated by the fact that 
several outbreaks of EV68 are reported from various parts of the world from 2010 onwards: it is highly 
unlikely that EV68 limits its circulation to these regions and is not present elsewhere. These findings 
provide additional arguments that the reported burden of EV68 infections is also influenced by the 
diagnostic capacities of the clinical laboratories.
Clinical Features
Until recently, reports of respiratory illness caused by EV68 have been rare. As a consequence, very 
limited information about the association of  EV68 with clinical symptoms and disease severity was 
available. During the last four years however, outbreaks and clusters of EV68 in different countries 
provided more data on EV68 as a respiratory pathogen. The clinical presentation of EV68 infections in 
these reports ranged from mild illness to complicated respiratory disease, for which hospitalization was 
necessary (Table 3.2). In a few cases, death as a consequence of EV68 infection was recorded.18,37 All cases 
presented with respiratory disease, except in one, where EV68 was detected in the cerebrospinal fluid 
and was implicated in a fatal infection of the central nervous system.37
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NK= not known; n.s.= not specified
mo=months, yrs=years
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ICU = intensive care unit
URTI= upper respiratory tract infection
LRTI= lower respiratory tract infection
ARI= acute respiratory illness; ILI = influenza like illness
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Based on observational studies, clinical presentation is dominated by signs and symptoms of acute 
respiratory illness like cough, fever and shortness of breath. A study of Meijer at al. in 2012 looked 
retrospectively in specimens from patients with respiratory symptoms, collected as part of the 
surveillance of respiratory illness among general practitioners and compared patients with EV68 with 
patients who were EV68 negative. EV68 positive patients had significantly more shortness of breath than 
EV68 negatives. In addition, EV68 positive patients had significantly more bronchitis. However, within 
this community based study, EV68 infection did not more often lead to complications compared with 
patients diagnosed with an acute respiratory illness because of other causes. EV68 was also sporadically 
found in asymptomatic patients.22
Reports from hospitalized patients, mainly pediatric patients, showed similar clinical patterns, with 
clinical diagnosis ranging from upper respiratory tract disease to bronchitis and pneumonia. However, 
only few studies mention the outcome of chest radiographs, and the diagnosis is mostly recorded based 
on clinical signs and symptoms. Whether the presence of a chronic underlying illness makes a patient 
more vulnerable to symptomatic EV68 infection is unclear. The majority of studies that recorded the 
presence of comorbidities focused on hospitalized patients (Table 3.2). Data suggest that the presence 
of a chronic underlying illness, more specifically chronic respiratory disease like asthma, might be 
associated with the presence of EV68 infection, however studies that systematically address this issue 
are lacking.
The pattern of illness associated with EV68 resembles that of rhinoviruses, although rhinovirus detection 
is much more frequently reported.18,23,38 Few studies directly compared clinical symptoms and patient 
characteristics of rhinovirus positive patients with patients with EV68. In a study in pediatric patients 
hospitalized for acute wheezing and bronchitis, enterovirus (of which 70% was EV68) was more 
frequently associated with respiratory distress and a need for oxygen therapy at the time of admission 
compared to patients with rhinovirus.23 Others detected comparable disease patterns in patients with 
EV68 and rhinovirus, particularly in patients with lower respiratory tract infections.38,39
Also, the association of rhinovirus with reactive airway disease like asthma, has become well established 
in recent years. Clinical data, although largely based on observational studies in selected study 
populations, suggest that this also could be true for EV68.
In summary, the hypothesis is that the spectrum of clinical disease caused by EV68 ranges from 
asymptomatic carriage to severe respiratory illness requiring hospitalization, with rare fatal cases. The 
association with reactive airway disease remains to be determined.
Pathogenesis and Immunity
The pathogenesis of EV68 in humans is largely unknown. However, as EV68 has been almost exclusively 
detected in respiratory material, it is likely that replication of EV68 takes place in the respiratory tract. 
Given the similarity between EV68 and rhinoviruses, it might be assumed that, comparable to rhinovirus, 
EV68 replicates in the epithelial cells of the nasopharynx and the nasal passages.40 Besides, the optimum 
temperature for growth of EV68 lies at 33°C, which is the temperature of the upper respiratory tract. 
Whether EV68 is capable of replicating in the lower respiratory tract is unknown. For rhinovirus, there 
is increasing evidence that infection from rhinovirus can occur throughout the airway and is not only 
confined to the upper respiratory tract.41,42
Experimentally infected persons with rhinovirus start shedding the virus after 8 till 18 hours, coinciding 
with the occurrence of respiratory symptoms.43 Virus shedding reaches a peak in 2 to 3 days after 
Chapter 32 49
infection and then rapidly declines. After three weeks, rhinovirus is no longer detectable in respiratory 
samples, however in immune-compromised patients, viral shedding can be prolonged and infection 
may be persistent.44 Whether EV68 has similar replication patterns as rhinovirus remains to be elucidated.
Rhinovirus induced wheezing in infancy and early childhood is associated with the development 
of asthma in children.45 Also, exacerbations of asthma, chronic bronchitis and cystic fibrosis can be 
precipitated by rhinovirus infections. Enhanced responsiveness of the lower airways has been described 
in rhinovirus infected persons.46,47 The relationship between EV68 and reactive airway disease remains 
to be determined. However, clinical data suggest that EV68 is indeed associated with the occurrence 
of bronchitis or bronchiolitis (Table 3.2). Also, EV68 has been shown to increase the severity of asthma 
attacks in children with pre-existing reactive airway disease.17 These data suggest that EV68, similar 
to rhinovirus, might be associated with enhanced responsiveness of the airways. Further studies are 
needed to explore this hypothesis.
In patients with a symptomatic rhinovirus infection, inflammatory response occurs rapidly after infection. 
In asymptomatic individuals, there is less viral shedding and also a decreased inflammatory response, 
however no differences are present in time to clearance of the virus between symptomatic and 
asymptomatic patients.40 The adaptive immune response with cell mediated and humoral components 
follows upon the initial inflammatory response. T-cells are recruited to the lung and may contribute 
to clearance of the virus through the production of cytokines.48 The termination of viral shedding and 
protection for subsequent infection coincides with the occurrence of neutralizing antibodies in serum 
as well as in nasal secretions several days after infection.49 Thus, the humoral immune response seems 
to play an important role in the final clearance of rhinovirus infection and not in the  initial recovery of 
illness.
Diagnosis
Before the advent of molecular diagnostic techniques, identification of enteroviruses relied on culture 
and subsequent virus  antibody neutralization tests using specific antibodies for further (sero)typing. 
Besides being time consuming and labor intensive,  identification of enteroviruses may fail because 
of the antigenic variability or lack of available specific clonal antibodies.50 In the last decade, the use of 
polymerase chain reaction (PCR) for the detection of enteroviruses has become increasingly common 
in diagnostic laboratories.
PCRs usually targets the highly conserved 5’-NCR.51-53 The detection of enteroviruses is complicated by 
the fact that enteroviruses and rhinoviruses have parts of their genome in common that are highly similar 
in nucleotide sequence. Thus, enterovirus could be misidentified as rhinovirus in routine molecular 
diagnostic tests. The detection of EV68 is further complicated by the fact that respiratory samples are in 
general not routinely tested for the presence of enteroviruses, whereas other patient material like feces 
or cerebrospinal fluid/liquor is much more likely to be tested for the presence of enteroviruses. However, 
EV68 is exclusively related to the respiratory tract and thus will not be found by regular and specific 
enterovirus testing. Recently, a survey was performed among ten clinical laboratories in the Netherlands 
to assess the capability of detecting EV68 during an EV68 epidemic in September and October 2010.36 
This study demonstrated that these ten laboratories were able to detect EV68 with their enterovirus 
specific real-time PCR, however, typing of enteroviruses was usually performed on stool specimens in 
the context of poliovirus eradication and not on respiratory samples, in which EV68 is found. The absence 
of reports of EV68 detection is thus most likely biased because of the specimens used for detection and 
typing of enteroviruses. 
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The 5’NCR used for detection of enteroviruses, is not discriminatory enough for enterovirus typing. 
Sequence based information of a part of the VP1 gene containing important neutralization sites has 
shown to have a good correlation with antigenic typing using the standard neutralization test.13 Also, 
sequencing of the VP4 and/or VP2 gene has been used as method for typing enterovirus. However, these 
regions have also shown to be less discriminatory as VP1, particularly for the enterovirus species B and 
C.54,55 Currently, the combination of PCR for detecting enterovirus and partial VP1 sequencing for further 
typing greatly reduces the time needed for identification and characterization of enteroviruses. 
Besides molecular techniques to diagnose enteroviral infections, serologic diagnosis can be made 
by determining the antibody titers in acute and convalescent serum specimen. The detection of IgM 
antibodies using enzyme-linked immunosorbent assays (ELISA) is regarded as evidence for a recent 
enterovirus infection. However, these tests measure broadly reactive antibodies and are not strictly 
serotype specific; thus, they are less useful in determining the infecting serotype.56 Besides, a definite 
serological diagnosis of enteroviral infection can be made only after the collection of two (acute and 
convalescent) serum samples, with at least 7-10 days in between. The use of molecular diagnostic 
techniques has therefore shortened the time to diagnosis considerably.
Treatment
Theoretically, every step in the lifecycle of enterovirus is a potential target in antiviral therapy (virus 
attachment, viral uncoating and capsid function, viral replication, viral protein synthesis). However, to 
date no therapy has been approved for the treatment of enteroviral or rhinoviral infection. The most well 
characterized targets are the viral capsid proteins and the viral proteases 3C and 2A.
Figure 3.5. Structure of Pleconaril 3-[3,5-dimethyl-4[[3-(3-methyl-5-isoxazolyl)propyl]oly]phenyl]-5(trifluoromethyl)-1,2,4-oxadiazole. 
Pleconaril binds to the hydrophobic sites in pockets in the base of canyons on the surface of picornaviruses.57
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clinical trials on viral meningitis were in progress, during
which time pleconaril was made available on a compassion-
ate basis for life threatening enteroviral infection, particularly
in immunocompromised patients who are prone to this com-
plication. Trials on rhinovirus infections in humans started
about a year later.
2. Anti-viral mechanism
The capsid of enteroviruses is composed of 60 protomers
in an icosahedrally symmetric arrangement. Each protomer
consists of three surface proteins (VP1, VP2 and VP3) and
a smaller internal protein (VP4) (Fig. 1). The three larger
proteins are folded into eight stranded antiparallel -barrel
structures forming a surface lattice. There is a c yon on
the surface surrounding each of the 12 pentamer axes, with
antigenic sites on t e rim that c n stimulate an immune re-
sponse i humans. There s evidence that structures in the
canyon bind to receptors on target cells (Ro smann et al.,
1985).
Pleconaril potentially inhibits uncoating of the capsid in
all enteroviruses, thereby preventing the virus from replicat-
ing its RNA. For rhinoviruses that use ICAM-1 as the cellular
receptor, the drug also inhibits attachment to the target cell
and infectivity of progeny virions (Staunton et al., 1989), but
for enteroviruses that use the LDL receptor the latter effect
dominates (Hofer et al., 1994). In an elegant crystallographic
study of related WIN compounds, Badger et al. (1988) did a
s ructural naly is of the binding of some WIN compounds t
rhinovirus 14. All bound into hydrophobic pocket beneath
the canyon ﬂoor causing large conformational changes in the
vicinity. The interaction between the WIN compounds and
Fig. 1. Pleconaril 3-[3,5-dimethyl-4[[3-(3-methyl-5-isoxazolyl)propyl]
oly]phenyl]-5(triﬂuoromethyl)-1,2,4-oxadiazole binds to hydrophobic sites
in pockets in the base of canyons on the surface of picanoviruses which
contain the binding sites for target cells.
the virus are hydrophobic, displacing two water molecules
from the pocket, with the conformational change mainly af-
fecting the FMDV loop; this alters the binding sites of a
further four water molecules and causes movement of the
-sheet. The presence of a WIN compound in the pocket
apparently increases the stability of the VP1 protein and in-
hibits disassembly of the capsid and subsequent release of
the core RNA. Drug resistant rhinoviruses have single amino
acid substitutions in polypeptide stretches lining the pocket,
possibly preventing full penetration into the pocket.
Apart from testing pleconaril in animal models of en-
teroviral infection, there was a prophylactic study in 33 adults
on either pleconaril or placebo for 7 days; the volunteers were
experimentally infected with an intranasal inoculum of Cox-
sackievirus A21 14 h after receiving the ﬁrst dose of either
pleconaril or placebo. There was a marked reduction in virus
shedding in nasal secretions and in nasal mucous production,
and a reductio in the symptom score in those on pleconaril
(Schiff an Sherwo d, 2000).
3. Pharmacology
Unlike its predecessor, WIN 54954, pleconaril has about
70% oral bioavailability, with the triﬂuoromethyl substituent
on the oxadiazole ring increasing the half-life by reducing
degradation in the liver by enzymes involved in oxidative
processes (Dian et al., 1995). In a single dose study with
50–1000 mg of pleconaril given orally, the disposition of the
d ug was best characterised using a two compartment model
with ﬁrst-order absorption. The Cmax and the ‘area under
the curve’ were linearly related to the dose, and a dose of
about 3 mg/kg body weight achieved a plasma concentra-
tion 12 h later that was 2.5-fold greater than required to in-
hibit 95% of enteroviral strains in culture (Abdel-Rahman
and Kearns, 1999). Pleconaril has a large volume of distribu-
tion with >99% plasma protein bound, has good penetration
into the central nervous system, and absorption is increased
when taken with food, particularly fats.
A six week prophylactic trial of pleconaril showed
induction of the cytochrome p450 3A enzyme involved
in the metabolism of a variety of drugs including ethinyl
estradiol (Hayden et al., 2003). A side effect of this longer
term use was an increase in menstrual irregularities (see
http://www.fda.gov/ohrms/dockets/ac/02/slides/3847s1 01
viropharma/sld001.htm).
4. Enteroviral disease in immunocompromised
patients
In 1974 a patient in England with X-linked agammaglob-
ulinaemia developed features of both ‘dermatomyositis’ and
meningitis, Echovirus 11 being isolated from the cerebro-
spinal ﬂuid (CSF) (Webster et al., 1978). Soon afterwards
there were further reports from USA and UK of immuno-
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Pleconaril is a capsid function inhibitor (Figure 3.5).57,58 Capsid inhibiting compounds block viral 
uncoating and attachment to the host cell by binding to the hydrophobic pocket formed between VP1 
and VP3. The filling of the pocket makes the virus more stable, thus preventing the necessary uncoating 
at entering the cell. Also, changes in the conformation of the canyon cleft may affect the attachment of 
the virus to the host cell receptor. Pleconaril has demonstrated activity against entero- and rhinoviruses 
and has a high oral bioavailability. It was made available in 1996 for compassionate use in patients with 
life-threatening enterovirus infections, including meningo-encephalitis, neonatal sepsis and myocarditis. 
Although small series of patients treated with pleconaril supported the clinical impression that it was 
effective in the majority of patients, other studies were not able to show significant improvement in 
patients treated with pleconaril.59,60 Because of difficulties in conducting trials in an epidemic illness 
and the inability to show a consistent treatment effect, further pursuit for licensing pleconaril for viral 
meningitis indication was stopped in 2000.
In patients with common cold, pleconaril was able to reduce the length of symptoms by one day with 
some minor gastrointestinal side effects of nausea and diarrhea.61 However, in a 6-week prophylactic 
study for the prevention of picornaviral respiratory tract infection, it was found that pleconaril induced 
cytochrome P450 3A, an enzyme of major importance for drug metabolism, thereby raising the possibility 
of drug interactions, in particular with oral contraceptives. Within the prophylactic study, a side effect 
of the use of pleconaril was increased menstrual irregularities, raising concerns that pleconaril might 
reduce the effectiveness of oral contraceptives. The Food and Drug Administration (FDA) concluded 
that the risks of using pleconaril did not outweigh the potential benefits and no license was given for 
pleconaril as treatment for the common cold.62 After this, the production of pleconaril was stopped and 
currently the drug is not available for clinical use.
Protease inhibitors are another attractive target for antiviral therapy, because proteases are important 
in the viral replication cycle and because they have a  unique and specific viral structure that is not 
present in host-cell proteases.58,63 However, until now only one drug (rupintrivir, Pfizer) entered clinical 
trials (Figure 3.6). Rupintrivir showed in vitro strong antiviral capacity against a broad spectrum of 
rhinoviruses and enteroviruses.64 However, in phase II clinical trials, rupintrivir had only limited effect 
on virus reduction and disease severity in patients with experimental rhinovirus infection, thus halting 
further development for clinical use.61
Currently, treatment of respiratory infection caused by enteroviruses or rhinoviruses in general and EV68 
in particular consists mainly of supportive care and symptomatic treatment (oral or inhaled steroids, 
nasal decongestion, supplemental oxygen, antipyretics).
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Figure 3.6. Structure of AG7088/Rupintrivir.64
Prevention and Control
Currently, no vaccine is available to prevent infections with enteroviruses, with the exception of poliovirus. 
Prevention of an infection thus relies on adequate hygienic measures, particularly in healthcare related 
institutions where vulnerable people are admitted. EV68 is a respiratory pathogen closely related 
to human rhinovirus;  transmission from one infected person to the other most likely occurs via the 
respiratory route. Direct contact with respiratory secretions and subsequent autoinoculation of nose, 
eyes and mouth contribute probably the most to transmission. Enteroviruses and rhinoviruses are 
known to survive for days to weeks upon environmental surfaces. Also, transmission via droplets is likely 
to play a role.
There is no information available about the occurrence of nosocomial infections by EV68. One study 
by Rahamat-Langendoen et al. mentioned three out of 23 hospitalized patients, who acquired EV68 
infection while being admitted in the hospital, based on the time period between first day of illness 
and date of admission to the hospital. This equals a percentage of 13%.19 However, for rhinovirus, 
outbreaks in long term care facilities have been recorded.65,66 Also, an outbreak of rhinovirus species C 
was reported on a neonatal intensive care unit.67 In a hospital based prospective cohort study among 
hospitalized children, 22% of rhinovirus positive disease episodes was acquired in the hospital.68 Besides, 
several clusters of infection could be identified in which nosocomial transmission of rhinovirus on the 
same hospital ward probably occurred. It is likely that nosocomial EV68 infections occur in comparable 
percentages. 
In general,  the detection of a respiratory pathogen leads to the implementation of infection control 
measures to prevent transmission in healthcare institutions. Interventions are focused on the most likely 
route of transmission. For respiratory pathogens, like and including EV68, precautions should be aimed 
at either direct contact with secretions or transmission via droplets. However, infectiousness is probably 
highest in the early stages of disease before the results of diagnostic tests are available. As a consequence, 
the implementation of infection control measures should probably be driven by the presence of 
respiratory symptoms themselves. To what extent asymptomatic patients or patients with only mild 
disease contribute to transmission to others is largely unknown, however the general assumption is that 
symptomatic patients are more likely than asymptomatic ones to spread infections.69 Within families, 
children are thought to be the ones that introduce and spread a respiratory virus, probably because 
of their level of personal hygiene and their need for parental attention.69 The contribution of visiting 
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Recent developments in molecular diagnostic tools have led to the easy and rapid detection of a large 
number of rhinovirus (HRV) strains. However, the lack of clinical and epidemiological data hampers 
the interpretation of these diagnostic findings. From October 2009 to January 2011, we conducted a 
prospective study in hospitalized children in whom samples were taken for the detection of respiratory 
viruses. Clinical, epidemiological and microbiological data from 644 patients with 904 disease episodes 
were collected. When HRV tested positive, strains were further characterized by sequencing the VP4/VP2 
region of the HRV genome. HRV was the single respiratory virus detected in 254 disease episodes (28%). 
Overall, 99 different serotypes were detected (47% HRV-A, 12% HRV-B, 39% HRV-C). Patients with HRV 
had more pulmonary underlying illness compared to patients with no virus (p=0.01), or patients with 
another respiratory virus besides HRV (p=0.007). Furthermore, cough, shortness of breath and a need for 
oxygen was significantly more present in patients with HRV infection. Particularly, patients with HRV-B 
required extra oxygen. No respiratory symptom, except for oxygen need, was predictive of the presence 
of HRV. In 22% of HRV positive disease episodes, HRV infection was hospital acquired. Phylogenetic 
analysis revealed several clusters of HRV; in more than 25% of these clusters epidemiological information 
was suggestive of transmission within specific wards.
In conclusion, the detection of HRV may help in explaining respiratory illness, particular in patients 
with pulmonary comorbidities. Identifying HRV provides opportunities for timely implementation of 
infection control measures to prevent intra hospital transmission.
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Introduction
In recent years, human rhinoviruses (HRVs) have been increasingly recognized as a potential cause 
of acute otitis media, bronchiolitis, asthma and pneumonia in children [1-3]. The development of 
sensitive and rapid molecular techniques markedly improved the detection rate of HRV and revealed 
the high genetic diversity. Over 150 serotypes of HRV have been described, classified into three main 
species: HRV-A,  HRV-B and HRV-C [4].  HRV-C is the most recently discovered species and is thought to 
contribute more to recurrent wheezing and exacerbations of asthma compared to HRV-A and HRV-B 
[1,5]. Also, recently published data suggest that HRV-A and HRV-C cause more severe illness than HRV-B, 
with greatest virulence during the winter [6]. Currently, molecular diagnostics are increasingly integrated 
into routine practice allowing detection and quantification of HRV, thereby also raising questions about 
the value in direct patient care and infection control. We performed a hospital based prospective study 
to determine the clinical, epidemiological and viral characteristics associated with HRV infection in 
children.
Material and methods
Patients and sample collection
In October 2009 a prospective study into respiratory infections in hospitalized children was initiated 
at the University Medical Center Groningen (UMCG), The Netherlands. The UMCG is a tertiary referral 
hospital with more than 1300 beds in the northern region of the country. Demographical, clinical and 
microbiological data were systematically collected from all children under 18 years, of whom respiratory 
samples have been taken for the detection of 15 respiratory viruses (influenza A/B, respiratory syncytial 
virus A/B, coronavirus 229E/NL63/OC43, para-influenzavirus type 1-4, metapneumovirus, adenovirus, 
bocavirus and rhinovirus). Samples positive for HRV were further characterized by sequence analysis of 
the VP4/VP2 region. Information on the presence of bacterial respiratory pathogens was included when 
bacteriological culture was performed at the same day, one day before or one day after the virological 
sample was taken.
Clinical data were collected using a standardized case record form with items regarding the presence of 
an underlying chronic illness (pulmonary, cardiovascular, gastrointestinal, neurological) and/or immune 
suppression (transplantation, malignancy, immune suppressive therapy), clinical symptoms (fever, cough, 
shortness of breath, otitis media, wheezing, vomit, diarrhea, oxygen need, mechanical ventilation), 
treatment (antibiotics, antivirals, inhalation therapy), clinical diagnosis (upper respiratory tract infection: 
pharyngitis, coryza, otitis media; lower respiratory tract infection: pneumonia, bronchiolitis, exacerbation 
of asthma, croup) and outcome. Pulmonary underlying illness included asthma, congenital pulmonary 
illness or anatomic malformations, cystic fibrosis and broncho-pulmonary disease. Cardiovascular 
disease was divided into inborn or acquired heart disease. Patients with partial resection of bowel, 
failure to thrive, and those who were waiting for a liver transplantation, were categorized as having 
gastrointestinal disease as underlying illness. Neurological disease was not further specified.  
Epidemiological data were gathered to determine whether the respiratory infection was community or 
hospital acquired, including measures that were taken in the hospital to prevent further transmission of 
respiratory viruses. Hospital acquired HRV infection was defined as a first day of illness two or more days 
after admission to the hospital. Infection control measures consisted of a combination of droplet and 
contact precautions (gown, gloves and mask for health care workers during patient care, patient in one 
person room) and were installed when HRV was detected. 
The study was approved by the local Medical Ethical Committee of the UMCG. Informed consent was 
obtained from parent or guardian.
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Real-time PCR and sequencing
The majority of samples (91%) arrived at the laboratory within one day after collection. Samples were 
divided in aliquots and stored at  4° Celsius if PCR testing was performed the same or the next day. 
Longer storage was carried out at -80° Celsius. In general, PCR testing was performed on a daily basis, 
providing results within 48 hours after arrival of the sample at the laboratory. 
All respiratory samples, either nasopharyngeal swabs, aspirates or sputum, were tested by a laboratory 
developed (LDT) real-time PCR as has been described elsewhere [7]. For rhinovirus detection, a real-time 
LDT-PCR was introduced using the SuperScript® III Platinum® One-Step qRT-PCR Kit. All reactions were 
performed with Phocine Distemper Virusas an internal control in a total volume of 25 µl containing 12.5 
µl of 2x reactionmix, 0,5 µl SuperScript® III RT/ Platinum® Taq mix, 0,5 µl of 1:10 Rox reference dye, 300 
nM of each forward primers, 600 nM reverse primer and 100 nM of each probe, and 5 µl of genomic RNA 
template. Primers and probes used are listed in Table 4.1. The inclusion of this large set of primers and 
probes is performed in a specific reaction to avoid bias and favoring against other respiratory viruses. Our 
rhinovirus PCR has been optimized during the last years based on the available genetic information, in 
particular regarding species C. By re-optimizing  the assay with new primers and probes, together with 
the use of Invitrogen SuperScript enzymes, we detected retrospectively more HRV positive samples at a 
lower Ct value. To ensure that these HRVs were not enteroviruses, all samples were sequenced. We only 
detected HRV, eventually 99 serotypes, as well as enterovirus 68, which is genetically identical to HRV. 
The cycle threshold (Ct) value (the number of amplification cycles needed for a PCR to become positive) 
was used as relative estimate for the amount of HRV present in the samples. 
Characterization of HRV was done by amplification and sequencing of a 549 nucleotide fragment 
spanning the hypervariable part of the 5’NTR, the entire VP4 gene and the 5’ terminus of the VP2 gene as 
described before [8,9]. For phylogenetic analysis a fragment of 395-401 bp were aligned with Clustal W 
2.0 and phylogenetic trees were constructed by the neighbor-joining method using MEGA 4.0 with the 
maximum likelihood model and complete deletion for missing data. The HRV sequences derived from 
this work are submitted to GenBank (accession numbers JQ042307-JQ042680).
Table 4.1. Primers and probes for HRV detection used in this study.
Primers/probes Sequence (5’ 3’) Position* Tm**
Rhino-fwdB-mod-TM GGTGTGAAGACTCGCATGTGC 408-427 60.1
Rhino-fwdA-mod-TM GGTGTGAAGAGCCCCGTGTG 408-426 62.4
Rhino-fwd-C-TM  GGTGTGAAGAGCCNANTGYGCTC 408-429 58.9
Rhino-fwd-D-TM GGTGYGAAGANCCNANTGTGC 408-427 58.9
Rhino-fwd-E-TM  GGTGTGAAGACYTGCATGTGC 408-427 57.9
Rhino-fwd-F-TM GGTGTGAAGAGYCNCGTGTGCT 408-428 58.1
Rhino-rev3 CCAAAGTAGTYGGTYCCRTCCC 523-544 58.4
Rhino-Probe-TM TCCTCCGGCCCCTGAATGCG 438-457 70.2
Rhino-Probe3 TCCTCCGGCCCCTGAATGTGG 438-458 69.1
*Primer positions are given according to the orientation of the primer; numbers are given according to a HRV-A16 reference strain 
(GenBank no. L24917)
**) Tm = melting temperature
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Data analysis
For data analysis, the first respiratory sample of each episode of infection was included. An episode of 
infection, or disease episode, was defined as a time period starting with a first day of illness and ending 
with discharge from the hospital or resolvement of clinical symptoms, during which a respiratory sample 
was taken for viral diagnostics. Statistical analyses were performed using SPSS software version 20.0. For 
normally distributed continuous variables, parametric tests were used (Student t-test). The distribution 
of categorical variables in comparison groups were analyzed using the Chi-square test. The association 
of HRV with chronic underlying illness and symptoms was determined using binary and multinomial 
logistic regression (with no infection, HRV mono-infection, HRV mixed infection, other respiratory 
infection as the dependent variable). A two sided p-value < 0.05 was considered statistically significant.
Results
Patients characteristics 
From October 2009 till January 2011, 644 unique patients were included with 904 disease episodes, 366 
(57%) were male and 278 (43%) female. Characteristics of the patients with no virus detected (n=242, 
with 341 disease episodes), those with only HRV (n=162, 254 disease episodes) and those with another 
respiratory virus than HRV (n=157, 195 disease episodes) are summarized in Table 4.2. In 83 patients 
(111 disease episodes), mixed infection of HRV with one or more other respiratory viruses was found, 
most frequently adenovirus (37 episodes), RSV-A/B (35 episodes), bocavirus (20 episodes) and influenza 
A virus (11 episodes). These patients did not differ significantly from the ones with HRV mono-infection 
(Table 4.2).
Table 4.2. Characteristics of patients with no respiratory virus detected (PCR negative), with HRV mono- or mixed infection and with 
another respiratory virus than HRV.





N=242 (%) N=162 (%) N=83 (%) N=157 (%)
















Underlying illness 142 (58.7) 108 (66.7)*b 45 (54.2) 69 (43.9)
Pulmonary 52 (21.5) 54 (33.3)*c 19 (22.9) 31 (19.7)
Cardiovascular 50 (20.7) 37 (22.8) 12 (14.4) 15 (9.6) *d
Gastro-intestinal 33 (13.6) 14 (8.6) 8 (9.6) 8 (5.1)
Neurology 21 (8.7) 15 (9.3) 7 (8.4) 13 (8.2)
Immune suppression† 36 (14.9) 36 (22.2) 11 (13.3) 14 (8.9)
*a p<0.0001
*bHRV mono-infection versus other virus: p<0.001
*cHRV mono-infection versus PCR negative p=0.01, versus other virus p=0.007
*dother virus versus PCR negative p=0.003, other virus versus HRV mono-infection p=0.001
†malignancy, transplantation, use of immune-suppressive therapy
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Patients with HRV infection had more pulmonary underlying illness, mainly caused by asthma (39%) 
or congenital pulmonary illness/anatomic malformations (44%), compared to PCR negative patients 
(p=0.01) or patients with another respiratory virus than HRV (p=0.007). 
Although the majority of patients were under the age of 5 years (80%), the prevalence of underlying 
illness was significantly higher in patients older than 5 years: in patients with HRV mono-infection, 86% 
had comorbidities compared to 64% in those under 5 (p=0.03), for PCR negatives this was 83% versus 
56% (p=0.001) and in patients with another respiratory virus 70% had a chronic underlying disease 
compared to 38% in those under 5 (p=0.002). These differences in prevalence of chronic underlying 
disease was mainly caused by a significantly higher prevalence of chronic respiratory disease in the older 
age category (data not shown).
Clinical symptoms
To determine the relationship between HRV and clinical symptoms, PCR negative disease episodes were 
compared with those with a HRV mono-infection. Because patients with HRV had significantly more 
chronic respiratory disease, we stratified disease episodes for this underlying condition. HRV positive 
patients who also had a chronic respiratory disease, experienced significantly more cough, shortness of 
breath and a need for oxygen compared to PCR negatives. However, in HRV positive patients without a 
pulmonary underlying illness, only cough and fever were significantly more present (Table 4.3).









N= 139 episodes (%)
fever 29 (34.9) 48 (49.0) 111 (46.6) 82 (59.0)§a
cough 13 (15.7) 38 (38.8)*a 28 (11.8) 35 (25.2) §b
dyspnoea 18 (21.7) 54 (55.1)*b 53 (22.3) 34 (24.5)
diarrhoea 4 (4.8) 12 (12.2) 27 (11.3) 24 (17.3)
vomit 6 (7.2) 12 (12.2) 27 (11.3) 19 (13.7)
oxygen need 31 (37.3) 62 (63.3)*c 57 (23.9) 29 (20.9)
mechanical ventilation 34 (41.0) 30 (30.6) 91 (38.2) 40 (28.8)
*ap=0.001 (HRV positives versus PCR negatives in patients with pulmonary underlying illness)
*bp < 0.001 (HRV positives versus PCR negatives in patients with pulmonary underlying illness)
*cp=0.001 (HRV positives versus PCR negatives in patients with pulmonary underlying illness)
§ap=0.02 (HRV positives versus PCR negatives in patients with no pulmonary underlying illness)
§bp=0.001(HRV positives versus PCR negatives in patients with no pulmonary underlying illness)
Pulmonary underlying illness No pulmonary underlying illness
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In multivariate analysis, the presence of a chronic respiratory disease remained positively associated with 
HRV mono-infection (OR 2.06, CI 1.43-2.97). This association was unique for HRV mono-infections and 
was not found for HRV mixed infections or other respiratory viral infections. Besides, in patients with a 
chronic respiratory illness a need for oxygen was exclusively related to HRV detection (odds ratio 3 for 
HRV mono-infection, and 3.3 for mixed infection). Cough and shortness of breath were equally strongly 
associated with the detection of other respiratory viruses as with HRV (Table 4.4). 



















































a) OR, odds ratio
b) CI, 95% confidence interval
Patients with a HRV infection were more often diagnosed with an exacerbation of asthma compared 
to PCR negatives and to patients with another respiratory virus, although the difference with the latter 
group was not statistically significant (Table 4.5). In contrast, pneumonia and bronchiolitis was more 
often associated with the detection of other respiratory viruses than HRV.
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Table 4.5. Clinical diagnosis in patients with HRV compared to patients who were PCR negative or who had another respiratory virus 
(% of episodes).
Clinical diagnosis PCR negative HRV infection Other respiratory virus
Upper respiratory tract 
infection
13.5% 52.8%a 49.7%a
Otitis media 0.9% 1.2% 3.6%
Exacerbation asthma 0.6% 5.1%b 1.0%
Bronchiolitis 0.9% 2.0% 15.4%c
Pneumonia 10.9% 12.2% 18.5%d
a) p<0.001 compared to PCR negative
b) p=0.008 compared to PCR negative, p=0.12 compared to other respiratory virus
c) p<0.001 compared to PCR negative and HRV positive 
d) p=0.02 compared to PCR negative, p=0.04 compared to HRV positive
The median length of stay in the hospital was significantly shorter for patients who had any respiratory 
virus compared to patients with no virus (7 days versus 25 days, p<0.001). Also, patients with HRV had 
to stay longer in the hospital compared to patients with another respiratory virus (median length of stay 
11 days versus 6 days, p<0.001).
The median Ct value of HRV in HRV mono-infection was 24, significantly lower than the median Ct value 
of HRV in HRV mixed infections (28, p< 0.001). However, we found no relationship between the presence 
of symptoms and the relative amount of virus in the samples.
Bacteriology and antibiotic use
Antibiotic use did not differ between the three patient groups (in 52% of PCR negatives, 50% of 
those with HRV and 53% with another respiratory virus, antibiotics were given). Also, the duration 
of antibiotic therapy was comparable (median duration of 7 days). In more than 60% of the disease 
episodes, no bacteriological culture was recorded around the time the virological sample was taken. 
In case bacteriological cultures were taken, significantly more H. influenzae was found in patients with 
HRV (17.4%, p=0.04) and in patients with another respiratory virus (19.4%, p=0.02) compared to the 
patients who had no respiratory virus detected (3.6%). S. pneumoniae was more often found in patients 
with another respiratory virus (19.4%) than in patients with HRV (2.2%, p=0.02).  The use of antibiotics 
was strongly associated with the clinical diagnosis pneumonia and the submission of samples for 
bacteriological culture: antibiotics were prescribed in 94% of the patients with pneumonia and in 75% 
of patients who had samples collected for bacteriological culture (both p<0.001). However, the outcome 
of the bacteriological culture (positive or negative) did not influence the use of antibiotics (p=0.5), nor 
did the presence of a chronic underlying illness (p=0.6).
HRV characterization
HRV was found throughout the study period, with the least frequent detection during February, July 
and August 2010 and peaks in spring (2010) and fall (2009 and 2010) (Figure 4.1). Still, during the winter 
period (December and January) HRV was detected in 40%-60% of the samples positive for respiratory 
viruses.
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Figure 4.1. Monthly distribution of the number of respiratory specimen taken in our patient population, the number of HRV 
detections (either as mono-infection or mixed infection) and the number of detected respiratory viruses other than HRV (non-HRV 
positive).
Sequence analysis of HRV was possible in 303 out of 365 HRV positive disease episodes; 221 episodes 
with HRV mono-infection and 82 with HRV mixed infection. The reason for unsuccessful sequence 
analysis was the low amount of HRV present in the samples. 
Overall, 99 different serotypes were detected, most often species HRV-A (47%) and HRV-C (39%) (Figure 
4.2). In 12% of the episodes, HRVs were detected belonging to species HRV-B. We did not observe a trend 
in circulating serotypes. Almost 50 patients were identified with serial infections with different serotypes 
or with different species. Three patients had detection of serotypes belonging to HRV-A, HRV-B and 
HRV-C consecutively. 
In patients with HRV-B, more pulmonary underlying illness was present (54%) compared to those 
with HRV-A and HRV-C (32% and 39%), although the difference was only statistically significant for the 
comparison of HRV-B with HRV-A (p=0.045). No significant differences were seen in clinical symptoms 
related to the species of HRV, except for the need for oxygen which was more present in patients with 
HRV-B (p=0.012). Patients with HRV-C had a shorter duration of stay in the hospital than patients with 










number of specimen 
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Figure 4.2. Phylogenetic tree of detected HRV serotypes in this study. In red the clusters of infection based on epidemiological and 
virological information. In bold the clusters of EV68 as described before [8].
Nosocomial infection
Based on epidemiological data (first day of illness in relation to admission to the hospital), hospital 
acquired infection was present in 81 out of 365 HRV positive episodes (22%), with a first day of illness 
ranging from 3 to 242 days after admission. In 69 of 81 episodes (85.2%) HRV was detected as a mono-
infection, compared to 179 out of 273 (66%) community acquired HRV infections (p<0.001). Even when 
the definition of hospital acquired infection was adjusted to a first day of illness five days or more after 
admission, still 20% of the HRV positive disease episodes were nosocomial related. No differences were 
observed in the age distribution in community and hospital acquired HRV infections. Although HRV-B 
was the least frequently detected HRV species, equal proportions of HRV-A and HRV-B infection were 
hospital acquired (33.3% resp. 38.5%), while HRV-C was in only 18.0% of the HRV positive episodes 
acquired during hospitalization. Due to the small number of HRV-B infections, these differences did 
not reach statistical significance. Using phylogenetic analysis, 41 clusters of three or more isolates with 
identical sequences could be identified during this study period. Nine of the 41 clusters were formed by 
three or more consecutively taken isolates from one patient per cluster.
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Two clusters of EV68 were identified, corresponding with an upsurge of EV68 related respiratory tract 
infections detected in the autumn of 2010, as described previously [8]. We collected more detailed 
information about the wards patients were admitted to, first day of illness, date of admission and sample 
date in the remaining 30 clusters, to see whether the clustering of patients based on the virological 
analysis was supported by epidemiological data. In 8 clusters epidemiological information was 
suggestive of transmission of HRV on the same hospital ward (Figure 4.2).
Discussion
In this large hospital-based prospective cohort study into viral respiratory infections in children, HRV 
was the most commonly detected respiratory virus, in majority as HRV mono-infections. Also, high 
nosocomial infection rates were observed. HRV infection was associated with substantial respiratory 
illness, especially among children with pre-existing pulmonary disease. 
Although the association of HRV with asthma is well established in recent years, the occurrence of HRV-
infections in our study was associated with chronic respiratory illness in general [5,10,11]. Whether these 
children are more vulnerable for the acquisition of HRV, or whether they have more symptomatic illness 
related to HRV, remains to be elucidated. In patients with a chronic respiratory condition, only the need 
for oxygen was predictive for HRV detection; cough and shortness of breath was not only associated 
with the detection of HRV, but also with the detection of other respiratory viruses. Thus, respiratory 
symptoms alone are not sufficient to predict the presence of a HRV infection.
Several studies tried to relate viral load with the presence or absence of symptoms. Although a positive 
relationship between a higher viral load and more (serious) respiratory symptoms has been reported, 
others were not able to reproduce these findings [11-15]. Adequate quantification of HRV in respiratory 
samples is currently limited by several factors, as addressed in recent reports [16,17]. One major limitation 
is the lack of a reference standard for the quantification of all HRV types. Secondly, HRV viral load is 
affected by the sample type and the method of collection and detection [18]. Thus, although in our 
study no relationship between the relative amount of virus (expressed as Ct value) and the presence of 
clinical symptoms could be demonstrated, the interpretation of Ct value in relation to severity of illness 
remains to be determined and is probably, with the current limitations in quantification of HRV, hardly 
feasible.
HRV was detected year round, with the least frequent detection in February, July and August 2010. 
Although peaks in detection were seen in fall and spring, as is known from literature, HRV was still 
detected in around half of the samples positive for respiratory viruses in the remaining months, including 
the winter period [6,17,19]. However, as most studies suggest variation of HRV detection by season and 
year, our study period may well have been too short to fully understand the seasonality of HRV in our 
hospital. 
Antibiotic use and duration of antibiotic therapy did not differ between the patients with and without 
a respiratory viral infection, suggesting that the decision to prescribe antibiotics was not influenced by 
the outcome of viral diagnostics, as has been observed elsewhere [20,21]. This might be explained by 
the concern of getting a bacterial co-infection. Indeed, antibiotic use was associated with submission 
of samples for bacteriological culture, assuming a suspicion of bacterial infection in those patients. 
However, although bacteria known to cause (secondary) respiratory infections in infants were more 
frequently cultured in patients with a respiratory viral infection compared to patients with no viral 
infection (H. influenzae,  S. pneumoniae), the outcome of the bacteriological cultures did not influence 
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the use of antibiotics. Because the collection of samples for bacteriological culture was not standardized, 
but dependent on the judgment of the clinician and were taken in only a minority of patients, these 
results might have been biased and more studies are needed to confirm our findings.
The high prevalence of co-morbidities and the associated vulnerability of our patient population 
could have lowered the threshold for prescribing antibiotics. However, we did not find a positive 
association between antibiotic therapy and the presence of a chronic underlying illness. We did find a 
strong correlation between antibiotic therapy and pneumonia as clinical diagnosis. This may suggest 
that clinical signs and symptoms were more important in deciding on antibiotic therapy than patient 
characteristics and microbiological results.
Sequence analysis revealed a high diversity of different HRV serotypes, as reported before [22-24]. In our 
population, species HRV-A and HRV-C were detected in equal amounts, and dominated over HRV-B. 
We observed no species specific pattern of clinical illness, except that HRV-B was associated with a 
higher need for oxygen. Besides, patients with HRV-A and HRV-B had to stay in the hospital significantly 
longer than patients with HRV-C. Until now, studies that addressed the relationship between species 
and severity of illness reported HRV-B as being the least virulent compared to HRV-A and HRV-C 
[6,17]. However, recently Miller et al. also showed that patients with HRV-B were more likely to require 
supplemental oxygen and had a longer duration of stay in the hospital [19]. Also, patients with HRV-B 
tended to have higher disease severity scores. The reason for the different observations regarding HRV-B 
associated severity of illness is not clear. Our study and the study of Miller et al. included hospitalized 
children, whereas in a recent study of Lee et al, who showed a clear distinction in severity of illness 
between HRV-A/C and HRV-B, the majority of patients were not admitted to the hospital [6]. Besides, 
we observed  a tendency for more chronic respiratory illness in patients with a HRV-B infection, possibly 
explaining the higher need for oxygen. These findings may suggest that HRV-B is associated with either 
asymptomatic carriage or mild respiratory disease, and that host factors like pre-existing pulmonary 
disease contribute to more serious, symptomatic respiratory illness caused by HRV-B. One of the most 
remarkable findings of our study is the frequency of hospital acquired HRV infection: in more than 20% 
of the HRV positive disease episodes, patients had a first day of illness more than 2 days after admission 
to the hospital. Phylogenetic analysis revealed several clusters of HRV with identical sequences; in more 
than 25% of these clusters epidemiological information was suggestive of transmission of the virus 
on specific wards. Although HRV-B is the least frequently found species in our study, almost 40% of 
HRV-B infections are acquired in the hospital. This suggests that the hospital environment is for some 
reason more favorable for transmission of HRV-B. Also, if HRV-B is indeed associated with asymptomatic 
carriage or mild respiratory disease, this would facilitate transmission within the hospital, only causing 
clear respiratory symptoms in patients with pre-existing pulmonary illness.
Outbreaks of rhinovirus infections have been described in long-term care facilities, but very little is 
known about the frequency of hospital acquired HRV infection [25,26]. Transmission mainly occurs via 
droplets or contact and although measures to prevent transmission were taken the moment HRV was 
detected in respiratory samples, infectiousness is probably highest in the early stages of disease, before 
the outcome of diagnostic tests is available and thus before infection control measures were taken. 
These findings advocates the implementation of infection control measures driven by the presence of 
respiratory symptoms instead of the outcome of a laboratory test. However, further investigations are 
needed to determine the contribution of health care workers, other patients  and visitors in nosocomial 
transmission of HRV.
Chapter 4390 71
The present study has some limitations. Being a tertiary referral hospital could have biased our findings 
towards more serious illness, as is reflected by the characteristics of the included patients: more than 
50% of the children had a chronic underlying illness, and even in the ones that had no respiratory virus 
detected, signs and symptoms of serious illness were present (e.g. mechanical ventilation). Furthermore, 
information on bacterial co-infection was based on cultures taken just around the time the viral 
sample was taken. Information on the presence of bacterial pathogens outside this timeframe was not 
included. Also, we had no information about the presence of so called atypical bacterial pathogens 
(eg Mycoplasma or Chlamydophila). However, given the high prevalence of HRV infection in our study 
population and the expected low prevalence of atypical pathogens, we assume that this limitation does 
not influence the main conclusions of our study [20,21].
In conclusion, HRVs are capable of causing serious respiratory disease in children hospitalized in a 
tertiary referral hospital, particularly in patients with pulmonary co-morbidities. Nosocomial infection 
occurs frequently. Most notably, HRV species B may have features that facilitate transmission within the 
hospital. Although antiviral therapy is not yet available for patients infected with HRV, the detection and 
identification of these viruses could help in explaining respiratory illness. Also, identifying HRV provides 
opportunities for implementing timely and accurately infection control measures to prevent further 
transmission. Our study illustrates the value of sequence analysis not only in gaining insight into the 
genetic diversity of rhinoviruses, but also as a tool in defining transmission routes within the hospital and 
in the detection of sources of nosocomial infection.
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Comparative data on severity and treatment of seasonal, pandemic and post-pandemic influenza virus 
infections are scarce.
Objectives
To systematically analyze characteristics of hospitalized patients with influenza in the post-pandemic 
period compared to seasonal and pandemic influenza.
Study Design
Clinical and virological data of patients hospitalized in a tertiary referral hospital with post-pandemic 
influenza (2010- 2011) were compared with those during seasonal influenza epidemics (2007- 2009) and 
the influenza A(H1N1)pdm09 pandemic (2009- 2010).
Results
82 patients were admitted during the post-pandemic period, compared to 85 during the pandemic and 
60 during seasonal influenza epidemics. No differences were observed in the occurrence of complicated 
illness and the need for intensive care. However, radiographic pneumonia was significantly more often 
diagnosed in patients with influenza A(H1N1)pdm09 compared to patients with seasonal influenza A 
(25% versus 71% in pandemic, p=0.004, and 55% in post-pandemic, p=0.047). Oseltamivir was more 
frequently prescribed in post-pandemic and pandemic patients compared to previous influenza seasons 
(48.9% resp. 76.5% versus 6.5%, p< 0.0001). During the post-pandemic period, patients with influenza 
B were significantly less often treated with oseltamivir compared to patients with influenza A (27.0% 
versus 48.9%, p=0.043), although the course of illness in patients with influenza B was comparable with 
influenza A. No upsurge of oseltamivir resistance was observed.
Conclusions
In our center, severity of illness was comparable for all influenza seasons, although more radiographic 
pneumonia was diagnosed in patients with influenza A(H1N1)pdm09. Despite the increased use of 
oseltamivir, no increase in oseltamivir resistance was detected.
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Background
In March 2009 a novel influenza A H1N1 virus ‘influenza A(H1N1)pdm09’ emerged and rapidly spread 
around the world causing the first pandemic of this century. Although severe illness and death have 
been reported, it was mostly regarded as a relatively mild disease, with a course of illness comparable 
to seasonal influenza.1-4 Historically, influenza in the immediate post-pandemic period has been known 
to be able to cause severe morbidity and mortality.5 Indeed, some countries reported a more severe 
influenza season in 2010-2011 compared to the pandemic waves.6 However, data based on systematic 
analysis of the impact of influenza in the post-pandemic period are scarce.
Objectives
In order to compare the characteristics of influenza in hospitalized patients in the post-pandemic period 
to those with seasonal and pandemic influenza, we systematically collected clinical information of 
patients hospitalized in a tertiary referral hospital with influenza from 2007-2011.
Study design
Study population
A retrospective observational study was conducted in all patients with influenza infection hospitalized 
in the University Medical Center Groningen (UMCG) from August 2007 till July 2011. Patients with 
acute respiratory illness were tested; only patients with real-time PCR (RT-PCR) confirmed influenza 
were included in the study. The UMCG is a large tertiary referral hospital with over 1300 beds in the 
northern region of the Netherlands. Patients were divided into three cohorts: patients with seasonal 
influenza (August 2007-May 2009), patients with pandemic influenza (June 2009-July 2010) and those 
with influenza during the first post-pandemic season (August 2010-July 2011). We compared clinical, 
epidemiological and virological data of patients with confirmed influenza A separately from those with 
influenza B infection. 
Clinical data and definitions
Clinical information was gathered using a standardized questionnaire, including clinical symptoms, 
underlying chronic illness, medical complications, and treatment. Influenza vaccination history was 
initially included in the questionnaire, however because this was poorly documented in patients 
records, it had to be excluded for analysis. Complications were listed as pulmonary (pneumonia, 
respiratory insufficiency, pneumothorax, other pulmonary symptoms) or extra-pulmonary (renal 
failure, sepsis, neurological symptoms). Radiographic findings were classified into infiltrates, pleural 
effusion, interstitial abnormalities and pneumothorax. Bacterial co-infection was defined by isolation 
of a significant pathogen in respiratory or blood samples of a patient within 3 days before or after the 
detection of influenza. Time from onset of symptoms to admission and to sample date was calculated 
for each patient. 
Laboratory methods
Nasopharyngeal swabs or nasopharyngeal aspirates were taken for the detection of respiratory viruses 
by a laboratory developed RT-PCR as has been described before.7,8 In 11% of patients, sputum was 
used. Identification of influenza types and subtypes during 2007-2011 was performed as described 
elsewhere.9-12 In short, RNA was isolated using the NucliSense EasyMag (bioMérieux, Lyon, France), or 
Magna Pure LC Total Nucleic Acid Isolation kit with external lysis protocol (Roche Diagnostics, Indianapolis, 
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Table 5.1. Primers used for screening and identification of influenza viruses used in this study (with adjustments from April 2011 
onwards)
Target Aim Primer Oligotide sequence 5’ => 3’ and labels









































USA). Both influenza A and influenza B were detected by generic RT-PCR assay targeting the matrix 
gene. Multiple primers were used for screening and subtyping (Table 5.1). All influenza A(H1N1) positive 
samples were subsequently screened for the presence of the H275Y mutation in the neuraminidase 
gene (N1 nomenclature), conferring full resistance to oseltamivir.12
Statistical analysis
Statistical analyses were performed using SPSS version 18.0 (Chicago, USA). Interseasonal comparisons 
were tested using Mann Whitney U test and Fisher’s exact test for continuous variables. Dichotomous 
variables were tested using χ2 test. The effect of age on outcome was analyzed using multinomial 
logistic regression, for which each cohort was divided in two groups: patients under the age of 15 and 
those above. P values ≤ 0.05 were considered as statistically significant.
Results
A total of 227 patients with confirmed influenza were included in the study: 60 patients during the pre-
pandemic seasons (47 with influenza A, of which 33 with influenza A(H3N2)), 85 during the pandemic 
(all influenza A(H1N1)pdm09), and 82 in the post-pandemic period (45 with influenza A(H1N1)pdm09, 
37 with influenza B) (Figure 5.1). For analysis, the pre-pandemic seasons (2007-2009) were compiled as 
no significant differences were observed with regard to patients’ characteristics, course of illness and 
clinical outcomes (data not shown).
Figure 5.1. Influenza (sub)type distribution during influenza seasons 2007-2011
Influenza A ntb=influenza A, subtype not determined
Influenza A
Characteristics of patients with influenza A are summarized in Table 5.2. No significant differences were 
observed in gender ratio, although there was a tendency towards more male patients admitted during 
the pandemic and post-pandemic period (57.6% and 55.6% versus 42.7% during seasonal influenza, 
p=0.11 resp. p=0.30) Age distribution among patients with seasonal, pandemic and post-pandemic 
influenza A differed significantly (Table 5.3). Fourty percent of patients hospitalized with seasonal 
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During the pandemic, a shift towards young adolescents was observed: almost 25% of patients with 
pandemic influenza A were aged 5-14 years, significantly more than during seasonal and post-pandemic 
influenza. In the post-pandemic period more patients aged 15-64 years were admitted (71%) compared 
to patients with seasonal influenza (38%, p=0.002) and with pandemic influenza (45%, p=0.004).
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Male gender (%) 42.6 57.6 55.6






Underlying medical condition (%) 87.2** 70.6 80.0
Timespan, median in days (IQR)
• From symptom onset to admission
• 
• From symptom onset to sample date
• 



















Received oseltamivir therapy (%) 6.5 76.5§ 48.9
Resistance to oseltamivir (absolute numbers) 4 4 1
Admitted to ICU (%) 25.5 29.4 22.2
Experienced complications (%) 38.3 49.4‡ 40.0
Death (absolute numbers) 3 7 3
IQR=interquartile ranges
*)   p=0.004 post-pandemic influenza A versus pandemic influenza A
**) p=0.03 seasonal influenza A versus pandemic influenza A
¶)   p=0.03 post-pandemic influenza A versus seasonal influenza A
†)   p=0.02 seasonal influenza A versus pandemic influenza A, p=0.008 seasonal influenza A versus post-pandemic influenza A
§)   p<0.0001 pandemic influenza A and post-pandemic influenza A versus seasonal influenza A, p=0.001 pandemic influenza A versus 
post-pandemic influenza A
‡)  p=0.2 pandemic influenza A versus seasonal influenza A
Chapter 5390 81
Table 5.3. Age distribution in patients with seasonal, pandemic and post-pandemic influenza A
 
seasonal influenza A 
(n = 22)
pandemic influenza A 
(n = 44)
post-pandemic influenza A
 (n = 11)
0-4 years 40.4% 21.7% 20.0%*
5-14 years 6.4% 24.7%** 4.4%
15-64 years 38.3% 44.7% 71.1%†
> 65 years 14.9%§ 3.5% 4.4%
  *) p=0.03 post-pandemic influenza A versus seasonal influenza A
**) p=0.004 pandemic influenza A versus post-pandemic influenza A, p=0.009 pandemic influenza A versus seasonal influenza A
   †) p=0.002 post-pandemic influenza A versus seasonal influenza A, p=0.004 post-pandemic influenza A versus pandemic influenza A
   §) p= 0.02 seasonal influenza A versus pandemic influenza A
The course of illness in patients with influenza A was similar for all seasons. No significant differences 
were observed in the occurrence of complicated illness and the need for admission to the intensive 
care unit (ICU), also after adjustment for the differences in age distribution (Table 5.2). During all 
seasons, patients were admitted to the hospital within a median time of 3 days after onset of symptoms, 
independent of the presence of complicated illness or necessity for ICU admittance. No differences in 
duration of hospitalization were seen; only complicated illness was associated with a longer hospital 
stay (p<0.0001, data not shown). In patients admitted during the pandemic and post-pandemic period, 
respiratory samples for the detection of influenza were taken significantly more rapidly compared to 
patients admitted in previous influenza seasons. 
Chronic underlying illness was significantly less present in patients with pandemic influenza A compared 
to those with seasonal influenza A (70.6% versus 87.2%, p=0.03). However, when adjusted for age, no 
significant differences of comorbidities were detected between the three influenza periods in patients 
over 15 years. In both the pandemic and post-pandemic period, comorbidites were significantly less 
present in patients under the age of 15: 59.1% with pandemic influenza A (p=0.025) and 54.4% with 
post-pandemic influenza A (p=0.044) compared to 86.4% of patients with seasonal influenza A.
The most remarkable differences however were seen in oseltamivir treatment: oseltamivir was more 
frequently prescribed in pandemic patients compared to previous influenza seasons (76.5% versus 6.5%, 
p< 0.0001). In the post-pandemic period, prescription rates diminished although still more patients 
received antiviral therapy compared to those with seasonal influenza A (48.9% versus 6.5%, p<0.0001). 
These differences remained after adjustment for the differences in age distribution. 
During the pandemic, patients not treated with oseltamivir were significantly younger, had less 
chronic underlying illness, were admitted to the hospital later in the course of illness and had to stay 
hospitalized relatively shortly compared to those who were treated with oseltamivir. Also, patients not 
treated with oseltamivir were less frequently admitted to the ICU (Table 5.4). During the post-pandemic 
period however, these differences between patients with and without oseltamivir treatment were not 
observed. Despite the strong increase in oseltamivir treatment, no increase in oseltamivir resistance 
was detected. During the seasonal influenza period, all oseltamivir resistant influenza A were subtyped 
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as influenza A(H1N1), as was expected considering reports of emerging oseltamivir-resistant seasonal 
influenza A(H1N1) since 2007.13 During the pandemic and post-pandemic period, four out of five 
patients developed oseltamivir resistance while being treated with oseltamivir; one patient was infected 
with primarily oseltamivir resistant influenza A(H1N1)pdm09.







age (median, years) 26.4 2.9 p=0.001
underlying illness (% of patients) 78.5 45.0 p=0.004
ICU admittance (% of patients) 35.4 10.0 p=0.047
complications (% of patients) 53.8 35.0 NS
duration of illness at 
admission(median, days)
2.0 3.5 p=0.024
length of hospital stay (median, days) 6.0 2.0 p=0.006
ICU=intensive care unit
NS=not statistically significant
Chest radiographs were performed in 68%, 67% and 76% of patients with seasonal, pandemic and post-
pandemic influenza A respectively. Radiographic abnormalities were reported in similar frequencies in 
pandemic and post-pandemic influenza A (60% and 59%), more than in seasonal influenza A (37.5%) 
although statistical significance could not be reached. Compared to seasonal influenza A however, 
radiographic pneumonia (25% in seasonal influenza A) was more often diagnosed in patients during 
the pandemic (71%, p=0.004) and post-pandemic period (55%, p=0.047). No significant differences 
were seen in isolated bacterial pathogens between all influenza seasons. Also, no difference was seen in 
the prescription rate of antibiotics: during all seasons approximately 70% of patients were treated with 
antibiotics. 
Influenza B
In the study period, 50 patients were included with confirmed influenza B infection, 13 during pre-
pandemic seasons, and 37 during the post-pandemic period. No differences were seen in patients’ 
characteristics and course of illness between patients with post-pandemic influenza B compared to 
those with seasonal influenza B. The clinical characteristics of patients with influenza B were remarkably 
similar to those with influenza A (Table 5.5). However, during the post-pandemic period, patients with 
influenza B were significantly less often treated with oseltamivir compared to patients with influenza 
A (27.0% versus 48.9%, p=0.043). Patients with post-pandemic influenza B were admitted later in the 
course of illness (median 3 versus 2.5 days, p=0.028) and were also tested later for the presence of 
influenza (median 4 versus 3 days, p=0.006).
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Underlying illness 41 (87.2) 10 (76.9) 36 (80.0) 31 (83.3)
ICU admittance 12 (25.5) 4 (30.8) 10 (22.2) 10 (27.0)
complications 18 (38.3) 6 (46.2) 18 (40.0) 17 (45.9)
Oseltamivir 
treatment
3 (6.4) 3 (23.1) 22 (48.9) 10 (27.0)*
*) p=0.043, post-pandemic influenza B versus post-pandemic influenza A
Discussion
Our study is one of the first to systematically assess the clinical, epidemiological and virological 
characteristics of patients with post-pandemic influenza. Influenza in the post-pandemic period, 
including both influenza A and influenza B, was in our center equally severe as the pandemic in terms of 
the number of patients admitted. The course of illness in patients with influenza A was comparable for 
all seasons, indicating no increased severity of influenza A(H1N1)pdm09 compared to other influenza 
A subtypes. Besides, patients with influenza B displayed similar clinical characteristics as those with 
influenza A. However, several aspects are noteworthy.
The age distribution of patients admitted with influenza differed significantly in the three study 
periods. Patients with seasonal influenza displayed the well known age distribution with relatively more 
infections in the young (<4 years) and the old (> 65 years) compared to pandemic and post-pandemic 
periods. During the pandemic, a shift was noticed towards the school-aged and adolescent population, 
as has been described by others.2,14,15 The relative lower risk of infection among older individuals has 
been explained by the presence of cross reactive antibodies due to exposure to circulating descendants 
of the 1918 H1N1 pandemic virus before 1957.16 The majority of hospitalized patients in the immediate 
post-pandemic period were significantly older compared to those admitted during the pandemic. 
Children might have been less susceptible for serious infection during the post-pandemic period 
because of a relatively high attack rate during the previous pandemic influenza season or to persisting 
vaccine-induced immunity.17 In the Netherlands, vaccination strategy during the pandemic focused on 
risk groups and young children below the age of four. Vaccination coverage among children reached 
around 60% in the northern region of the Netherlands (personal communication B. Wolters, Municipal 
Health Service Groningen). 
During all seasons patients were admitted relatively early in the course of illness. These findings suggest 
that serious illness is mainly due to effects of the influenza virus itself and not because of the occurrence 
of bacterial co-infection, although this is a well known complication of influenza. Still, more than two 
thirds of the patients during all seasons were treated with antibiotics. Although no significant differences 
were observed in severity of illness between the influenza seasons, more radiographic pneumonia was 
diagnosed during the pandemic and post-pandemic period. This is supported by in vitro data, which 
showed that influenza A(H1N1)pdm09 has an increased affinity for α2, 3-linked receptors on epithelial 
cells in the lower respiratory tract, in contrast to seasonal influenza subtypes.18
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The majority of patients in our study had chronic underlying illness, regardless the season, emphasizing 
the impact of influenza in these high risk groups, and the importance of yearly influenza vaccination. 
Earlier reports recorded less comorbidities in patients admitted during the pandemic compared to other 
influenza seasons.1,15 However, in our center, this was only observed in patients under the age of 15 years. 
During the post-pandemic period, a similar pattern was observed. These findings suggest that influenza 
A(H1N1)pdm09 can cause serious illness especially in previously healthy young patients. It probably 
also reflects the tertiary referral function of our hospital and might have biased our findings towards 
more complicated patients and more severe illness. However, the observed similarity in severity of illness 
between patients with seasonal and pandemic influenza is confirmed by a recent study in which the 
estimated burden of disease caused by pandemic influenza in the Netherlands, based on incidence, 
sequelae and mortality, was comparable with the burden of seasonal influenza.19
Another finding of our study is the frequency of oseltamivir treatment in patients with influenza 
infection. We observed a more than tenfold increase in the use of oseltamivir during the pandemic 
compared to seasonal influenza. This was probably at least partly due to national public health guidelines 
recommending treatment with oseltamivir in hospitalized patients, a phenomenon that very recently 
also has been described for the United States.20 In contrast to the US-study however, where people 
above 65 years old were less likely to receive antiviral agents, we found that especially relatively healthy, 
young children who were already ill for a couple of days and required only short term admission, did 
not receive oseltamivir. These findings suggest that during the pandemic these patients were admitted 
out of cautiousness rather than because of the seriousness of illness. During the post-pandemic 
period, oseltamivir was less frequently prescribed in patients with influenza A, although still significant 
differences remained compared with seasonal influenza. The reasons for this remain unclear. Compared 
to the pandemic, the use of oseltamivir was much less advocated by national guidelines or professional 
standards. Besides, influenza A(H1N1)pdm09 was by then generally regarded as causing relatively 
mild disease, possibly accounting for more reluctance among physicians to start antiviral treatment. 
The frequent use of oseltamivir did not lead to an upsurge of oseltamivir resistance of the influenza 
virus, suggesting that other mechanisms than antiviral pressure are responsible for the occurrence of 
resistance. This is not unknown for influenza, as in recent years the emergence of drug resistant influenza 
strains have been described in the absence of antiviral drug pressure, e.g. adamantine resistant influenza 
A(H3N2) since 2003 and oseltamivir resistant influenza A(H1N1) since 2007.21
Influenza B caused illness similar to influenza A, regardless the season. This is rather remarkable as 
previous studies showed that influenza A(H3N2) was associated with highest annual rates of influenza 
associated hospitalizations (with pneumonia, respiratory and circulatory hospitalizations as discharge 
diagnoses) compared to influenza A(H1N1) and influenza B.22 Despite similarity in severity of illness, 
patients with influenza B during the post-pandemic period were less treated with oseltamivir compared 
to the patients with influenza A. This might be explained by the observation that patients with influenza 
B were admitted later in the course of illness. Treatment with oseltamivir can shorten the duration of 
illness when given early (within 48 hours) in the course of illness.
A limitation of our study is the relative small amount of patients included, hospitalized in one single 
tertiary referral hospital. Larger studies in different patient populations are necessary to confirm our 
findings.
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In conclusion, in our center, seasonal, pandemic and post-pandemic influenza showed many similarities 
with regard to patients’ characteristics, severity of illness and clinical outcome. Influenza in the post-
pandemic period led to an equally severe season in terms of number of patients admitted as compared 
to the pandemic. Although the use of oseltamivir became common practice, no increase in oseltamivir 
resistance was detected. Our findings particularly highlight the fact that influenza is an important cause 
of illness and death each year, and emphasizes the need for influenza vaccination.
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Background: Highly transmissible viruses like influenza are a potential source of nosocomial infections 
and thereby cause increased patient morbidity and mortality. 
Aim: We assessed whether influenza virus sequence data can be used to link nosocomial influenza 
transmission between individuals. 
Methods: Dutch A(H1N1)pdm09 positive specimens from one hospital (n=107) were compared with 
samples from community cases (n=685). Gene fragments of haemagglutinin, neuraminidase and 
PB2 were sequenced and subsequently clustered to detect patients infected with identical influenza 
viruses. The probability to detect a second patient was calculated for each hospital cluster against the 
background diversity observed in hospital and community strains. All clusters were further analysed for 
possible links between patients. 
Findings: Seventeen A(H1N1)pdm09 hospital clusters were detected of which eight had a low probability 
of occurrence compared with background diversity (p<0.01). Epidemiological analysis confirmed a total 
of eight nosocomial infections in four of these eight clusters, and a mother and child combination in a 
fifth one. The nine clusters with a high probability of occurrence involved community cases of influenza 
without a known epidemiological link. 
Conclusion: Our data indicate that, presuming a background sequence dataset is available, the detection 
of hospital sequence clusters that differ from dominant community strains can be used to select 




Despite its overall mild appearance, the 2009 influenza A(H1N1) pandemic (A(H1N1)pdm09) resulted 
in a significantly increased demand on health services.1,2 Outbreaks of nosocomial influenza can 
occur, facilitated by transmission from HCWs to patients and colleagues.3,4 Ward closure is frequently 
performed when preventive measures fail to control virus spread, illustrating the problems in containing 
nosocomial outbreaks of viruses that are highly transmissible and require a low infectious dose like 
influenza viruses.5-7 Consequently, identification of sources of nosocomial virus infection can direct 
outbreak control measures, leading to reduced patient morbidity and mortality, and preserving a 
functioning health care system.7
In this study we assessed whether influenza sequence data can be used to detect nosocomial 
influenza transmission, identify its sources and risk factors associated with nosocomial spread. Since 
April 2009, we have systematically sequenced clinical samples from A(H1N1)pdm09 positive cases for 
mutations previously associated with increased virulence and reduced antiviral susceptibility as part 
of our role in monitoring the emergence of the new influenza virus. We use these data to explore the 
potential for use in patient cluster detection. The sequencing protocol was implemented by several 
health care institutes like the University Medical Center Groningen (UMCG). We analyzed the national 
and UMCG sequence dataset for clusters of nosocomial influenza. A sensible sequencing strategy 
targeting antiviral resistance markers is discussed for retrospective as well as real-time characterization 
of nosocomial influenza infections in healthcare institutes during an epidemic. 
Methods
Cases in the UMCG hospital
Between week 40 and week 53 in 2009, throat or nose swabs from patients as well as HCWs with 
symptoms of acute respiratory illness were tested by RT-PCR for the presence of influenza A(H1N1)
pdm09 virus.8, 9 Further characterization was done by sequence analysis as described below. Clinical 
and epidemiological data of hospitalized patients with influenza A(H1N1)pdm09 were gathered using 
a standardized case report form. Based on the previously reported two day (median) incubation period 
for A(H1N1)pdm09 virus infections, nosocomial infection was defined as development of respiratory 
illness two or more days after hospital admission.10 The influenza viruses in this UMCG hospital dataset 
are referred to in the text as “hospital influenza viruses”.
Cases from national surveillance
A background dataset consisting of all (n=685) sequenced A(H1N1)pdm09 positive samples obtained 
from the Dutch influenza GP sentinel surveillance system (n=103), and 582 non-sentinel samples that 
were collected between October 2009 and April 2010 were used to compare with hospital influenza 




Throat or nose swabs from A(H1N1)pdm09 positive cases were sequenced directly for surveillance of 
virulence and antiviral resistance markers, as described previously.11 Briefly, RNA was extracted from the 
clinical specimen and transcribed into cDNA using ThermoScript ™ reverse transcriptase (Invitrogen) 
following target amplification using HotstarTaq Master Mix (Qiagen). PCR primers targeted the receptor 
binding site within haemagglutinin (HA) (nt 8–789), the neuraminidase inhibitor resistance markers in 
neuraminidase (NA) (nt 669–1323) and known virulence markers for influenza A viruses in the polymerase 
binding protein 2 (PB2) (nt 1684–2223). A viral load cut-off below Ct 25 in the Matrix RT-PCR assay was 
used for sequencing specimens obtained from HCWs. DNA sequences were analyzed using Bionumerics 
V6.5 (Applied Maths, Sint-Martens-Latem, Belgium). 
Molecular data analysis
The character data from a concatenated HA (nt 58–713), NA (nt 702–1323) and PB2 (nt 1684–2218) 
nucleotide alignment was used to build a Maximum Parsimony network in BioNumerics.12 This method 
was chosen for its ability to link A(H1N1)pdm09 positive cases to their suspected source of infection using 
a minimum number of “evolutionary events” based on the simplest, most parsimonious, explanation of 
an observation and free of specific evolutionary assumptions. Patient clusters were defined by 100% 
sequence identity of the sequenced A(H1N1)pdm09 gene fragments. As antiviral resistant influenza 
viruses can emerge during oseltamivir therapy of immunocompromised patients nucleotide variation 
at NA codon 275 encoding resistance marker H275Y was excluded from the cluster analysis.11, 13  
Furthermore, hospital and community influenza virus datasets were compared for their Maximum 
Parsimony using character data and the evolutionary divergence over all sequence pairs using the 
Kimura 2-parameter model conducted in MEGA5.14, 15 Standard error estimates were obtained by a 
bootstrap procedure (1000 replicates). 
After sequence clustering, the resolution of the hospital sequence data was analysed by calculating 
the probability of observing a second patient with identical virus sequence for each virus strain that 
defined a hospital cluster (n≥2). This was done per gene fragment using the combined community and 
hospital virus sequence data sets as a measure for the total sequence diversity observed during the 2009 
influenza epidemic, assuming that the proportions of sequence clusters in our dataset correspond with 
the proportions of clusters within circulating viruses in the Dutch population.
Epidemiological analysis
Influenza sequence clusters were analyzed further by reviewing the date of hospitalization, reported 
onset of illness and ward(s) where the person was hospitalized to find epidemiological links between 
patients. For HCW, reported onset of illness, absenteeism from work, presence of patient contacts during 
regular work and the ward or specialty where the HCW was working before illness was collected.
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Results
Between October and December 2009, 288 of 1470 hospital respiratory samples (20%) tested positive 
for influenza A(H1N1)pdm09 virus. They were obtained from 121 patients (75 hospitalized patients and 
46 out-patients) and 71 HCWs. Most prevalent symptoms were fever, cough and shortness of breath. 
Almost 30% of the patients had to be admitted to the Intensive Care Unit. In 7 patients (9%) the onset 
of symptoms occurred two or more days after admission to the hospital, suggesting hospital acquired 
infection. A total of 107 influenza A(H1N1)pdm09 positive hospital samples were sequenced: 43% of 
the out-patients (n=20), 83% of the hospitalized patients (n=62) and 35% of the HCWs (n=25), yielding 
sequence information on 101 NA fragments, 102 PB2 fragments and 69 HA fragments. 
Molecular resolution in the hospital sequence dataset
To distinguish clusters of hospitalized patients, the hospital sequence dataset was compared with the 
national dataset to assess whether influenza viruses obtained from one hospital are either closely related 
or reflect community influenza virus diversity. This was achieved by using Maximum Parsimony networks 
built with influenza HA, NA or PB2 gene fragments, supplemented by a sequence diversity comparison 
using a character and a substitution based method (Figure 6.1&6.2). Both methods demonstrate that 
influenza viruses obtained from the hospital show similar diversity as the national dataset. This could 
allow the detection of patient clusters using hospital sequence data. 
Figure 6.1. Maximum Parsimony network of influenza A(H1N1)pdm09 NA sequences obtained from the hospital (n=101; grey) and 
the community (N=601; white), supplemented by vaccine strain A/California/07/09 (black), showing that hospital A (H1N1)pdm09 






































































Figure 6.2. Influenza virus sequence diversities of the hospital and community datasets were compared using a character and 
substitution based method and expressed as the relative maximum pasimony per gene fragment (left y-axis) and the evolutionary 
divergence over alle sequence pairs per gene fragment (right y-axis), respectively. Both methods demonstrate similar sequence 






































































Initially, hospital sequence data were used without community data to detect patient clusters. Maximum 
Parsimony networks were constructed using 101 NA fragments, 96 PB2 fragments, 65 HA fragments, 96 
combined NA and PB2 fragments, and 65 combined HA, NA and PB2 fragments to detect clusters (n≥2) 
of 100% identical influenza A(H1N1)pdm09 sequences. Clustering of hospital sequence data based on 
HA, NA or PB2 fragments identified 7, 14 and 7 sequence clusters, respectively. When combining the 
clustering results obtained using individual gene fragments, a total of 17 molecular distinct clusters were 
identified (Figure 6.3). Six of the seven patients with onset illness two or more days after hospitalization 
were present in four clusters. The seventh patient did not cluster with hospital and community sequences 
due to a silent mutation in NA codon 413.
A proportion of the hospital clusters was characterized by unique sequences compared with community 
sequence data. To enumerate the uniqueness of all detected hospital sequence clusters, a probability 
was assigned to each sequence cluster based on the frequency these variants were observed. Eight 
patient clusters were identified with a low probability (p<0.01) that these were expected based on 
random selection in a background diversity of hospital and community influenza strains (Figure 6.3).
Figure 6.3. Sequence clustering of hospital A(H1N1)pdm09 viruses identified a total of 17 molecular clusters based on the combined 
results obtained from the individual gene fragments. Sequence analysis of haemagglutinin (HA) fragments identified seven 
molecularly distinct clusters (genotypes A-G), of neuraminidase (NA) 14 clusters (NA genotypes A-N) and of PB2 seven clusters (PB2 
genotyeps A-G). By combining these results, NA genotype C and F viruses are subdivided by addition of HA and/or PB2 sequence 
data, and NA genotype J viruses are subdivided by addition of HA data, yielding the 17 molecular distinct patient clusters. The 
probability of observing a second patient with an identical influenza gene fragment sequence is provided for all sequence clusters 
per separate and combined gene fragment (s). The left column shows the result of the epidemiological cluster investigation. Patients 
with epidemiological links are marked A, B or C, corresponding with the analysis of patient clusters in Figure 6.4. +Gene fragment 
sequence data present. *Patients with onset illness ≥ 2 days after hospitalization. HCW, health care worker.
Figure 6.3.  next page
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Epidemiological analysis of nine sequence clusters that had a clustering probability p>0.01 could not 
identify any epidemiological relations between the patients and/or HCWs within these clusters, except 
for the detection of a mother-child link within one cluster. Based on first day of illness, all patients within 
these nine clusters were infected with community acquired influenza virus infection. 
Epidemiological analysis of the eight clusters that had a low probability (p<0.01) that these were expected 
based on random selection, was not able to identify any associations between the patients and/or HCWs 
within three out of eight clusters. One cluster included a mother and child, and epidemiological analysis 
of the remaining four clusters was suggestive for transmission of influenza virus between patients (Figure 
6.3 and 6.4). These four clusters each contained one or more patients with a presumed hospital acquired 
influenza virus infection based on the first day of illness two or more days after admission.
1. Hospital cluster 1 contained three A(H1N1)pdm09 virus infected patients. Patient A, infected with 
community acquired influenza, was probably the source of infection for patient B and patient C. 
All three were on the same ward at the time patient A tested positive for influenza A(H1N1)pdm09 
virus infection. Patient C was temporarily sent home, but was re-admitted with influenza like illness 
4 days after leaving the hospital for the first time. Based on onset of symptoms compared to date of 
admission, patient C initially was considered as having a community acquired infection. 
2. Hospital cluster 2 contained three patients with A(H1N1)pdm09 virus infection including two 
patients that had a first day of illness respectively 2 and 7 days after admission to the hospital. 
Patient A, infected with community acquired influenza, is regarded as the index patient for the 
other two patients. 
3. Hospital cluster 3 consisted of three patients including 2 patients with hospital acquired influenza 
virus infection. As the third patient stayed at a different ward and was discharged before patient 
B was admitted, the actual source of infection is missing. Both nosocomial patients were on the 
same ward before becoming ill, but were already transferred to other wards when tested positive 
for influenza A(H1N1)pdm09 virus. Most likely the source of these two hospital acquired infections 
occurred in ward J. 
4. Hospital cluster 4 consisted of two patients including one patient with a hospital acquired influenza 
virus infection. Both patients were on the same ward at the time patient A developed a respiratory 
illness caused by influenza A(H1N1)pdm09 virus. Patient B was discharged from the hospital but 
got ill 4 days after returning home, 8 days after the first day of illness of patient A. Patient B was 
re-admitted because of respiratory illness and subsequently tested positive for influenza A(H1N1)
pdm09 virus infection. This re-admitted patient was not considered a patient with a hospital 
acquired infection in the initial comparison of first day of illness with date of admission. Like in 
cluster 3, the source of infection is missing and most likely was a patient, HCW or visitor from ward 
N.
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Figure 6.4. Epidemiological analysis of four patient clusters each containing ≥ 1 patients with presumed hospital-acquired A(H1N1)
pdm09 virus infection suggests that the source of nosocomial influenza virus infections within clusters 1 and 2 was a patient with 
community-acquired influenza. This analysis identified two additional nosocomial influenza patients (cluster 1, patient C; cluster 
4, patient B) that initially were considered as having a community-acquired infection. An index case of nosocomial influenza virus 















































































































Retrospective analysis of sequence data combined with epidemiological data was performed to 
evaluate the usefulness of sequencing influenza gene fragments for the characterization of nosocomial 
influenza virus infections. Although characterization of nosocomial A(H1N1)pdm09 cases by a combined 
molecular and epidemiological approach has been reported16, 17, the evaluation of this approach to 
guide the identification of nosocomial influenza clusters to our knowledge is not reported yet. 
Our analysis identified nine nosocomial influenza infections during the 2009 influenza epidemic in a 
tertiary referral hospital, which comprises 15% of all the diagnoses during the study period. Although 
transmission from an index case to a hospitalized patient was observed four times, no onward 
transmissions could be demonstrated. In addition, the molecular and epidemiological analysis did not
provide evidence for transmission between patients and staff. Our results highlight some important 
observations. First, patient transfer from a ward with influenza positive patients to another ward should 
be done with great care and follow up of the transferred patient. Secondly, follow up of recently 
discharged patients could identify possible spread of infection, which is highly relevant if antiviral 
resistant or virulent influenza virus variants are identified in the hospital. Finally, our analysis was able to 
link patients across wards in two clusters that would be difficult to detect using epidemiological data 
only.
Sequencing of HA fragments was less often successful than sequencing of the NA and PB2 fragments 
due to a reduced sensitivity for the HA fragment amplification, compared with NA and PB2 amplification 
(data not shown). This affected HA-based clustering as these sequences were missing for 52% of 
the hospital patients. Consequently, an unbiased comparison of HA with NA sequence data for the 
detection of patient clusters was not possible. The lower substitution rate for A(H1N1)pdm09 PB2 gene 
segments compared with NA segments, explains the discrepancy between the number of molecular 
clusters detected using NA (n=14) and PB2 (n=7) sequence data.18  Nevertheless, the calculation of the 
probabilities that A(H1N1)pdm09 positive patients were infected by viruses with 100% identical gene 
fragments proved to be a useful selection. When comparing the NA sequences with GenBank (consulted 
on February 6, 2012), the five strains that defined NA clusters with p<0.01 all remained unique, while the 
strains that defined clusters with p>0.01 demonstrated on average 57 identical strains. This suggests that 
our observations did not result from the lack of resolution in the background data. It implies that during 
an influenza epidemic, commonly circulating influenza strains are detected at all geographical areas 
and can be used to express the uniqueness of a local patient cluster. Although sequence-based typing 
is possible in advanced clinical laboratories, routine application is relatively costly when considering its 
use for the sole purpose of identification of nosocomial infections. Therefore, we looked at the potential 
for using this approach on the basis of data collected for a different purpose, i.e. sequencing to detect 
markers of antiviral resistance.  As antiviral treatment of immuno-compromised patients is associated 
with the emergence of antiviral resistance, monitoring for emergence of resistance is vital for both the 
patient as well as public health, and is increasingly common practice.13 Hospital molecular diagnostics 
commonly utilize a targeted approach for the rapid identification of the primary oseltamivir resistance 
substitution H275Y in NA subtype 1, but our results demonstrate the possible added value of Sanger 
sequencing a larger region (>600bp).19-21 Currently, sequence capacities and application of routine 
sequence analysis in clinical laboratories are increasing, especially in academic hospitals. Although the 
capacity to perform sequence analysis is not present in all hospitals, these hospitals could benefit from 
the knowledge generated on the characterization of influenza virus transmission chains in hospitals that 
are able to incorporate sequence analysis into routine clinical use. 
Chapter 6390 103
Both retrospective and prospective approaches produce valuable insights in nosocomial virus spread 
that can direct outbreak control measures, leading to reduced patient morbidity and mortality.
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Human rhinovirus (HRV) is associated with serious respiratory illness, particularly in patients with 
pulmonary comorbidities. HRV is increasingly considered as a nosocomial pathogen with a considerable 
burden of disease in certain groups of patients. However, little is known about the factors that determine 
and prevent nosocomial transmission of HRV. The objective of this study was to quantify patient-to-
patient transmission of HRV in our hospital and to determine the impact of infection control measures.
Methods
Data on HRV detection, clinical symptoms and infection control measures were retrieved from a 
prospective project into respiratory infections in hospitalized children between October 2009 and 
January 2011. Data were used to inform a stochastic, individual-based, multi-ward model to assess the 
relative contributions of factors that drive HRV transmission dynamics: patient-to-patient transmission, 
introduction by newly admitted patients, visitors and health care workers and existing infection control 
measures. 
Results
Given the yearly admission of 200 patients with a community acquired HRV infection, infection 
control policies reduce the number of hospital acquired HRV infections from 92, when no infection 
control measures at all are implemented, to 61 patients, when baseline infection control policies and 
HRV specific measures exist. Based on our model, a further reduction in nosocomial HRV infections is 
accomplished when all patients infected with HRV would be put in isolation as soon as they show 
symptoms of respiratory disease instead of based on a positive laboratory result or when a rapid point-
of-care test could be implemented. However, the fraction of hospital acquired cases would still be 21% 
because of introduction of HRV from outside the hospital via visitors or health care workers (HCW). For 
our hospital, 80% of the hospital acquired HRV cases observed during one year would be due to a source 
other than patient-to-patient transmission (like introduction of HRV into the hospital by visitors or health 
care workers).
Conclusions
Infection control measures reduce the number of hospital acquired HRV cases. However, because of the 
continues introduction of HRV from the community into the hospital and the delay in implementation 
of appropriate infection control measures after a patient becomes infected, a considerable amount of 




Human rhinoviruses are the most common cause of upper respiratory tract infections and are also 
associated with more severe clinical syndromes particularly in patients with pulmonary comorbidities.1-5 
Nosocomial viral infections occur frequently among pediatric patients, with respiratory tract infections 
as one of the most prevalent manifestations.6-9 With the exception of a few recent publications, data 
on the frequency of hospital acquired HRV infections are scarce and mostly limited to the description 
of outbreaks of respiratory tract infections caused by HRV.1,6,10,11 Currently, infection control measures 
are centered around the infected patient. Less attention is paid to visitors and health care workers, 
although working in or visiting a relative in a hospital when having symptoms of respiratory disease is 
not recommended. Also, HRV is usually not part of national guidelines on infection control within health 
care institutions. 
Infection control measures have the goal to prevent transmission of pathogens from one patient to 
the other. Measures are focused on the main transmission routes of the pathogen, being either via 
contact with contaminated hands or surfaces, or via the air. Knowledge on the transmission dynamics 
of a pathogen is a prerequisite for the implementation of the appropriate infection control measures. In 
recent years mathematical modelling has been increasingly used to study the transmission dynamics 
of nosocomial infections, as well as the assessment of the effectiveness of control measures.12-14 These 
models have mainly addressed the dissemination of bacterial pathogens such as Methicillin resistant 
Staphylococcus aureus (MRSA), Vancomycin resistant enterococci (VRE), and Clostridium difficile. Viral 
pathogens in the hospital setting have also been studied recently, with norovirus and influenza the most 
relevant examples.15,16
We present a mathematical model of nosocomial HRV transmission in a multi-ward hospital setting. By 
combining this model with HRV epidemiological data collected at a children’s hospital, part of a large 
university hospital in northern Netherlands, we aim to answer the following two questions: firstly, what 
is the impact of different patient isolation strategies in stopping the nosocomial dissemination of HRV 
infections. Secondly, what is the relative contribution of two different transmission routes, namely direct 
patient-to-patient transmission, and introduction from the community by visitors and HCW.
Methods
We employ a stochastic SEIS simulation model that tracks the infection status of individual patients during 
their hospital stay. Patient admission, discharge and between-ward transfers follow typical movement 
patterns inferred from a large patient-location data set. The model is asynchronous and proceeds in 
discrete time steps of length δt = 1 day, motivated by the temporal granularity of the epidemiological 
and patient-location data. 
Patients can be in one of three possible infection states: uninfected and susceptible to infection (S), 
infected but non-infectious (exposed: E), and infectious (I) (SEIS compartment transmission model, 
Figure 7.1). When susceptible patients become infected they enter the exposed state. After a length of 
time known as the exposed period, the patient becomes infectious. Infectious patients remain in this 
state for a length of time known as the infectious period, after which they recover from the infection. 
Due to the large diversity in circulating HRV serotypes we assume that HRV infection does not confer 
long-lasting immunity. Thus, patients return to the susceptible state after recovery from infection.
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Figure 7.1. SEIS compartment transmission model: background transmission rate βbkg, patient-patient transmission rate β  and 
infectious period d.  
We consider two different transmission routes. Direct transmission involves the transmission of HRV 
between two patients in the same hospital ward, either due to direct or HCW-mediated patient-to-
patient contact. We assume homogeneous mixing between patients within each ward. Background 
transmission accounts for all other transmission mechanisms and we assume that is mainly due to 
visitors and HCW becoming infected in the community, and subsequently transmitting the pathogen 
to hospitalized patients.
Two infection control strategies are modelled: baseline and HRV-specific isolation. Baseline isolation 
consists of placing of HRV-infected patients under isolation, during part or all of their infectious period, 
because of clinical or infection control considerations unrelated to the HRV infection. Conversely, HRV-
specific isolation involves the isolation of laboratory confirmed HRV-infected patients according to 
existing HRV-specific isolation guidelines used in our hospital. HRV-specific isolation may depend on 
patient location and other characteristics and starts only after laboratory test results are obtained.
We evaluate five different infection control scenarios:
• The first scenario corresponds to only implementing baseline isolation (i.e. no HRV-specific 
isolation). 
• The second scenario corresponds to implementing baseline isolation, as well as HRV-specific 
isolation for HRV-infected patients in ICUs and hematological wards with a positive PCR test result 
for HRV with a Ct value <30 (a randomly chosen value). These two scenarios are consistent with the 
existing isolation guidelines during the collection of epidemiological data. 
• The third scenario corresponds to baseline isolation, as well as HRV-specific isolation for all HRV-
infected patients (i.e. independent of ward and Ct value). 
• The fourth scenario is similar to the third, except that in this case there is no delay between onset of 
symptoms and HRV-specific isolation (i.e. the time interval between onset of symptoms, availability 
of test results and patient isolation, is less than one day). 
• The fifth scenario, which we used to counterfactually assess the overall impact of isolation measures, 
corresponds to no isolation.
ßbkg ß
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Direct transmission is modelled as a density dependent process, whereas background transmission 
occurs with a constant daily probability per susceptible patient (i.e. a Poisson process with constant 
rate). The probability of a susceptible patient i becoming infected with HRV while located in ward w on 
day t can then be written as:
where β is the direct transmission rate, βbkg is the background transmission rate, α is the efficacy of 
isolation, Iw is the number of infected patients in ward w, Cw is the number or infected patients in ward 
w which are also under isolation, and Nw is the total number of patients in ward w. We assume that the 
effect of isolation is to reduce the direct transmission rate associated with an infected patient under 
isolation by a multiplicative factor (1-α).
The model is employed to calculate the proportion of all HRV-infected patients that are considered 
hospital associated, as well as the relative fraction of hospital-associated cases due to either direct 
or background transmission. We classify a HRV infection as hospital associated by employing the 
conventional cut-off approach: a hospital-associated case is defined as the onset of symptoms two or 
more days after hospital admission. To capture all stochastic variation we obtain our results from 1000 
simulation replicates per infection control scenario and set of input parameters. Each simulation replicate 
starts with a number of patients (all susceptible) in each ward consistent with observed occupancy rates. 
Seeding occurs continuously by the admission of community-associated cases of HRV infection. These 
patients amount to a fraction ρ of all daily admissions. We run the model for a one year burn-in period, 
such that the initial transient has passed, and then we run the model for a further year during which we 
calculate the above mentioned metrics.
Epidemiological data
Data on HRV detection, clinical symptoms and infection control measures were retrieved from a 
prospective project into respiratory infections in children hospitalized in the Beatrix Children’s Hospital 
between October 2009 and January 2011, as has been described in detail elsewhere.1 The Beatrix 
Children’s Hospital has 142 beds and is part of the University Medical Center Groningen, a tertiary referral 
hospital in het northern region of the Netherlands. Demographic, clinical and microbiological data 
were systematically collected from all children under 18 years of age, from whom respiratory samples 
were taken for the detection of 15 respiratory viruses (influenza A/B, respiratory syncytial virus A/B, 
coronavirus 229E/NL63/OC43, para-influenzavirus type 1-4, metapneumovirus, adenovirus, bocavirus 
and human rhinovirus). Samples were taken based on the clinical judgment of the physician. Clinical 
data were collected using a standardized case report form. Epidemiological data were gathered to 
determine whether the respiratory infection was community or hospital acquired, including infection 
control measures that were taken in the hospital to prevent further transmission of respiratory viruses. 
During the study period there was a change in the infection control guidelines associated with HRV-
infected patients. This change splits the study period into an early and late stage. During the early stage, 
which runs from 1 October 2009 up to 20 June 2010, there were no HRV-specific isolation measures in 
place. During the late stage, which run from 1 July 2010 up to 31 December 2010, laboratory confirmed 
HRV-infected patients (Ct value <30) admitted in any of the intensive/high care wards, or hematological 
units, were placed under isolation until discharge or resolution of symptoms. The different infection 
control guidelines in the two stages in the study period are modelled by the first two infection control 
scenarios described in the previous subsection. Infection control measures consisted of a combination 
of droplet and contact precautions (gown, gloves and mask for health care workers during patient care, 
and patient in a single room) and were installed when HRV was detected. 
P SEi,w (t) =   β δt + βbkgδt
Iw (t) - a Cw(t)
Nw (t)
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Patients with HRV mono-infections (no other respiratory virus detected except HRV) and mixed infections 
(HRV detected together with one or more other respiratory viruses) were included in the model. One 
unique patient could be included with more than one disease episode, which was defined as a period 
of time starting with a first day of illness and ending with full recovery from respiratory symptoms or 
discharge, during which one or more samples were taken for the detection of respiratory viruses. Each 
disease episode generated one record in the final data set. Each record includes information on: patient 
date of birth and sex, first day of illness (i.e. date of symptoms onset), sampling date, admission and 
discharge dates, location, presence and duration of symptoms (for the following signs and symptoms: 
cough, dyspnoea, need of oxygen, fever, and intubation), isolation data (type, and start/end dates), 
presence of other respiratory virus (which), HRV genotype, and Ct value associated with PCR detection 
of HRV.
Detection of HRV
All respiratory samples (mainly nasopharyngeal swabs or nasopharyngeal aspirates) were tested for the 
presence of HRV by a laboratory developed real-time PCR test (RT-PCR) as described elsewhere.1 The Ct 
value (the number of amplification cycles needed for a PCR to become positive) was used as an estimate 
for the amount of HRV present in the samples.
Patient location data
We extracted patient location data from the University Medical Center Groningen hospital information 
system. These data cover the one year period 6 January 2011 – 5 January 2012 and consist of 365 snapshots 
of the Beatrix Children’s Hospital patient population. Each snapshot, generated daily at approximately 
13:30 hours, consists of a list of records corresponding to all currently hospitalized patients. Each record 
contains a unique patient identification number, date and detailed patient location information (ward, 
room, bed and medical specialty). By comparing consecutive snapshots, we determined between-ward 
patient movements, as well as ward admission and discharge rates, length of stay, discharge/transfer 
probabilities and daily ward change in number of occupied beds.
Model parameterisation
Most of the model parameters can be sampled from probability distribution functions directly estimated 
as relative frequencies from the epidemiological and patient location data sets. A comprehensive list 
is shown in Table 7.1. We note that the length of the exposure period is sampled from the probability 
distribution function reported in Lessler et al.17 We assume that the exposure period equals the 
incubation period.
Direct (β) and background (βbkg) transmission rates are free parameters of the model. We estimate their 
values by minimising the average relative error E between observed and model-predicted proportion of 
hospital-associated HRV infections:
  
   
E (β, βbkg )  =  + 





(β, βbkg ; late) – (late) fmodel
HA HAfdata
(late) HAfdata
E (β, βbkg )  =  + 





(β, βbkg ; late) – (late) fmodel
HA HAfdata
(late) HAfdata
E (β, βbkg )  =  + 





(β, βbkg ; late) – (late) fmodel
HA HAfdata
(late) HAfdata
In the above expression          is the fraction of hospital-associated cases according to the data, and 
is the model-predicted fraction of hospital-associated cases for a given value of the free parameters; 
early/late refer to stage of the epidemiological studie period, wich in turn determines the isolation 
scenario used by the model.
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Table 7.1. Summary of model parameters. o.p.d.f: observed probability distribution function.
parameter Notes
Admission rate of HRV community cases      
Exposed period                             
Infectious period                          
Fraction of cases under baseline isolation 
Delay onset symptoms-baseline isolation             
Duration of baseline isolation             
Delay onset symptoms-sampling                       
Delay sampling-HRV-specific isolation      
Direct transmission rate                   
Background transmission rate               
 Directly calculated from data
 Sampled from published incubation time distribution 17
 Assumed to be equal to duration of coughing
 Directly calculated from data
 Sampled from o.p.d.f
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
 Minimisation of average relative error
 Minimisation of average relative error
Parameter (per ward) Notes
Lengt of stay                              
Initial occupancy                          
Daily change in occupancy                  
Destination after discharge                
Admission and discharge rates            
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
 Sampled from o.p.d.f 
Results
Epidemiological data
From October 2009 till January 2011, 339 HRV positive disease episodes were included. Hospital acquired 
infection, based on the first day of illness and date of admission to the hospital, was present in 88/339 
(26.0%) episodes divided into 58/226 (25.7%) in the early stage of the study and 26/106 (24.5%) in the 
late stage (Table 7.2). The transition stage reflects the period in which infection control policy changes 
were implemented. In 238/339 (70.2%) disease episodes information on infection control measures was 
present. In the early stage of the study, with no HRV specific infection control policies, 84 patients were 
however in isolation because of other reasons (84/129=65%).
Epidemiological data
Patient location data
(early)  =  0,26 HAfdata (late) =  0,25 
HAfdataFrom the data:                           and                            . Minimization was performed by a simple scan of the 
two-dimensional parameter space.
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Table 7.2. Overview of the number of HRV cases (either community associated (CA) or hospital associated (HA)) and infection control 
measures. 






















Early: 01.10.2009-20.06-2010; transition 21.06.2010-31.06.2010; late: 01.07.2010-31.12.2010.
Model predictions
Figure 7.2 shows the contour curves of the relative error between the data and the model predictions. 
These curves quantify the relative error between the model and the epidemiological data. The free 
parameters direct (β) and background (βbkg ) transmission rates are estimated minimizing the average 
relative error between observed and model-predicted proportion of hospital acquired cases (depicted 
as the yellow dot in figure 7.2). Figure 7.3 shows the heat map of the model predicted fraction of hospital 
acquired cases as a function of direct (patient-to-patient) and background (introduction by visitors, 
health care workers) transmission rate. This describes how the model behaves for each combination of 
the free parameters β and βbkg.
Figure 7.2. Contour curves for relative error between the data and the model, quantifying the relative error between the model and 
the epidemiological data. The free parameters direct (β) and background (βbkg ) transmission rates are estimated minimizing the 
average relative error between observed and model-predicted proportion of hospital acquired cases. The yellow dot represents the 



















Direct transmission rate [1/day] 
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Figure 7.3. Heat-map of model-predicted fraction of hospital acquired cases as a function of direct (patient-patient) and background 
(introductions by visitors, health care workers) transmission rate, describing how the model behaves for each of the combination of 
the free parameters β and β
bkg
.
The model predicted number of observed hospital acquired cases, based on the admission of 200 
patients with community associated HRV infection, for the five different infection control scenarios 
is given in figure 7.4. The lowest number of hospital acquired HRV cases is reached when all patients 
with HRV are put in isolation the moment they show symptoms of infection (the “all (no delay)” 
scenario). Approximately 54 patients will develop a hospital acquired HRV infection given an influx of 
200 community associated infections, corresponding to a fraction of hospital acquired cases of 21.4% 
(52/252 patients). Our current policy, i.e. installment of infection control measures based on a positive 
laboratory result, leads to an increase in the number of nosocomial HRV infections from 54 to 61 patients 
(corresponding to a fraction of hospital acquired cases of 23.3%). In the imaginary situation that no 
infection control measures at all are in place (not for HRV but neither for other reasons), the number 
of hospital acquired cases would increase to 92 (fraction of hospital acquired HRV infections of 31.6%).
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Figure 7.4. Model predicted number of hospital acquired cases for five different infection control scenarios as depicted in the method 
section of the paper (blue boxes). The contribution of patient-to-patient transmission (red boxes) and background transmission (green 
boxes) for the given number of hospital acquired cases is also given.
The model was further used to predict the fraction of hospital acquired cases due to patient-to-patient 
and background transmission (Figure 7.4 and Table 7.3). Overall, the model predicated contribution of 
background transmission to the number of hospital acquired cases varied between 58% (given the 
scenario that no infection control is implemented at all) and 100% (given the scenario that all patients 
are put in isolation the moment they show symptoms). As expected, infection control measures 
lower the amount of hospital acquired cases due to patient-to-patient transmission. However, even 
when all HRV infected patients are in isolation, direct transmission still contributes to nosocomial HRV 
transmission because of the delay in the implementation of infection control measures. The combination 
of infection control measures for all HRV infected patients plus no delay between onset of symptoms 
and implementation of infection control measures reduces the amount of hospital acquired cases due 
to direct transmission to zero. As this does not effect the contribution of background transmission 
on nosocomial infection, still a substantial number of hospital acquired cases will occur. As the “early” 
and “late” scenarios reflect the two stages of our study, between 77% en 81% of hospital acquired HRV 
infections were in our case due to introduction from outside the hospital by visitors or health care 
workers (corresponding with approximately 55 patients given an influx of 200 patients with community 
acquired HRV infection).
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Table 7.3. Fraction of hospital acquired cases due to direct (patient-to-patient, fDirect) and background (visitors, health care workers, 
fBackground) transmission for the five different scenarios (with 90% confidence interval).
Scenario fDirect fBackground
Early 0.232 (0.181-0.287) 0.768 (0.713-0.819)
Late 0.190 (0.139-0.243) 0.810 (0.757-0.861)
All 0.108 (0.065-0.154) 0.892 (0.846-0.936)
All (no delay) 0.000 (0.000-0.000) 1.000 (1.000-1.000)
No isolation 0.421 (0.359-0.480) 0.579 (0.520-0.641)
Discussion
To our knowledge, our study is one of the first to try to unravel the transmission dynamics of nosocomial 
HRV infections by combining epidemiological methods and diagnostic results with mathematical 
modeling techniques in order to gain more insight into the impact of infection control on nosocomial 
infections. Our study focuses on the relative contribution of three factors that drive HRV transmission 
within our children’s hospital in order to get to a more quantitative assessment of the infection control 
policy and the lessons we can learn from this: patient-to-patient transmission, introduction from outside 
the hospital and delay in implementation of infection control measures.
Several conclusions can be drawn based on the model predicted impact of infection control measures 
on hospital acquired HRV infections. First, adding HRV specific infection control measures to existing 
infection control policies would only slightly reduce the number of hospital acquired HRV infections. 
A further reduction in nosocomial HRV infections would be accomplished by reducing the delay 
between the onset of symptoms and the implementation of infection control measures. In our case, 
patients are placed in isolation based on a positive laboratory results instead of clinical symptoms, thus 
creating a timeframe in which a patient is not isolated while already able to spread the virus to others. 
This period should be as short as possible. The period of delay can be divided into four sections: (1) 
the time between the first day of illness and the actual collection of material for viral diagnostics, (2) 
the time between the collection of the material and the arrival at the laboratory, (3) the time to result 
and (4) the time between result and actual isolation of the patient. Rapid diagnostic tests will shorten 
section 3 and, in case of point-of-care testing at the bedside of the patient, section 2. However, rapid 
diagnostics will not influence the time between onset of symptoms and the collection of respiratory 
material, or the actual implementation of infection control measures. Rather, the implementation of 
infection control measures based on symptoms will reduce section 1. Thus, rapid diagnostic tests (or 
point-of-care tests) in combination with an infection control policy based on clinical syndromes instead 
of a positive laboratory result would benefit a further reduction in the occurrence of nosocomial HRV 
infections. The time between a positive laboratory result and the actual implementation of infection 
control measures relies on close collaboration between the laboratory and infection control nurses, 
clinical microbiologists and clinicians.
Another important finding in this study is the relative contribution of sources of nosocomial HRV infection 
other than patient-to-patient transmission. In our situation, with either no HRV specific infection control 
guidelines or only if the patient is on specific high risk wards, approximately 80% of the hospital acquired 
HRV cases is due to introduction of HRV from outside the hospital. Family members of the patient and 
health care workers can carry HRV into the hospital, and transmit the virus by close contact with the 
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patient. Also, public areas dedicated to parents of admitted children could lead to transmission of the 
virus from one visitor to the other, thus putting also other patients than their own children at risk for 
infection. These findings strongly suggest that infection control policies should also take into account 
people surrounding the patient in order to reduce the prevalence of nosocomial infections. Although 
for other, mostly enteric, viruses persistence of the virus in the environment has a role in prolongation of 
an outbreak, the role of contaminated environmental surfaces in the transmission of HRV is not clear.18 
Infectious virus can be transferred from surfaces to fingertips, however a loss of infectivity is reported 
by 24 hours after deposition.19 Education of visitors on the prevention of transmission of pathogens, 
stressing the importance of hand hygiene and the advice to retain from visiting the hospital when signs 
and symptoms of infection are present, are examples of the measures that could be taken. Also, health 
care workers should be educated about the necessity to stay at home while experiencing respiratory 
or influenza like illnesses. The role of HCW in nosocomial outbreaks has been described before.20,21 
A recent paper assessing the impact of impact of 2009 influenza A (H1N1) pandemic on health care 
workers showed that health care workers with influenza like illness often worked while ill.22 Education 
and support of health care workers were described to be of critical value.
Our study has some limitations. Several assumptions had to be made because specific clinical and 
epidemiological data were lacking: we had no information on HRV positivity and infection control status 
of asymptomatic patients or patients with subclinical symptoms. Only when the physician suspected 
respiratory illness and decided to take samples for viral diagnostics, patients were included in the 
study. We assumed a period of infectiousness which is distributed equal to the length of coughing for 
disease episodes in the data, not for other symptoms. Also, a lot of patients were already in isolation 
because of other reasons (e.g. the presence of other respiratory viruses or multi drug resistant bacteria 
or because of immune suppression that made protective infection control measures necessary). We 
assumed that these isolation measures were sufficient to prevent transmission of HRV to others and that 
baseline infection control policies did not change over time. We have no information about the infection 
control status of so called susceptible, non-HRV infected patients. Some of these patients are probably 
in isolation, which most likely reduces the probability of them acquiring HRV infection. Because this 
information is not available, the model did not take into account these different probabilities of acquiring 
nosocomial HRV infections of susceptible patients. The model is based on epidemiological and patient 
transfer data from our hospital. Therefore, the results are dependent on our particular patient population 
and type of hospital. 
In conclusion, infection control measures reduce the number of hospital acquired HRV cases. 
However, because of the importance of introduction of HRV from outside the hospital and the delay 
in implementation of appropriate infection control measures after a patient becomes infected, a 
considerable amount of hospital acquired HRV infection will persist despite effective infection control 
policies. All measures attempting to reduce this delay are highly recommended and directly influence the 
outcome of infection prevention. Infection control measures should also focus on people surrounding 
the patient, not only on the infected patient itself. Besides, strategies should be developed in which 
highly sensitive (molecular based) and rapid point-of-care diagnostic tests play an important role. 
Combining epidemiological methods and mathematical modeling techniques improve the 
understanding of nosocomial HRV transmission dynamics, which contributes to the implementation of 
appropriate infection control interventions.
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Sequence based information is increasingly used to study the epidemiology of viruses, not only 
to provide insight in viral evolution, but also to understand transmission patterns during outbreaks. 
However, sequence analysis is not yet routinely performed by diagnostic laboratories, limiting its use in 
clinical practice. 
Objectives
To describe the added value of sequence based information available within 3 days after the detection 
of  norovirus in fecal samples of patients and personnel during a suspected outbreak on a hospital ward. 
Results were used to guide the implementation of appropriate infection control measures, in particular 




Norovirus infection was detected in seven patients and two health care workers on an oncology ward 
of the children’s hospital. Six of seven patients had a hospital acquired infection defined as a first day of 
illness more than two days after admission. After notification of the first two patients, supplementary 
infection control measures were taken to prevent further spread. Despite these measures, three 
additional patients with norovirus infection were identified. Characterization of the noroviruses of 5 out 
of 7 patients was available within 7 days after the notification of the first patient. Four different genotypes 
were detected, providing evidence for multiple introductions of different norovirus strains with only 
a few secondary cases rather than ongoing nosocomial transmission. Therefore, we maintained the 
already implemented infection control interventions without closure of the ward.  
Conclusions
Sequence based information available in real-time is helpful for understanding norovirus transmission in 
the hospital and facilitates appropriate infection control measures during an outbreak.
Chapter 8390 125
Background
In recent years, the use of sequence based typing techniques for viral surveillance has become more 
common. Virus characterization and typing may be used to explain clinical illness and guide treatment 
(as in resistance profiling).1-3 Apart from this, sequence based information is increasingly used as a tool to 
define transmission routes in outbreaks.4-6
Since most laboratories have not incorporated sequence analysis in their daily routine testing, information 
on typing and characterization of viruses is mostly available retrospectively and useful in understanding 
transmission of, on the basis of epidemiological data, suspected outbreaks.4 Shortening the timeframe 
by which sequence based information becomes available during an actual outbreak might benefit the 
unraveling of nosocomial transmission and thus may guide the implementation of appropriate infection 
control measures. We describe a suspected norovirus outbreak on a hospital ward, where sequence 
analysis results were made available immediately after the detection of norovirus and enabled us to 
decide on the necessary measures to prevent further spread.
Objectives
To describe the added value of providing sequence based information in real-time, available immediately 
after detection of  norovirus in fecal samples of patients and personnel during a suspected outbreak 
on an oncology ward of the children’s hospital. Sequence analysis results were used to understand 
transmission routes and to guide infection control measures.
Study design
Study population
Fecal samples of all patients with gastrointestinal symptoms (diarrhea, vomitus) admitted on the 
oncology ward of the Beatrix Children’s Hospital from January 14th until January 30th, were collected for 
the detection and characterization of norovirus. Personnel with gastrointestinal complaints were also 
asked to submit fecal samples. Only fecal specimen from patients or personnel with gastrointestinal 
symptoms were analyzed, no asymptomatic persons were included. First day of illness, date of admission 
to the hospital ward, sample date and date of discharge were collected for all norovirus positive patients. 
Patients who tested norovirus positive, were isolated and health care workers were advised to wear 
gloves and a gown during patient care. Additional measures consisted of emphasizing the importance of 
hand hygiene using soap and water or appropriate alcohol-based hand wash, extra cleaning of relevant 
surfaces on the ward using hypochlorite, providing information about norovirus and the risk factors 
for transmission to parents and caregivers, and cohorting patients and staff. Staff with gastrointestinal 
complaints were not allowed to work until symptoms had resolved. 
Ethical approval of the institutional review board was not required.
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Laboratory methods
Stool samples were suspended in NucliSens easyMAG lysisbuffer (2x volume of feces, bioMérieux, Marcy 
l’Etoil, France). After centrifugation, 100 µl was used as input for RNA/DNA extraction using NucliSens 
easyMAG extraction buffer and magnetic silica (bioMérieux). cDNA was synthesized using 10 µl of 
extracted RNA in an iCycler thermocycler (Biorad, California, USA). All fecal samples were tested for the 
presence of seven enteric viruses (norovirus, rotavirus, parechovirus, enterovirus, adenovirus, bocavirus 
and astrovirus) using a multiplex real-time PCR as has been described elsewhere.7
All reactions were performed with Phocine Distemper Virus as an internal control in a total volume of 
25 µl containing 6.25 µl 4x Fast Virus reactionmix (Life Technologies, California, USA), 30 pmol of each 
primer, 10 pmol of probe and 10 µl of genomic RNA template.8 Characterization of norovirus was done 
by amplification and sequencing of a 285 nucleotide fragment of the ORF1 gene using an automated 
genotyping tool (www.noronet.nl).9,10 
Multiple alignment was performed using BioNumerics software (Applied Maths, Sint-Martens-Latem, 
Belgium) and phylogenetic trees were constructed using the neighbor-joining method with complete 
deletion of missing data.
Results
From January 14th till January 30th, norovirus was detected in seven patients and two health care 
workers (Figure 8.1). In six of the seven patients (P2-P7), norovirus infection was hospital acquired: 
gastrointestinal symptoms occurred between four and 22 days after admission. The first patient, P1, was 
admitted with a community acquired norovirus infection and was placed in isolation at the moment 
norovirus was detected in fecal material (one day after admission). After notification of the first two 
patients (P1-P2), the importance of hand hygiene (i.e. washing hands with water and soap) was stressed. 
Despite this, another three patients were detected with norovirus infection within three days (Figure 8.1, 
P3-P5). Meanwhile, gastrointestinal complaints in health care workers of the same ward and possibly 
also in caregivers became known. Because of the suspicion of ongoing norovirus transmission on the 
ward, additional infection control measures were taken: use of appropriate alcohol hand rubs, rigorous 
environmental cleaning, education of parents/caregivers, excluding ill staff from working and separating 
staff to infected and non-infected patients. After identification of the sixth norovirus positive patient 
(P6), the necessity of closure of the ward to stop further transmission was discussed. However, within 
half a day after detection of P6,  sequence analysis results of the noroviruses detected in P1-P5 became 
available. Four different genotypes were found: norovirus genotype II.4 2009 (P1 and P3), genotype 
II.b (P4), genotype II.7 (P2) and genotype II.2 (P5). This strengthened us in our policy to maintain the 
infection control measures that were already implemented, without closing of the ward, despite the 
notification of patient P6. During the following days, norovirus was detected in fecal samples of two 
health care workers and one patient (P7). After patient P7, no additional patients or health care workers 
were found to be infected with norovirus.
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Figure 8.1. Timeline of norovirus positive patients (in black, numbered P1-P7) and health care workers (in grey, HCW1-HCW2), based 
on date of sample collection. The different norovirus genotypes are given above each bar. The time after admission to onset of 
symptoms is depicted in bold numbers for each patient.
In addition to the sequence analysis results of the first five patients, we were able to characterize norovirus 
in patient P6 (genotype II.4 2009) and in both health care workers (both norovirus genotype  II.4 2009) 
(Figure 8.2); the detected norovirus in patient P7 could not be genotyped. A cluster of norovirus II.4 2009 
was found (three patients and both health care workers); the remaining patients were all infected with 
different norovirus genotypes
Figure 8.2. Neighbor Joining tree of the norovirus strains identified in this study. The positive patients are depicted in green (P1-P6), 
the health care workers in red (HCW1-2). Reference strains are named “ref” followed by the various norovirus genotypes.
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Discussion
Our report of a norovirus pseudo-outbreak on an oncology ward in our children’s hospital shows that 
results from sequence analysis, made available in real-time and immediately after the detection of 
norovirus, were essential for understanding the actual nosocomial transmission of norovirus, in a season 
when admission of different patients with norovirus occurs frequently. The sequence based information 
supported us in deciding on infection control measures to prevent further spread. 
Norovirus is the most common cause of gastroenteritis worldwide and known for its ability to 
cause outbreaks, especially affecting health care institutions as nursing homes and hospitals.11 
It causes substantial morbidity and mortality in vulnerable people (the young, the elderly and 
immunocompromised patients).12,13 In addition, norovirus outbreaks have significant impact on hospital 
resources, notably because of the necessity to close wards.14-16 
Timely detection of norovirus with immediate implementation of appropriate infection control 
measures is one of the key factors in the containment of an outbreak.15,17 The detection of seven patients 
with norovirus infection within two weeks on one oncology hospital ward should lead to rigorous 
infection control interventions, regardless of the norovirus genotypes. However, knowing that the rise in 
infections is in fact due to several introductions of different genotypes of norovirus instead of ongoing 
transmission of the same virus between patients, helps deciding on high impact measures like closure 
of a ward. Apart from this, rapid diagnostic tests for detection and characterization of pathogens help 
regulating adequate admission policies and provide the opportunity to act pro-actively in prevention of 
further spread within the hospital.
The technique of sequence analysis is commonly used in clinical laboratories, for example antiviral 
resistance profiling of HIV, but to our knowledge not many have incorporated characterization of viruses 
like norovirus into their standard diagnostic workflow. Costs,  hands-on time of technicians and unknown 
clinical benefit are often used as arguments hampering the implementation of sequence analysis in the 
daily routine of diagnostic laboratories. In our laboratory setting, a workflow is implemented, which 
enables performance of sequence analysis routinely on a weekly basis. Students are trained to assist 
the technicians in this routine. As illustrated by this report, the potential benefits of having sequence 
based information available in real-time, should be taken into account when addressing only the costs 
of performing sequence analysis routinely; the closing of a ward is also expensive for a hospital. The 
developments in next-generation sequencing are moving fast forward, which also can make real-time 
sequencing become more feasible in the near future.
In conclusion, we have shown that adding real-time sequence based information to the classical 
epidemiological tool of clustering in place, time and person, provides essential information for 
understanding and controlling transmission routes of norovirus infections within a hospital.
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The benefit of molecular viral diagnostics
Molecular diagnostic techniques are a common tool within the daily routine in microbiological 
laboratories, especially in the field of clinical virology. 1,2 The potential benefits of molecular diagnostics 
are threefold. First, the use of molecular tests may benefit clinical management of a patient with signs 
and symptoms of an infection.  By providing a rapid and accurate diagnosis, it has been hypothesized 
that unnecessary and additional laboratory testing and imaging can be prevented. If indicated, antibiotic 
treatment can be discontinued and proper antiviral therapy (if available) can be started which may all 
reduce the length of hospital stay. Secondly, the timely detection of a viral pathogen may benefit “in-
hospital infection control”: appropriate infection control measures can be installed in a timely manner in 
order to prevent nosocomial transmission. A third potential benefit of molecular diagnostic techniques 
is the opportunity to provide accurate epidemiological information to public health authorities through 
a more detailed surveillance of viral pathogens. 
The presented studies in this thesis focus on the first two benefits of molecular diagnostic tests. Firstly, 
the value of molecular diagnostic tests in clinical management of the patient: the association of detected 
virus with clinical syndromes and the effect of finding a virus on clinical care. Secondly, the applicability 
and added value of molecular tests in in-hospital infection control to understand the transmission 
patterns of viral pathogens within the hospital, thereby supporting the timely implementation of 
appropriate infection control measures. 
The benefits of molecular viral diagnostics for patient management
The advantage of molecular tests in explaining patterns of clinical illness was illustrated by the presented 
studies on Enterovirus 68 (EV68). EV68 is a member of the genus Enterovirus species D together with 
a small group of related viruses, like EV70 and EV94. In contrast to other enteroviruses, the biological 
properties of EV68 resemble those of human rhinoviruses. EV68 is acid labile and grows efficiently at an 
optimum temperature of 33°C, the temperature of the upper respiratory tract (chapter 3). Although until 
2010 only sporadically detected worldwide, EV68 gained much interest in recent years because of its 
association with outbreaks of respiratory illness with varying severity, as illustrated by the description of 
an upsurge of infections of EV68 in the autumn of 2010 in the Northern part of the Netherlands in chapter 
2. Although much of the clinical data associated with the detection of EV68 are based on observational 
studies in selected study populations, the virus can be regarded as an emerging respiratory pathogen, 
with a spectrum of clinical disease ranging from asymptomatic carriage to severe respiratory illness 
requiring hospitalization, with rare fatal cases (chapter 3). Also, the reviewed and our data suggest that 
the presence of a chronic respiratory disease might be a risk factor for EV68 infection.3 The use of applied 
molecular diagnostic tests greatly enhanced the ability to detect EV68 in respiratory material, thereby 
facilitating the understanding of patterns of clinical illness observed by clinicians. Furthermore, the use 
of sequence analysis techniques made it possible to link clinical and epidemiological observations to 
distinct phylogenetic clustering of the virus in 2010 compared to 2009, suggesting sequence variation 
as a possible contributing factor to more and severe infections caused by EV68, as is shown in chapter 
2. Interestingly, the global emergence of the virus was initially not recognized, but as a result of 
collaboration with colleagues from the CDC in the USA and from Japan, we were able to show the 
occurrence of the virus in different places of the world during a certain time period.4
Chapter 4 addressed the clinical and epidemiological features of infection with another important 
respiratory virus, the human rhinovirus (HRV), in hospitalized children in our university hospital. The 
development of sensitive and rapid molecular techniques markedly improved the detection rate of HRV, 
thereby also revealing a high genetic diversity with over 150 serotypes described so far.5 The presented 
study in this thesis focused on the relationship between the detection of HRV and clinical symptoms, 
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the underlying chronic illness, patient management and nosocomial transmission patterns. HRV was the 
most frequently detected virus in respiratory samples from 644 patients with 904 disease episodes during 
a 15 month study period. In particular, HRV was detected in patients with chronic pulmonary illness 
(asthma, congenital pulmonary illness). These patients had significantly more complaints of coughing 
and shortness of breath and a higher need for oxygen, compared to children without HRV. All detected 
HRV were further characterized by sequence analysis, which revealed a predominance of species HRV-A 
and HRV-C over species HRV-B. No species-specific patterns of illness could be identified, although 
HRV-B was more often associated with a need for oxygen. This study showed that the detection of HRV 
can be associated with serious respiratory illness, especially in patients with a pulmonary underlying 
illness and underlines the additional value of molecular diagnostics in understanding disease patterns. 
We also examined the influence of detecting HRV in patients with respiratory illness on clinical 
management, more specifically on the use of antibiotics. Regardless of the outcome of viral diagnostics, 
antibiotics were given in more than half of the patients. The prescription of antibiotics was strongly 
associated with the clinical diagnosis of pneumonia, and was neither influenced by the outcome of 
bacterial cultures nor detected viruses or the presence of underlying illness. These findings suggest that 
for the clinician, signs and symptoms may be more important in deciding on antibiotic therapy than 
patient characteristics and microbiological results.
Chapter 5 focused on a pandemic influenza virus. In 2009 a new variant of influenza A H1N1, called 
H1N1pdm09, rapidly spread around the world, resulting in the first influenza pandemic of the 21th 
century.6 Historically, influenza in the immediate post-pandemic period has been associated with severe 
morbidity and mortality.7 In the presented study a comparison between seasonal, pandemic and post-
pandemic influenza is made in patients hospitalized in our medical center. Seasonal, pandemic and 
immediate post-pandemic influenza showed many similarities with regard to patients’ characteristics, 
severity of illness and clinical outcome. Influenza in the post-pandemic period led to an equally severe 
influenza season in terms of number of patients admitted compared to the pandemic. Treatment 
with oseltamivir was much more frequently given during the pandemic and post-pandemic period, 
however, no increase in oseltamivir resistance of influenza A H1N1pdm09, as detected by molecular 
characterization of the influenza viruses, was seen. Although clinical and epidemiological data in patients 
with influenza virus suggested that the influenza virus itself was most probably the cause of respiratory 
illness, still more than two thirds of patients during all influenza seasons were treated with antibiotics. 
The benefits of molecular viral diagnostics for infection control
The influenza A H1N1 pandemic also made clear the importance of a rapid, accurate diagnosis of influenza 
virus infection for preventing nosocomial transmission. Patients, health care workers or visitors infected 
with the influenza virus can spread the virus to vulnerable patients, causing nosocomial outbreaks with 
increased patient morbidity and mortality.8,9 Appropriate and timely implemented infection control 
measures are necessary to prevent transmission of influenza virus within the hospital. The added value 
of characterization of the influenza virus by sequence analysis in the detection of clusters of patients 
with influenza is shown in chapter 6. By combining sequence based information with epidemiological 
data several clusters of nosocomial influenza virus infection could be identified, some of which would 
not have been detected based on available epidemiological data on their own.
To obtain knowledge on the nosocomial spread of HRV infections the same approach was used. In the 
prospective study among hospitalized children, almost a quarter of the HRV positive disease episodes 
were acquired when the patient was already in the hospital for several days because for other reasons 
(chapter 4). Phylogenetic analysis revealed several clusters of HRV with identical sequences; in more than 
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a quarter of these clusters epidemiological information was suggestive of intra-hospital transmission. 
Furthermore, although HRV-B was the least frequently found species in our study, almost 40% of HRV-B 
infections were acquired in the hospital, suggesting that the hospital environment is for some reason 
more favorable for transmission of HRV-B and that perhaps more stringent infection control measures 
could be necessary when HRV-B is detected.
We further theoretically explored the factors that drive nosocomial transmission of HRV by mathematical 
modeling (chapter 7). Data on HRV detection, clinical symptoms and infection control measures were 
retrieved from the prospective project into respiratory infections in hospitalized children and were used 
in an agent-based, multi-ward, stochastic mathematical model to assess the relative contributions of 
factors that drive HRV transmission dynamics: patient-to-patient transmission, introduction by visitors 
and health care workers and existing infection control measures. Based on model predictions, timely 
implementation of infection control measures (i.e. the moment the patient displays symptoms of 
respiratory infection) in combination of infection control policies which include HRV specific measures 
would  reduce the number of hospital acquired HRV cases almost by half. However, still a considerable 
amount of hospital acquired HRV infections would exist because of introduction of HRV from outside the 
hospital via visitors or health care workers. For our hospital, up to 80% of the hospital acquired HRV cases 
observed during one year would be due to a source other than patient-to-patient transmission. Infection 
control policies should also focus on people surrounding the patient, not only on the infected patient 
itself. Besides, strategies should be developed in which sensitive (molecular based) and rapid point-
of-care diagnostic tests play an important role. This study illustrates that combining epidemiological 
methods and mathematical modeling techniques improve the understanding of nosocomial HRV 
transmission dynamics, which contributes to the implementation of appropriate infection control 
interventions.
The use of sequence based data in the surveillance of (hospital acquired) viral infections and in infection 
control is not a common practice and is mainly used to characterize pathogens when an outbreak is 
already over in order to understand on hindsight the possible transmission routes, as is also shown in 
chapter 4 and chapter 6.10-12 In chapter 8 the benefit of providing sequence based information in real-time, 
immediately after detection of a pathogen, is illustrated. In this chapter a norovirus pseudo-outbreak is 
described on a children’s oncology ward. Rapid characterization of the detected norovirus in 5 out of 7 
patients was available within 7 days after notification of the first patient. Four different genotypes were 
detected and this provided evidence for multiple introductions of different norovirus strains with only 
a few secondary cases rather than ongoing nosocomial transmission. This rapidly available information 
strengthened us not to close the hospital ward, but to maintain the already installed infection control 
measures. During the outbreak, gastrointestinal complaints in health care workers of the same ward 
and possibly also in caregivers became known, again stressing the importance of visitor- or healthcare 
mediated transmission in nosocomial infections. Adding real-time sequence based information to the 
classical epidemiological tool of clustering in place, time and person, provides essential information in 
order to understand and to control transmission routes of norovirus within a hospital setting.
Concluding remarks and future prospective studies
The outcome of a molecular test should, as with every diagnostic method, be translated into clinical 
signs and symptoms of the patient in order to determine whether a positive test clarifies the etiology of 
the illness of the patient. As developments in molecular diagnostics go rapidly, clinical data related to 
these tests are lagging behind. Clinical studies addressing patterns of disease and patients characteristics 
associated with the outcome of molecular diagnostics are necessary to fully understand the clinical value 
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of these tests. This is a common feature of every new technology or treatment option, but is seems that 
within molecular technologies, there are some hurdles to be taken.  These studies should include data to 
answer the questions whether the use of molecular diagnostic methods improve patients outcome and 
whether the use of these techniques benefits the health care system (length of stay, drug prescription, 
infection control practices, costs). 
An important factor in the optimal integration of molecular diagnostic tests in patient management is 
the role of the clinician. Effort should be put into the education of health care providers about the value 
and utility of available molecular tests. Results of clinical studies and cost effectiveness analyses should 
be shared with and disseminated to physicians. Also, the reasons for, for example, continuing empirically 
started antibiotic treatment despite an alternative viral diagnosis should be explored: is it a lack of 
knowledge on the clinical value of a molecular test, a lack of confidence that a viral diagnosis indeed 
explains the patient’s illness or the lack of implementation of molecular tests in clinical guidelines?
Optimal integration of molecular tests in clinical care implies that results of these tests should be known 
the moment the patient is cared for. The ability to provide results ‘in real time’ maximizes the impact 
of molecular tests on clinical care and infection control.13 Easy to use tests which can be performed 
on demand with short turnaround time without losing sensitivity and specificity are needed for the 
optimal integration of molecular technologies in clinical care (like for instance with the currently 
used GeneXpert® or Filmarray® assays).  Equally important is probably the value of molecular tests in 
excluding viral infection and disease, thereby focusing clinical care and preventing the implementation 
of unnecessary infection control practices. Rapid test results with high positive as well as high negative 
prognostic value are needed in order to be able to predict on a more solid basis which care is needed 
for whom. 
Rapid characterization of viruses provides information on epidemiological linkage between patients, not 
on hindsight but during clinical care. As such, sequence based information is not only useful in gaining 
insight in transmission routes, but also serves as input for actual infection control policies. This creates 
the possibility to focus human and material resources in a more efficient way. However, to maximize 
the impact of real time sequencing on in-hospital infection control, information on circulating strains 
of viruses outside the hospital is necessary: this enables analysis of possible transmission routes and 
clusters of infections within the hospital against a known background of circulating virus types.  Patients 
travel along networks of health care associated institutes, moving to and from homes for (elderly) 
care, regional and university hospitals and rehabilitation centers, carrying their different viruses with 
them. Collaboration and data sharing between regional laboratories are necessary to gain insight on 
circulating types of viruses and to use this information for unraveling transmission patterns on a regional 
scale. We call this initiative in our region REGIOTYPE, which compares to (inter)national networks like 
VIRO-TYPENED and Noronet.14,15
Much of the discussions about the integration of molecular diagnostic tests in patient management and 
infection control is dominated by costs. The benefits and thus cost savings for patient management and 
infection control are insufficiently taken into account. Cost effectiveness studies are currently needed 
to properly address the impact of a timely and accurate diagnosis on all aspects of patient care: do the 
benefits of molecular techniques in clinical care and infection control outweigh the costs of performing 
the tests (the “euro-hour concept”: costs of molecular tests relative to the hours of unnecessary treatment 
or isolation measures waiting for test results compared to standard diagnostic procedures). 
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Although antiviral therapy for respiratory viruses is currently limited, much effort is put in the 
development of potent antivirals against picornaviridae, most notably rhinovirus and enterovirus.16,17 
These developments towards newly available antiviral therapy for highly prevalent viruses, like HRV, 
should be taken into account when cost effectiveness studies are being performed.
In conclusion, molecular diagnostic methods have gained a solid position in clinical virology. The value 
of a rapid, accurate diagnosis on patient management and infection control is becoming clearer in 
recent years. More data, especially resulting from cost effectiveness studies, are needed to overcome 
current questions regarding costs and clinical value of molecular tests in clinical virology. For this, many 
clinical and epidemiological data associated with results of molecular tests are needed. To enable an 
optimal integration of molecular diagnostic techniques in patient management education of health care 
providers on the proper use and interpretation of these tests is crucial. As such, a “diagnostic stewardship” 
model could be developed aimed at the most accurate and cost effective diagnostic algorithms given 
clinical and epidemiological questions related to viral infections.
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De diagnostiek naar virale infecties kent een relatief korte geschiedenis. Het duurde tot aan het einde 
van de 19e eeuw voordat het bestaan van virussen in een laboratorium werd aangetoond.1,2 Het besef 
dat virussen levende cellen nodig hadden voor vermenigvuldiging en dat infectie van een cellijn met 
een virus een cytopathisch effect tot gevolg had, leidde tot het gebruik van celkweken bij de detectie 
van virussen in klinische materialen. Naast het feit dat niet alle virussen te kweken waren, duurde het 
vaak (te) lang voordat een resultaat bekend was. De ontwikkeling van snellere diagnostiek met behulp 
van specifieke antistoffen tegen virusantigeen maakte het mogelijk vaker een relatie te leggen tussen 
specifieke virusinfecties en klinische symptomatologie.3,4 Bovendien werd het gebruik van specifieke 
antistoffen ingezet bij de zoektocht naar preventieve methodes om dodelijke ziekten als pokken te 
voorkomen: succesvolle vaccinatiestrategieën waren het gevolg. Aan de overtuiging dat (virale) infecties 
voorgoed tot het verleden behoorden, kwam begin jaren tachtig abrupt een eind met de ontdekking 
van het HIV-virus als verwekker van het immuun deficiëntie syndroom bij jonge homoseksuele 
mannen.5 In dezelfde periode dat de HIV epidemie zich over de wereld verspreidde, deden moleculaire 
technieken hun intrede in de klinische diagnostische virologie. De ontdekking van de polymerase 
chain reactie (PCR), waarbij zeer kleine hoeveelheden genetisch materiaal gedetecteerd kon worden 
door exponentiële vermenigvuldiging, leidde tot een doorbraak in de diagnostiek van virale infecties.6 
Moleculaire technieken speelden een belangrijke rol in het ontwarren van de replicatiecyclus van HIV 
en in de ontwikkeling van anti-retrovirale middelen. Tevens bleek dat progressie van ziekte samenhing 
met de hoogte van de virale load in het bloed (en het CD4 + getal).7 Het monitoren van de virale load 
met behulp van moleculaire technieken werd een belangrijk middel om prognose van ziekte te bepalen 
en het effect van therapie te vervolgen. Zo vormden moleculaire technieken niet alleen een middel om 
virussen te detecteren, maar werden ze ook een essentieel onderdeel van de patiëntenzorg.
Moleculaire diagnostiek van virale infecties
De afgelopen twintig jaar is er veel ontwikkeling geweest in moleculaire diagnostische methoden. 
Inmiddels zijn moleculaire testen een onmisbaar onderdeel geworden van de routine diagnostiek in een 
microbiologisch laboratorium, vooral op het gebied van de klinische virologie.8,9 Door de hoge sensitiviteit 
en specificiteit van moleculaire testen vooral in het begin van klinische ziekte is de tijdige en adequate 
detectie van virale pathogenen verbeterd. Het ontwikkelen van multiplex PCR, waarbij meerdere 
targets in een test zijn geïncorporeerd, maakte het mogelijk bij specifieke klinische syndromen te kijken 
naar verschillende virale verwekkers. Naast de detectie van virussen zijn kwantitatieve moleculaire 
technieken belangrijk in het bepalen van progressie en prognose van ziekte. Het monitoren van de 
virale load en het bepalen van resistentie bij onvoldoende respons op adequate antivirale therapie is 
een belangrijk toepassingsgebied van moleculaire methoden. De meest recente ontwikkelingen gaan 
richting zogenaamde “point-of-care” testen: snelle, makkelijk te gebruiken moleculaire testen die dichtbij 
de patiënt kunnen worden uitgevoerd. 
De technische ontwikkelingen rondom moleculaire diagnostische methoden gaan snel. Dit roept vragen 
op met betrekking tot de klinische toepasbaarheid van moleculaire testen: wat betekent een testuitslag 
voor de zorg rondom een patiënt, niet alleen voor wat betreft therapie en aanvullende diagnostiek maar 
ook voor wat betreft maatregelen ter voorkoming van verdere verspreiding van virussen. Om tot een 
optimale integratie van moleculaire testen in de patiëntenzorg te komen, moeten dergelijke vragen 
gericht op klinische toepasbaarheid beantwoord worden.
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De voordelen van moleculaire virale diagnostiek
De voordelen van moleculaire diagnostische methoden zijn drieledig. Ten eerste kan het gebruik 
van moleculaire testen de zorg rondom patiënten met tekenen van infectie verbeteren. Een snelle 
en accurate diagnose van een virale infectie voorkomt de inzet van onnodige extra diagnostiek 
(laboratoriumonderzoek, beeldvorming), maakt het mogelijk empirisch gestarte antibiotische therapie 
te staken, eventueel antivirale therapie te starten en kan zorgen voor een verkorting van de ligduur 
in het ziekenhuis. Ten tweede maakt een tijdige detectie van een virus het mogelijk adequaat en snel 
maatregelen te treffen ten behoeve van infectiepreventie in het ziekenhuis om zo verdere verspreiding 
van een virus te voorkomen. Typering van virussen helpt om mogelijke transmissieroutes van virussen 
in het ziekenhuis te begrijpen, zodat infectiepreventiemaatregelen daar kunnen worden ingezet waar 
ze het grootste effect hebben in het stoppen van verdere verspreiding. Als laatste spelen moleculaire 
methoden een belangrijke rol in de openbare gezondheidszorg. Moleculaire technieken maken een 
meer gedetailleerde surveillance van virale pathogenen mogelijk. Ook zijn moleculaire technieken 
belangrijk bij de identificatie en detectie van nieuw opkomende virussen zoals MERS-Coronavirus.10
De gepresenteerde studies in dit proefschrift richten zich op de voordelen van moleculaire diagnostische 
methoden voor de directe patiëntenzorg en voor infectiepreventie bij respiratoire en enterale 
virusinfecties.
Voordelen van moleculaire diagnostische methoden voor de patiëntenzorg
De ontwikkelingen in moleculaire diagnostische testen hebben ertoe geleid dat een palet aan nieuwe 
virussen is ontdekt in respiratoir en fecaal materiaal. Voor sommige virussen wordt de relatie tussen 
detectie van het virus en klinische symptomatologie erkend. Voor andere virussen is de klinische 
betekenis nog onduidelijk en onderwerp van debat. Hoewel er steeds meer informatie beschikbaar 
komt over de relatie tussen de detectie van een virus en symptomen van ziekte, laten de meeste studies 
tot nu toe zien dat detectie van een virus niet leidt tot bijvoorbeeld het stoppen van empirisch gestarte 
antibiotische therapie. Naast de behoefte aan aanvullende studies naar klinisch relevante uitkomstmaten 
(mortaliteit, complicaties) is het van wezenlijk belang dat clinicus de betekenis van een positieve test in 
het verklaren van ziekte bij de patiënt leert begrijpen.
In dit proefschrift worden de voordelen van moleculaire technieken in het verklaren van ziekte 
beschreven aan de hand van studies naar Enterovirus 68 (EV68), rhinovirus (HRV) en influenzavirus. 
EV68 behoort tot het genus Enterovirus groep D. In tegenstelling tot andere enterovirussen is EV68 zuur 
labiel en groeit optimaal bij een temperatuur van 33°C, de temperatuur van de bovenste luchtwegen. 
De biologische kenmerken van EV68 lijken daarmee erg op die van rhinovirus (hoofdstuk 3).
De detectie van EV68 is tot aan 2010 slechts sporadisch beschreven. De laatste jaren staat EV68 echter 
in de belangstelling als oorzaak van uitbraken van respiratoire infecties waarbij de ernst van de ziekte 
varieert van asymptomatisch dragerschap tot aan ernstige respiratoire ziekte met opname in het 
ziekenhuis als gevolg. Hoewel de meeste gegevens die tot nu toe gepubliceerd zijn, gebaseerd zijn op 
observationele studies in geselecteerde populaties kan EV68 als een opkomend pathogeen worden 
beschouwd. Door het gebruik van moleculaire testen is de detectie van EV68 in respiratoir materiaal 
vergemakkelijkt, waardoor het mogelijk wordt klinische ziektebeelden beter te begrijpen, zoals wordt 
geïllustreerd door de toename van respiratoire infecties door EV68 in het najaar van 2010 in het noorden 
van Nederland (hoofdstuk 2). Typering van EV68 met behulp van sequentie-analyse liet zien dat er 
sprake was van twee fylogenetische clusters, wat suggereert dat variatie in sequenties mogelijk heeft 
bijgedragen tot de plotse toename van EV68 infecties.
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In hoofdstuk 4 worden de klinische en epidemiologische kenmerken van HRV infecties bij kinderen 
opgenomen in ons universitair medisch centrum beschreven. De detectie van HRV is sterk gestimuleerd 
door de ontwikkeling van gevoelige moleculaire testen, waarbij tevens duidelijk werd dat HRV een 
enorme genetische diversiteit kent met inmiddels meer dan 150 beschreven serotypes. In de in dit 
proefschrift beschreven studie is de relatie bestudeerd tussen de detectie van HRV en klinische 
symptomatologie, patiëntkenmerken en antibiotisch beleid bij kinderen. HRV was het meest frequent 
gedetecteerde virus in respiratoire materialen van 644 patiënten met 904 ziekte-episodes gedurende 
een periode van 15 maanden. De detectie van HRV was geassocieerd met de aanwezigheid van 
chronische longaandoeningen (astma, aangeboren longafwijkingen). Deze kinderen hadden significant 
meer klachten van hoesten en benauwdheid met daarbij een hogere zuurstofbehoefte vergeleken 
met kinderen zonder HRV. De gedetecteerde HRVs zijn getypeerd waarbij species HRV-A en HRV-C de 
meerderheid vormden. De data lieten geen verband zien tussen species en klinische symptomatologie, 
hoewel HRV-B meer geassocieerd was met verhoogde zuurstofbehoefte. Antibiotica werden in meer 
dan de helft van de patiënten voorgeschreven, ongeacht de uitkomst van virale diagnostiek. Het 
voorschrijven van antibiotica was sterk geassocieerd met de klinische diagnose pneumonie en hing niet 
samen met de uitkomst van de bacteriële kweek of de aanwezigheid van onderliggend lijden. Deze data 
suggereren dat voor de behandelaar klinische symptomen wellicht belangrijker zijn in de afweging om 
antibiotische therapie voor te schrijven dan microbiologische diagnostiek en patiëntkenmerken.
Hoofdstuk 5 heeft als onderwerp het pandemische influenzavirus. In 2009 verspreidde een nieuwe 
variant van influenza A H1N1 zich snel over de hele wereld, resulterend in de eerste influenza pandemie 
van de 21e eeuw. Historisch gezien wordt ook influenza in het eerste post-pandemische seizoen 
vaak gekenmerkt door een hoge morbiditeit en mortaliteit. De in dit proefschrift gepresenteerde 
studie vergelijkt de in ons universitair medisch centrum opgenomen patiënten met seizoensgriep 
(2007-2009), pandemische influenza (2009-2010) en post-pandemische influenza (2010-2011). Er 
werden veel overeenkomsten gezien in ernst van ziekte, patiëntkenmerken en klinische uitkomsten 
tussen de verschillende influenzaseizoenen. Het aantal patiënten dat moest worden opgenomen met 
influenza was in het post-pandemische seizoen gelijk aan het aantal tijdens de pandemie. Oseltamivir 
werd veel vaker gebruik tijdens de pandemie en het post-pandemische seizoen, maar leidde niet tot 
meer oseltamivir resistentie (gedetecteerd met behulp van sequentie-analyse). Hoewel klinische en 
epidemiologische data suggereerde dat het influenzavirus zelf de meest waarschijnlijke oorzaak was 
van de respiratoire ziekte, werd meer dan tweederde van de patiënten behandeld met antibiotica.
Voordelen van moleculaire diagnostiek voor infectiepreventie
De influenza A H1N1 pandemie liet ook het belang zien van een tijdige en accurate diagnose in het 
voorkomen van nosocomiale transmissie. Patiënten, medisch personeel of bezoekers met influenza 
kunnen het virus verspreiden naar anderen, waardoor nosocomiale uitbraken kunnen ontstaan met 
verhoogde morbiditeit en mortaliteit bij patiënten. Tijdige implementatie van adequate infectiepreventie 
maatregelen zijn nodig om transmissie van influenza virus te voorkomen. De toegevoegde waarde 
van sequentie analyse in de detectie van clusters van patiënten met influenza wordt beschreven in 
hoofdstuk 6. Door het combineren van epidemiologische data met informatie gebaseerd op sequentie 
analyse van gedetecteerde influenza virussen konden verschillende clusters van nosocomiale infecties 
worden geïdentificeerd. Sommige daarvan zouden op basis van alleen de epidemiologische data niet 
zijn gevonden.
Dezelfde aanpak is gebruikt om inzicht te krijgen in nosocomiale HRV infecties. In de in dit proefschrift 
gepresenteerde prospectieve studie onder kinderen opgenomen in ons ziekenhuis (hoofdstuk 4) bleek 
bijna een kwart van de HRV positieve ziekte-episodes in het ziekenhuis te zijn opgelopen. Op basis van 
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fylogenetische analyse konden meerdere clusters van identieke HRV sequenties worden aangetoond; in 
meer dan 25% van deze clusters was ook de epidemiologische informatie suggestief voor nosocomiale 
transmissie van HRV. Opvallend was dat, hoewel species HRV-B de minst frequent aangetoonde species 
was, bijna 40% van de HRV-B infecties in het ziekenhuis waren opgelopen. Dit suggereert dat de 
ziekenhuisomgeving om wat voor reden ook gunstig zou kunnen zijn voor transmissie voor HRV-B.
In hoofdstuk 7 zijn we dieper ingegaan op de factoren die nosocomiale transmissie van HRV kunnen 
beïnvloeden. De klinische en epidemiologische data uit de prospectieve studie onder kinderen 
dienden als input voor een stochastisch mathematisch model. Dit model werd gebruikt om de invloed 
van patiënt-op-patiënt transmissie, introductie van HRV door bezoekers en ziekenhuispersoneel, en 
infectiepreventie maatregelen op de hoeveelheid nosocomiale HRV infecties te bepalen. Berekeningen 
gebaseerd op dit model lieten zien dat infectiepreventie maatregelen, welke een combinatie waren van 
algemene en HRV specifieke maatregelen, zorgden voor een halvering van nosocomiale HRV infecties, 
vooral door een afname in patiënt-op-patiënt transmissie. Verdere reductie van het aantal nosocomiale 
HRV infecties zou te bewerkstelligen zijn door het zo kort mogelijk maken van de tijd tussen eerste 
symptomen van respiratoire infectie en start van de isolatie. Dit zou kunnen worden gerealiseerd door 
bijvoorbeeld de inzet van snelle point-of-care testen. Wanneer alle patiënten met een HRV infectie 
meteen bij de eerste ziektedag in isolatie zouden worden gelegd, zou echter nog steeds een aanzienlijk 
aantal nosocomiale HRV infecties ontstaan. Dit is toe te schrijven aan introductie van HRV in het 
ziekenhuis door bronnen anders dan geïnfecteerde patiënten zoals bezoekers en ziekenhuispersoneel. 
In ons ziekenhuis zou, gebaseerd op het model, circa 80% van de nosocomiale HRV infecties toe te 
schrijven zijn aan deze introductie van buitenaf. Dit maakt duidelijk dat infectiepreventiemaatregelen 
niet alleen gericht moeten zijn op de geïnfecteerde patiënt, maar dat de focus ook moet worden gelegd 
op bezoekers en ziekenhuispersoneel. Deze studie illustreert hoe het combineren van epidemiologische 
data met mathematische modelleringtechnieken het mogelijk maakt nosocomiale transmissie van 
virussen beter te begrijpen. 
Het gebruik van op sequentie analyse gebaseerde informatie bij de surveillance van (nosocomiale) virale 
infecties en in infectiepreventie is nog geen gemeengoed. Het wordt tot op heden vooral gebruikt 
om achteraf te begrijpen hoe transmissie tijdens een uitbraak is verlopen, zoals in hoofdstuk 4 en 
hoofdstuk 6 wordt getoond. In hoofdstuk 8 laten we het voordeel zien van het leveren van op sequentie 
analyse gebaseerde informatie op het moment dat er een uitbraak is, meteen volgend op de detectie 
van in dit geval norovirus. In dit hoofdstuk wordt een norovirus pseudo-uitbraak beschreven op een 
kinderoncologie afdeling. Karakterisering van het virus was voor 5 van de 7 patiënten bekend binnen 
een week na de melding van de eerste patiënt. Vier verschillende genotypen werden aangetoond, wat 
suggestief was voor verschillende onafhankelijke introducties van buitenaf in plaats van voortgaande 
nosocomiale tranmissie van norovirus. Op basis van deze aanvullende informatie is besloten niet over 
te gaan tot het sluiten van de afdeling om verdere transmissie te voorkomen, maar om de al ingestelde 
intensieve infectiepreventiemaatregelen te handhaven. Tijdens de uitbraak werd bekend dat ook 
personeel en bezoekers gastro-intestinale klachten hadden, wat opnieuw het belang duidelijk maakt 
van de rol van personeel en bezoekers in nosocomiale transmissie van virussen. Het toevoegen van 
“real-time” typeringsinformatie aan de klassieke epidemiologische methode van clustering in plaats, tijd 
en persoon, levert essentiële informatie op voor een beter begrip en adequate controle van nosocomiale 
transmissie van norovirus infecties.
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Conclusie en toekomstperspectieven
De voordelen van moleculaire diagnostische methoden zijn meer dan alleen detectie, kwantificering en 
karakterisering van een pathogeen. Moleculaire testen komen de patiëntenzorg ten goede en versterken 
infectiepreventie. Door een snelle en accurate diagnose helpen moleculaire testen bij het verklaren van 
ziekte. Dit kan het klinisch handelen rondom een patiënt positief beïnvloeden: juiste antivirale therapie 
kan worden voorgeschreven, onnodige antibiotische therapie kan worden gestopt en aanvullende 
laboratoriumtesten en diagnostiek kunnen worden verminderd. Daarnaast zijn moleculaire methoden 
van belang in het begrijpen van transmissie van virussen in het ziekenhuis, informatie die als input kan 
dienen voor adequate infectiepreventie.
Tot op heden zijn moleculaire testen nog niet optimaal geïntegreerd in de klinische patiëntenzorg en 
infectiepreventie. Inzicht krijgen in de factoren die een optimaal gebruik van moleculaire diagnostische 
methoden hinderen, is noodzakelijk. 
Het resultaat van een moleculaire test moet, zoals bij elke diagnostische methode, vertaald worden 
naar de symptomatologie van de patiënt om te bepalen of een testuitslag de ziekte van de patiënt 
kan verklaren. De ontwikkelingen in de moleculaire diagnostiek gaan snel en klinische gegevens 
gerelateerd aan uitkomsten van moleculaire diagnostiek lopen hierbij achter. Klinische studies gericht 
op ziektebeelden en patiënt karakteristieken zijn nodig om de toepasbaarheid en waarde van de 
moleculaire diagnostiek ten volle te begrijpen en te benutten. In deze studies moeten ook gegevens 
verzameld worden die antwoord kunnen geven op de vraag naar de effecten van moleculaire 
diagnostiek op klinische uitkomstmaten, ligduur, het voorschrijven van antimicrobiële middelen en 
infectiepreventiemaatregelen. 
Een belangrijke factor bij de optimale integratie van moleculaire diagnostische methoden in klinische 
patiëntenzorg is de behandelaar. Resultaten van klinische studies en kosteneffectiviteitanalyses moeten 
worden gedeeld met en verspreid onder clinici. Zij moeten uitleg krijgen over de waarde en de 
bruikbaarheid van moleculaire testen. Daarnaast moet worden onderzocht wat de redenen zijn voor 
het bijvoorbeeld continueren van empirisch gestarte antibiotische therapie ondanks de aanwezigheid 
van een alternatieve diagnose van virale infectie: is dit door een gebrek aan kennis over de klinische 
betekenis van een moleculaire testuitslag, een gebrek aan vertrouwen dat een virale diagnose inderdaad 
de ziekte van de patiënt verklaart of zijn moleculaire testen niet (goed genoeg) geïmplementeerd in 
klinische richtlijnen?
Optimale integratie van moleculaire testen in patiëntenzorg is alleen mogelijk als de uitslagen van deze 
testen bekend zijn op het moment dat de patiënt de zorg ontvangt. De mogelijkheid om resultaten “in 
real time” te genereren leidt tot een zo groot mogelijke impact van moleculaire testen op de klinische 
patiëntenzorg en de infectiepreventie. Makkelijk te gebruiken testen die random kunnen worden 
ingezet met een korte doorlooptijd, zonder dat dit ten koste gaat van sensitiviteit en specificiteit, zijn 
nodig om tot deze optimale integratie te komen. Dergelijke testen zijn niet alleen van belang in het 
aantonen van virale infecties; het uitsluiten ervan is waarschijnlijk net zo belangrijk. Dit leidt tot een meer 
gerichte klinische behandeling en voorkomt het instellen van onnodige infectiepreventie maatregelen. 
Het snel typeren van virussen levert informatie op over transmissieroutes tussen patiënten, niet achteraf, 
maar op het moment dat patiënten zorg ontvangen. Op sequentie analyse gebaseerde informatie is niet 
alleen nuttig om inzicht te krijgen in nosocomiale transmissie van virussen, maar is ook belangrijke input 
voor infectiepreventiebeleid, juist op het moment dat de patiënt nog in het ziekenhuis ligt. Dit maakt 
het mogelijk menskracht en materiaal efficiënt en effectief in te zetten. 
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Voor een juiste interpretatie van typeringsgegevens van virussen in het ziekenhuis is inzicht in en 
informatie over circulerende virusvarianten buiten het ziekenhuis noodzakelijk: zo kunnen clusters 
van identieke virussen in het ziekenhuis geanalyseerd worden tegen een bekende achtergrond van 
circulerende virusvarianten. Patiënten met hun verschillende soorten virussen verplaatsen zich langs 
netwerken van gezondheidszorginstellingen, van verpleeghuizen naar regionale ziekenhuizen, 
revalidatiecentra of universitaire centra en weer terug. Door deze zorgnetwerken is samenwerking 
tussen regionale laboratoria en het uitwisselen van gegevens noodzakelijk om inzicht te krijgen in 
de variatie aan circulerende virustypes en om deze informatie te gebruiken bij het doorgronden van 
transmissieroutes. Binnen onze regio noemen we dit initiatief “REGIOTYPE”, als lokale aanvulling op het 
(inter)nationale TYPENED en Noronet netwerk.11,12
De discussie over het gebruik en de integratie van moleculaire testen in klinische patiëntenzorg en 
infectiepreventie wordt vaak gedomineerd door kosten. De voordelen, en dus kostenbesparingen, van 
het gebruik van moleculaire testen worden hierin vaak niet meegenomen. Om de impact van snelle 
en accurate moleculaire testen op alle aspecten van de patiëntenzorg goed te kunnen bepalen, zijn 
kosteneffectiviteitstudies noodzakelijk: wegen de voordelen van moleculaire testen voor patiëntenzorg 
en infectiepreventie op tegen de kosten van het uitvoeren van de testen (het “euro-uur” concept: de 
kosten van moleculaire diagnostiek ten opzichte van met de tijd dat patiënten (ten onrechte) in isolatie 
liggen of onnodige therapie ondergaan in afwachting van de testuitslag).
Hoewel antivirale therapie voor respiratoire virussen op dit moment beperkt beschikbaar is, zijn er veel 
ontwikkelingen vooral voor picornavirussen (rhinovirus, enterovirus).13 Deze ontwikkelingen moeten 
worden meegenomen in kosteneffectiviteitanalyses, zeker wanneer het gaat om veel voorkomende 
virussen als rhinovirus met daardoor een hoge directe en indirecte ziektelast.
Concluderend kan worden gesteld, dat moleculaire diagnostische methoden een stevige positie 
hebben ingenomen in de klinische virologie. De waarde van een snelle, accurate diagnose voor de 
patiëntenzorg en de infectiepreventie in het ziekenhuis wordt de laatste jaren steeds duidelijker. Meer 
data, vooral gebaseerd op kosteneffectiviteitstudies, zijn nodig om vraagstukken rondom kosten en 
klinische betekenis van moleculaire diagnostiek in de klinische virologie te beantwoorden. Om tot een 
optimale integratie van moleculaire diagnostische methoden in de klinische patiëntenzorg te komen, is 
educatie van medisch personeel over het juiste gebruik van moleculaire testen en een juiste interpretatie 
van de uitslagen cruciaal.
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was dit onderzoek niet mogelijk geweest. Zelfs in het weekend zijn jullie bereid geweest materialen 
in het kader van mijn onderzoek te verwerken, heel veel dank daarvoor! In het bijzonder wil ik Renze 
Borger bedanken, voor het geduld en het meedenken gedurende het hele traject. En natuurlijk dank aan 
“onze” studenten: jullie bijbaantje, het doen van sequentie-analyses, heeft veel input voor dit onderzoek 
geleverd. 
Caroline, ontzettend bedankt voor alles wat je hebt gedaan, jij wist altijd een oplossing voor kleine en 
grote praktische problemen.
In het algemeen wil ik de organisaties waar ik heb gewerkt en waar ik nu werk, danken voor de 
mogelijkheden en kansen die ik heb gekregen en nog steeds krijg. Ik waardeer dit zeer.
Tot slot, Imro, Juliëtte en Ivo. Imro, we hebben dit samen gedaan. Ik ben ongelooflijk trots op wat wij 
hebben gepresteerd, ik ben blij dat jij er bent. Juliëtte en Ivo, bedankt voor jullie begrip en relativerende 
woorden (zonder dat jullie er erg in hadden dat het relativerend was!), jullie zijn een bijzonder stel.
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